

NUCLEIC ACIDS AND PROTEINS FROM GROUP B STREPTOCOCCUS

The present invention relates to proteins derived from *Streptococcus agalactiae*, nucleic acid molecules encoding such proteins, and the use of the proteins as antigens and/or immunogens and in detection/diagnosis. It also relates to a method for the rapid screening of bacterial genomes to isolate and characterise bacterial cell envelope associated or secreted proteins.

The *Group B Streptococcus* (GBS) (*Streptococcus agalactiae*) is an encapsulated bacterium which emerged in the 1970s as a major pathogen of humans causing sepsis and meningitis in neonates as well as adults. The incidence of early onset neonatal infection during the first 5 days of life varies from 0.7 to 3.7 per 1000 live births and causes mortality in about 20% of cases. Between 25-50% of neonates surviving early onset infections frequently suffer neurological sequelae. Late onset neonatal infections occur from 6 days to three months of age at a rate of about 0.5 - 1.0 per 1000 live births.

There is an established association between the colonisation of the maternal genetic tract by GBS at the time of birth and the risk of neonatal sepsis. In humans it has been established that the rectum may act as a reservoir for GBS. Susceptibility in the neonate is correlated with the a low concentration or absence of IgG antibodies to the capsular polysaccharides found on GBS causing human disease. In the USA strains isolated from clinical cases usually belong to capsular serotypes Ia, Ib, II, III although serotype V may be of increasing significance. Type VIII GBS is the major cause of neonatal sepsis in Japan.

A possible means of prevention involves intra or postpartum administration of antibiotics to the mother but there are concerns that this might lead to the emergence of resistant organisms and in some cases allergic reactions. Vaccination of the adolescent females to induce long lasting maternally derived immunity is one of the most promising approaches to prevent GBS infections in neonates. The capsular

polysaccharide antigens of these organisms have attracted most attention as with regard to vaccine development. Studies in healthy adult volunteers have shown that serotype Ia, II and III polysaccharides are non-toxic and immunogenic in approximately 65%, 95% and 70% of non-immune adults respectively. One of the problems with using capsule antigens as vaccines is that the response rates vary according to pre-immunisation status and the polysaccharide antigen and not all vaccinees produce adequate levels of IgG antibody as indicated in vaccination studies with GBS polysaccharides in human volunteers.

Some people do not respond despite repeated stimuli. These properties are due to the T-independent nature of polysaccharide antigens. One strategy to enhance the immunogenicity of these vaccines is to enhance the T cell dependent properties of polysaccharides by conjugating them to a protein. The use of polysaccharide conjugates looks promising but there are still unresolved questions concerning the nature of the carrier protein. A conjugate vaccine against GBS would require at least 4 different conjugates to be prepared adding to the cost of a vaccine.

Recent evidence also suggests that bacterial surface proteins may be useful to confer immunity. A protein called Rib which is found on most serotype III strains but rarely on serotypes Ia, Ib or II confers immunity to challenge with Rib expressing GBS in animal models (Stalhammar-Carlemalm *et al.*, *Journal of Experimental Medicine* 177:1593-1603 (1993)). Another surface protein of interest as a component of a vaccine is the alpha antigen of the C proteins which protected vaccinated mice against lethal infection with strains expressing alpha protein. The amount of antigen expressed by GBS strains varies markedly.

Approaches to vaccination against GBS infections which rely on the use of capsular polysaccharides have the disadvantage that response rates are likely to vary considerably according to pre-immunisation status and the particular type of polysaccharide antigen used. Results of trials in human volunteers have indicated that

response rates may only be around 65% for some of the key capsule antigens (Larsson *et al.*, *Infection and Immunity* 64:3518-3523 (1996)). It is also not clear whether all individuals responding to the vaccine would have adequate levels of polysaccharide specific IgG which can cross the placenta and afford immunity to neonates. By
5 conjugating a protein carrier to the polysaccharide antigen it may be possible to convert them to T-cell dependent antigens and enhance their immunogenicity.

Preliminary studies with GBS type III polysaccharide-tetanus toxoid conjugate have been encouraging (Baker *et al.*, *Reviews of Infectious Diseases* 7:458-467 (1985),
10 Baker *et al.*, *The New England Journal of Medicine* 319:1180-1185 (1988), Paoletti *et al.*, *Infection and Immunity* 64:677-679 (1996), Paoletti *et al.*, *Infection and Immunity* 62:3236-3243 (1994)) but in developed countries the use of tetanus may be disadvantageous since most adults will have been immunised against tetanus within the past five years. Additional boosters with tetanus toxoid may cause adverse
15 reactions (Boyer., *Current Opinions in Pediatrics* 7:13-18 (1995)). The polysaccharide conjugate vaccines have the disadvantage of being costly to produce and manufacture in comparison with many other kinds of vaccines. There is also the possible risk of problems caused by the cross reactivity between GBS polysaccharides and sialic acid-containing human glycoproteins.

20

An alternative to polysaccharides as antigens is the use of protein antigens derived from GBS. Recent evidence suggest that the GBS surface associated proteins Rib and alpha C protein may be used to confer immunity to GBS infections in experimental model systems (Stalhammar-Carlemalm *et al.*, (1993) [*supra*], Larsson *et al.*, (1996)
25 [*supra*]). However these two proteins are not conserved in all serotypes of GBS which cause disease in humans. Assuming that these antigens would be immunogenic and elicit protective level responses in humans they would not confer protection against all infections as 10% of infectious *Group B streptococci* do not express Rib or C protein alpha.

30

5 This invention seeks to overcome the problem of vaccination against GBS by using a novel screening method specifically designed to identify those *Group B Streptococcus* genes encoding bacterial cell surface associated or secreted proteins (antigens). The proteins expressed by these genes may be immunogenic, and therefore may be useful in the prevention and treatment of *Group B Streptococcus* infection. For the purposes of this application, the term immunogenic means that these proteins will elicit a protective immune response within a subject. Using this novel screening method a number of genes encoding novel *Group B Streptococcus* proteins have been identified.

10 Thus in a first aspect, the present invention provides a *Group B Streptococcus* protein, having a sequence selected from those shown in figure 1, or fragments or derivatives thereof.

15 It will be apparent to the skilled person that proteins and polypeptides included within this group may be cell surface receptors, adhesion molecules, transport proteins, membrane structural proteins, and/or signalling molecules.

20 Alterations in the amino acid sequence of a protein can occur which do not affect the function of a protein. These include amino acid deletions, insertions and substitutions and can result from alternative splicing and/or the presence of multiple translation start sites and stop sites. Polymorphisms may arise as a result of the infidelity of the translation process. Thus changes in amino acid sequence may be tolerated which do not affect the proteins function.

25 Thus, the present invention includes derivatives or variants of the proteins, polypeptides, and peptides of the present invention which show at least 50% identity to the proteins, polypeptides and peptides described herein. Preferably the degree of sequence identity is at least 60% and preferably it is above 75%. More preferably still is it above 80%, 90% or even 95%.

30

The term identity can be used to describe the similarity between two polypeptide sequences. A software package well known in the art for carrying out this procedure is the CLUSTAL program. It compares the amino acid sequences of two polypeptides and finds the optimal alignment by inserting spaces in either sequence as appropriate.

- 5 The amino acid identity or similarity (identity plus conservation of amino acid type) for an optimal alignment can also be calculated using a software package such as BLASTx. This program aligns the largest stretch of similar sequence and assigns a value to the fit. For any one pattern comparison several regions of similarity may be found, each having a different score. One skilled in the art will appreciate that two
- 10 polypeptides of different lengths may be compared over the entire length of the longer fragment. Alternatively small regions may be compared. Normally sequences of the same length are compared for a useful comparison to be made.

- 15 Manipulation of the DNA encoding the protein is a particularly powerful technique for both modifying proteins and for generating large quantities of protein for purification purposes. This may involve the use of PCR techniques to amplify a desired nucleic acid sequence. Thus the sequence data provided herein can be used to design primers for use in PCR so that a desired sequence can be targeted and then amplified to a high degree.

- 20 Typically primers will be at least five nucleotides long and will generally be at least ten nucleotides long (e.g. fifteen to twenty-five nucleotides long). In some cases primers of at least thirty or at least thirty-five nucleotides in length may be used.

- 25 As a further alternative chemical synthesis may be used. This may be automated. Relatively short sequences may be chemically synthesised and ligated together to provide a longer sequence.

Thus in a further aspect, the present invention provides , a nucleic acid molecule comprising or consisting of a sequence which is:

- 5
- (i) any of the DNA sequences set out in figure 1 herein or their RNA equivalents;
 - (ii) a sequence which is complementary to any of the sequences of (i);
 - (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
 - (iv) a sequence which shows substantial identity with any of those of (i), (ii) and (iii); or
 - (v) a sequence which codes for a derivative or fragment of a nucleic acid molecule shown in figure 1.

10 The term identity can also be used to describe the similarity between two individual DNA sequences. The 'bestfit' program (Smith and Waterman, *Advances in applied Mathematics*, 482-489 (1981)) is one example of a type of computer software used to find the best segment of similarity between two nucleic acid sequences, whilst the GAP program enables sequences to be aligned along their whole length and finds the
15 optimal alignment by inserting spaces in either sequence as appropriate.

The term 'RNA equivalent' when used above indicates that a given RNA molecule has a sequence which is complementary to that of a given DNA molecule, allowing for the fact that in RNA 'U' replaces 'T' in the genetic code. The nucleic acid molecule may
20 be in isolated or recombinant form.

The nucleic acid molecule may be in an isolated or recombinant form. DNA constructs can readily be generated using methods well known in the art. These techniques are disclosed, for example in J. Sambrook *et al*, *Molecular Cloning 2nd Edition*, Cold
25 Spring Harbour Laboratory Press (1989). Modifications of DNA constructs and the proteins expressed such as the addition of promoters, enhancers, signal sequences, leader sequences, translation start and stop signals and DNA stability controlling regions, or the addition of fusion partners may then be facilitated.

Normally the DNA construct will be inserted into a vector which may be of phage or plasmid origin. Expression of the protein is achieved by the transformation or transfection of the vector into a host cell which may be of eukaryotic or prokaryotic origin. Such vectors and suitable host cells form yet further aspects of the present invention.

The *Group B Streptococcus* proteins (antigens) described herein can additionally be used to raise antibodies, or to generate affibodies. These can be used to detect *Group B Streptococcus*.

Thus in a further aspect the present invention provides, an antibody, affibody, or a derivative thereof which binds to any one or more of the proteins, polypeptides, peptides, fragments or derivatives thereof, as described herein.

Antibodies within the scope of the present invention may be monoclonal or polyclonal. Polyclonal antibodies can be raised by stimulating their production in a suitable animal host (e.g. a mouse, rat, guinea pig, rabbit, sheep, goat or monkey) when a protein as described herein, or a homologue, derivative or fragment thereof, is injected into the animal. If desired, an adjuvant may be administered together with the protein. Well-known adjuvants include Freund's adjuvant (complete and incomplete) and aluminium hydroxide. The antibodies can then be purified by virtue of their binding to a protein as described herein.

Monoclonal antibodies can be produced from hybridomas. These can be formed by fusing myeloma cells and spleen cells which produce the desired antibody in order to form an immortal cell line. Thus the well-known Kohler & Milstein technique (*Nature* 256 (1975)) or subsequent variations upon this technique can be used.

Techniques for producing monoclonal and polyclonal antibodies that bind to a particular polypeptide/protein are now well developed in the art. They are discussed in standard

immunology textbooks, for example in Roitt *et al*, *Immunology* second edition (1989), Churchill Livingstone, London.

5 In addition to whole antibodies, the present invention includes derivatives thereof which are capable of binding to proteins etc as described herein. Thus the present invention includes antibody fragments and synthetic constructs. Examples of antibody fragments and synthetic constructs are given by Dougall *et al* in *Tibtech* 12 372-379 (September 1994).

10 Antibody fragments include, for example, Fab, F(ab')₂ and Fv fragments. Fab fragments (These are discussed in Roitt *et al* [*supra*]). Fv fragments can be modified to produce a synthetic construct known as a single chain Fv (scFv) molecule. This includes a peptide linker covalently joining V_h and V_l regions, which contributes to the stability of the molecule. Other synthetic constructs that can be used include CDR peptides. These are
15 synthetic peptides comprising antigen-binding determinants. Peptide mimetics may also be used. These molecules are usually conformationally restricted organic rings that mimic the structure of a CDR loop and that include antigen-interactive side chains.

20 Synthetic constructs include chimaeric molecules. Thus, for example, humanised (or primatised) antibodies or derivatives thereof are within the scope of the present invention. An example of a humanised antibody is an antibody having human framework regions, but rodent hypervariable regions. Ways of producing chimaeric antibodies are discussed for example by Morrison *et al* in *PNAS*, 81, 6851-6855 (1984) and by Takeda *et al* in *Nature*. 314, 452-454 (1985).

25 Synthetic constructs also include molecules comprising an additional moiety that provides the molecule with some desirable property in addition to antigen binding. For example the moiety may be a label (e.g. a fluorescent or radioactive label). Alternatively, it may be a pharmaceutically active agent.
30

Affibodies are proteins which are found to bind to target proteins with a low dissociation constant. They are selected from phage display libraries expressing a segment of the target protein of interest (Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA, Department of Biochemistry and Biotechnology, Royal Institute of Technology (KTH), Stockholm, Sweden).

In a further aspect the invention provides an immunogenic composition comprising one or more proteins, polypeptides, peptides, fragments or derivatives thereof, or nucleotide sequences described herein. A composition of this sort may be useful in the treatment or prevention of *Group B Streptococcus* infection in subject. In a preferred aspect of the invention the immunogenic composition is a vaccine.

In other aspects the invention provides:

- i) Use of an immunogenic composition as described herein in the preparation of a medicament for the treatment or prophylaxis of *Group B Streptococcus* infection. Preferably the medicament is a vaccine.
- ii) A method of detection of *Group B Streptococcus* which comprises the step of bringing into contact a sample to be tested with at least one antibody, affibody, or a derivative thereof, as described herein.
- iii) A method of detection of *Group B Streptococcus* which comprises the step of bringing into contact a sample to be tested with at least one protein, polypeptide, peptide, fragments or derivatives as described herein.
- iv) A method of detection of *Group B Streptococcus* which comprises the step of bringing into contact a sample to be tested with at least one nucleic acid molecule as described herein.

- v) A kit for the detection of *Group B Streptococcus* comprising at least one antibody, affibody, or derivatives thereof, described herein.
- 5 vi) A kit for the detection of *Group B Streptococcus* comprising at least one *Group B Streptococcus* protein, polypeptide, peptide, fragment or derivative thereof, as described herein.
- vii) A kit for the detection of *Group B Streptococcus* comprising at least one nucleic acid of the invention.

10

As described previously, the novel proteins described herein are identified and isolated using a novel screening method which specifically identifies those *Group B Streptococcus* genes encoding bacterial cell envelope associated or secreted proteins.

15 The information necessary for the secretion/export of proteins has been extensively studied in bacteria. In the majority of cases, export requires a signal peptide positioned at the N-terminus of the precursor protein to target the precursor to translocation sites on the membrane. During or after translocation, the signal peptide is removed by a signal peptidase. The ultimate destination/localisation of the protein, (whether it be
20 secreted extracellularly or anchored to the bacterium's surface, etc) is determined by sequences other than the leader peptide sequence.

25 Recently, Poquet *et al.* (*J. Bacteriol.* **180**:1904-1912 (1998)) have described a screening vector incorporating the *nuc* gene lacking its own signal leader as a reporter to identify exported proteins in Gram positive bacteria, and have applied it to *L. lactis*. Staphylococcal nuclease is a naturally secreted heat-stable, monomeric enzyme which has been efficiently expressed and secreted in a range of Gram positive bacteria (Shortle., *Gene* **22**:181-189 (1983), Kovacevic *et al.*, *J. Bacteriol.* **162**:521-528 (1985), Miller *et al.*, *J. Bacteriol.* **169**:3508-3514 (1987), Liebl *et al.*, *J. Bacteriol.*

174:1854-1861(1992), Le Loir *et al.*, *J. Bacteriol.* 176:5135-5139 (1994), Poquet *et al.*, 1998 [*supra*]). The screening vector (pFUN) contains the pAM β 1 replicon which functions in a broad host range of Gram-positive bacteria in addition to the ColE1 replicon that promotes replication in *Escherichia coli* and certain other Gram
5 negative bacteria. Unique cloning sites present in the vector can be used to generate transcriptional and translational fusions between cloned genomic DNA fragments and the open reading frame of the truncated *nuc* gene devoid of its own signal secretion leader. The *nuc* gene makes an ideal reporter gene because the secretion of nuclease can readily be detected using a simple and sensitive plate test: Recombinant colonies
10 secreting the nuclease develop a pink halo whereas control colonies remain white (Shortle, 1983 [*supra*], Le Loir *et al.*, 1994 [*supra*]).

A direct screen to identify and isolate DNA encoding bacterial cell envelope associated or secreted proteins (antigens).in pathogenic bacteria has been developed by
15 the present inventors which utilises a vector-system (pTREP1 expression vector) in *Lactococcus lactis* that specifically detects DNA sequences which are adjacent to, and associated with DNA encoding surface proteins from *Group B Streptococcus*. The screening vector also incorporates the *nuc* gene encoding the *Staphylococcal* nuclease as a reporter gene.

20 Only the part of the *nuc* gene encoding the mature nuclease protein (minus its signal peptide sequence) is cloned into the pTREP1 expression vector in *L. lactis*. In this form, the *nuc*-encoded nuclease cannot be secreted even when expressed intracellularly. The reporter vector is then randomly combined with appropriately
25 digested genomic DNA from *Group B Streptococcus*, cloned into *L. lactis* and used as a screening system for sequences permitting the export of nuclease. In this way gene/partial gene sequences encoding exported proteins from *Group B Streptococcus* are isolated. Once a partial gene sequence is obtained, full length sequences encoding exported proteins can readily be obtained using techniques well known in the art.

In possessing a promoter, the pTREP1-*nuc* vectors differ from the pFUN vector described by Poquet *et al.* (1998) [*supra*], which was used to identify *L. lactis* exported proteins by screening directly for *Nuc* activity directly in *L. lactis*. As the pFUN vector does not contain a promoter upstream of the *nuc* open reading frame the cloned genomic DNA fragment must also provide the signals for transcription in addition to those elements required for translation initiation and secretion of *Nuc*. This limitation may prevent the isolation of genes that are distant from a promoter for example genes which are within polycistronic operons. Additionally there can be no guarantee that promoters derived from other species of bacteria will be recognised and functional in *L. lactis*. Certain promoters may be under stringent regulation in the natural host but not in *L. lactis*. In contrast, the presence of the P1 promoter in the pTREP1-*nuc* series of vectors ensures that promoterless DNA fragments (or DNA fragments containing promoter sequences not active in *L. lactis*) may still be transcribed. Thus yet another advantage of this invention is that genes missed in other screening methods may be identified.

Hence in a further aspect the present invention provides a method of screening for DNA encoding bacterial cell wall associated or surface antigens in gram positive bacteria comprising the steps of:

- combining a reporter vector including the nucleotide sequence encoding the mature form of the staphylococcus nuclease gene and an upstream promoter region with DNA from a gram positive bacteria.
- transforming the resultant vector into *Lactococcus lactis* cells.
- assaying for the secretion of *staphylococcus* nuclease protein in the transformed cells.

Preferably, the reporter vector is one of the pTREP1-*nuc* vectors shown in figure 4.

In another aspect, the present invention provides a vector as shown in figure 4 for use in screening for DNA encoding exported or surface antigens in gram positive bacteria. Examples of gram positive bacteria which may be screened include *Group B Streptococcus*, *Streptococcus pneumoniae*, *Staphylococcus aureus* or pathogenic
5 *Group A Streptococci*.

Given that the inventors have identified a group of important proteins, such proteins are potential targets for anti-microbial therapy. It is necessary, however, to determine whether each individual protein is essential for the organism's viability.
10 Thus, the present invention also provides a method of determining whether a protein or polypeptide as described herein represents a potential anti-microbial target which comprises inactivating said protein and determining whether *Group B Streptococcus* is still viable.

15 A suitable method for inactivating the protein is to effect selected gene knockouts, ie prevent expression of the protein and determine whether this results in a lethal change. Suitable methods for carrying out such gene knockouts are described in Li *et al* , *P.N.A.S.*, **94**:13251-13256 (1997) and Kolkman *et al*

20 In a final aspect the present invention provides the use of an agent capable of antagonising, inhibiting or otherwise interfering with the function or expression of a protein or polypeptide of the invention in the manufacture of a medicament for use in the treatment or prophylaxis of *Group B Streptococcus* infection.

25 The invention will now be described by means of the following example which should not in any way be construed as limiting. The examples refer to the figures in which

Fig 1: (A) Shows a number of full length nucleotide sequences encoding antigenic *Group B Streptococcus* proteins. (B) Shows the corresponding amino acid sequences.

5 Fig 2: Shows a number of oligonucleotide primers used in the screening process

nucS1 primer designed to amplify a mature form of the nuc A gene

nucS2- primer designed to amplify a mature form of the nuc A gene.

nucS3 primer designed to amplify a mature form of the nuc A gene

10 **nucR** primer designed to amplify a mature form of the nuc A gene

nucseq primer designed to sequence DNA cloned into the pTREP-Nuc vector

pTREPF nucleic acid sequence containing recognition site for ECORV. Used for cloning fragments into pTREX7.

15 **pTREPR** nucleic acid sequence containing recognition site for BAMH1. Used for cloning fragments into pTREX7.

PUCF forward sequencing primer, enables direct sequencing of cloned DNA fragments.

VR example of gene specific primer used to obtain further antigen DNA sequence by the method of DNA walking.

20 **V1** example of gene specific primer used to obtain further antigen DNA sequence by the method of DNA walking.

V2 example of gene specific primer used to obtain further antigen DNA sequence by the method of DNA walking.

25

Fig 3: (i) Schematic presentation of the nucleotide sequence of the unique gene cloning site immediately upstream of the mature *nuc* gene in pTREP1-*nuc1*, pTREP1-*nuc2* and pTREP1-*nuc3*. Each of the pTREP-*nuc* vectors contain an

EcoRV (a *Sma*I site in pTREP1-*nuc*2) cleavage site which allows cloning of genomic DNA fragments in 3 different frames with respect to the mature *nuc* gene.

(ii) A physical and genetic summary map of the pTREP1-*nuc* vectors. The expression cassette incorporating *nuc*, the macrolides, lincosamides and streptogramin B (MLS) resistance determinant, and the replicon (rep) *Ori*-pAM β 1 are depicted (not drawn to scale).

(iii) Schematic presentation of the expression cassette showing the various sequence elements involved in gene expression and location of unique restriction endonuclease sites (not drawn to scale).

Fig 4: Shows the results of various DNA vaccine trials;

Fig 5: Shows the results of a second group of DNA vaccine trials;

Figs 6-11: Show various Southern Blot analyses of different Group B streptococcus strains.

Example 1

Thus far more than 100 gene/partial gene sequences putatively encoding exported proteins in *S. agalactiae* have been identified using the nuclease screening system of the invention. These have been further analysed to remove artifacts. The nucleotide sequences of genes identified using the screening system has been characterised using a number of parameters described below. All of these sequences are novel in that they have not been described previously.

1. All putative surface proteins are analysed for leader/signal peptide sequences. Bacterial signal peptide sequences share a common design. They are characterised by a short positively charged N-terminus (N region) immediately preceding a stretch of hydrophobic residues (central portion-h region) followed by a

more polar C-terminal portion which contains the cleavage site (c-region). Computer software is used to perform hydropathy profiling of putative proteins (Marcks, *Nuc. Acid. Res.*, 16:1829-1836 (1988)) which is used to identify the distinctive hydrophobic portion (h-region) typical of leader peptide sequences. In addition, the presence/absence of a potential ribosomal binding site (Shine-Dalgarno sequence required for translation) is also noted.

2. All putative surface protein sequences are used to search the OWL sequence database which includes a translation of the GENBANK and SWISSPROT database.. This allows identification of similar sequences which may have been previously characterised not only at the sequence level but at a functional level. It may also provide information indicating that these proteins are indeed surface related and not artifacts.

3. Putative *S. agalactiae* surface proteins are also be assessed for their novelty. Some of the identified proteins may or may not possess a typical leader peptide sequence and may not show homology with any DNA/protein sequences in the database. Indeed these proteins may indicate the primary advantage of our screening method, i.e. isolating atypical surface-related proteins, which would have been missed in all previously described screening protocols.

The construction of three reporter vectors and their use in *L. lactis* to identify and isolate genomic DNA fragments from pathogenic bacteria encoding secreted or surface associated proteins is now described.

Construction of the pTREP1-*nuc* series of reporter vectors

(a) Construction of expression plasmid pTREP1

The pTREP1 plasmid is a high-copy number (40-80 per cell) theta-replicating gram positive plasmid, which is a derivative of the pTREX plasmid which is itself a derivative of the the previously published pIL253 plasmid. pIL253 incorporates the

broad Gram-positive host range replicon of pAM β 1 (Simon and Chopin, 1988) and is non-mobilisable by the *L lactis* sex-factor. pIL253 also lacks the *tra* function which is necessary for transfer or efficient mobilisation by conjugative parent plasmids exemplified by pIL501. The Enterococcal pAM β 1 replicon has previously been transferred to various species including *Streptococcus*, *Lactobacillus* and *Bacillus* species as well as *Clostridium acetobutylicum*, (LeBlanc *et al.*, *Proceedings of the National Academy of Science USA* 75:3484-3487 (1978)) indicating the potential broad host range utility. The pTREP1 plasmid represents a constitutive transcription vector.

The pTREX vector was constructed as follows. An artificial DNA fragment containing a putative RNA stabilising sequence, a translation initiation region (TIR), a multiple cloning site for insertion of the target genes and a transcription terminator was created by annealing 2 complementary oligonucleotides and extending with Tfl DNA polymerase. The sense and anti-sense oligonucleotides contained the recognition sites for NheI and BamHI at their 5' ends respectively to facilitate cloning. This fragment was cloned between the XbaI and BamHI sites in pUC19NT7, a derivative of pUC19 which contains the T7 expression cassette from pLET1 (Wells *et al.*, *J. Appl. Bacteriol.* 74:629-636 (1993)) cloned between the EcoRI and HindIII sites. The resulting construct was designated pUCLEX. The complete expression cassette of pUCLEX was then removed by cutting with HindIII and blunting followed by cutting with EcoRI before cloning into EcoRI and SacI (blunted) sites of pIL253 to generate the vector pTREX (Wells and Schofield, *In Current advances in metabolism, genetics and applications-NATO ASI Series. H* 98:37-62. (1996)). The putative RNA stabilising sequence and TIR are derived from the *Escherichia coli* T7 bacteriophage sequence and modified at one nucleotide position to enhance the complementarity of the Shine Dalgarno (SD) motif to the ribosomal 16s RNA of *Lactococcus lactis* (Schofield *et al.* pers. coms. University of Cambridge Dept. Pathology.).

A *Lactococcus lactis* MG1363 chromosomal DNA fragment exhibiting promoter activity which was subsequently designated P7 was cloned between the EcoRI and BglII sites present in the expression cassette, creating pTREX7. This active promoter region had been previously isolated using the promoter probe vector pSB292 (Waterfield *et al.*, *Gene* 165:9-15 (1995)). The promoter fragment was amplified by PCR using the Vent DNA polymerase according to the manufacturer.

The pTREP1 vector was then constructed as follows. An artificial DNA fragment which included a transcription terminator, the forward pUC sequencing primer, a promoter multiple cloning site region and a universal translation stop sequence was created by annealing two overlapping partially complementary synthetic oligonucleotides together and extending with sequenase according to manufacturers instructions. The sense and anti-sense (pTREP_F and pTREP_R) oligonucleotides contained the recognition sites for EcoRV and BamHI at their 5' ends respectively to facilitate cloning into pTREX7. The transcription terminator was that of the *Bacillus penicillinase* gene, which has been shown to be effective in *Lactococcus* (Jos *et al.*, *Applied and Environmental Microbiology* 50:540-542 (1985)). This was considered necessary as expression of target genes in the pTREX vectors was observed to be leaky and is thought to be the result of cryptic promoter activity in the origin region (Schofield *et al.* pers. coms. University of Cambridge Dept. Pathology.). The forward pUC primer sequencing was included to enable direct sequencing of cloned DNA fragments. The translation stop sequence which encodes a stop codon in 3 different frames was included to prevent translational fusions between vector genes and cloned DNA fragments. The pTREX7 vector was first digested with EcoRI and blunted using the 5' - 3' polymerase activity of T4 DNA polymerase (NEB) according to manufacturer's instructions. The EcoRI digested and blunt ended pTREX7 vector was then digested with Bgl II thus removing the P7 promoter. The artificial DNA fragment derived from the annealed synthetic oligonucleotides was then digested with EcoRV and Bam HI and cloned into the EcoRI(blunted)-Bgl II digested pTREX7 vector to

generate pTREP. A *Lactococcus lactis* MG1363 chromosomal promoter designated P1 was then cloned between the EcoRI and BglII sites present in the pTREP expression cassette forming pTREP1. This promoter was also isolated using the promoter probe vector pSB292 and characterised by Waterfield *et al.*, (1995) [*supra*]. The P1 promoter fragment was originally amplified by PCR using vent DNA polymerase according to manufacturers instructions and cloned into the pTREP as an EcoRI-BglII DNA fragment. The EcoRI-BglII P1 promoter containing fragment was removed from pTREP1 by restriction enzyme digestion and used for cloning into pTREP (Schofield *et al.* pers. coms. University of Cambridge, Dept. Pathology.).

(b) PCR amplification of the *S. aureus* nuc gene.

The nucleotide sequence of the *S. aureus* nuc gene (EMBL database accession number V01281) was used to design synthetic oligonucleotide primers for PCR amplification.

The primers were designed to amplify the mature form of the nuc gene designated nucA which is generated by proteolytic cleavage of the N-terminal 19 to 21 amino acids of the secreted propeptide designated Snase B (Shortle, 1983 [*supra*]). Three sense primers (nucS1, nucS2 and nucS3, shown in figure 3) were designed, each one having a blunt-ended restriction endonuclease cleavage site for EcoRV or SmaI in a different reading frame with respect to the nuc gene. Additionally BglII and BamHI were incorporated at the 5' ends of the sense and anti-sense primers respectively to facilitate cloning into BamHI and BglII cut pTREP1. The sequences of all the primers are given in figure 3. Three nuc gene DNA fragments encoding the mature form of the nuclease gene (NucA) were amplified by PCR using each of the sense primers combined with the anti-sense primer. The nuc gene fragments were amplified by PCR using *S. aureus* genomic DNA template, Vent DNA Polymerase (NEB) and the conditions recommended by the manufacturer. An initial denaturation step at 93°C for 2 min was followed by 30 cycles of denaturation at 93°C for 45 sec, annealing at 50°C for 45 seconds, and extension 73°C for 1 minute and then a final 5 min extension step

at 73°C. The PCR amplified products were purified using a Wizard clean up column (Promega) to remove unincorporated nucleotides and primers.

(c) Construction of the pTREP1-*nuc* vectors

The purified *nuc* gene fragments described in section b were digested with Bgl II and BamHI using standard conditions and ligated to BamHI and BglII cut and dephosphorylated pTREP1 to generate the pTREP1-*nuc*1, pTREP1-*nuc*2 and pTREP1-*nuc*3 series of reporter vectors. These vectors are described in figure 4.

General molecular biology techniques were carried out using the reagents and buffers supplied by the manufacturer or using standard techniques (Sambrook and Maniatis, Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbour (1989)). In each of the pTREP1-*nuc* vectors the expression cassette comprises a transcription terminator, lactococcal promoter P1, unique cloning sites (BglII, EcoRV or SmaI) followed by the mature form of the *nuc* gene and a second transcription terminator. Note that the sequences required for translation and secretion of the *nuc* gene were deliberately excluded in this construction. Such elements can only be provided by appropriately digested foreign DNA fragments (representing the target bacterium) which can be cloned into the unique restriction sites present immediately upstream of the *nuc* gene.

(d) Screening for secreted proteins in *Group B Streptococcus*.

Genomic DNA isolated from and *Group B Streptococcus* (*S. agalactiae*) was digested with the restriction enzyme Tru9I. This enzyme which recognises the sequence 5'-TTAA-3' was used because it cuts A/T rich genomes efficiently and can generate random genomic DNA fragments within the preferred size range (usually averaging 0.5 - 1.0 kb). This size range was preferred because there is an increased probability that the P1 promoter can be utilised to transcribe a novel gene sequence. However, the P1 promoter may not be necessary in all cases as it is possible that many Streptococcal promoters are recognised in *L. lactis*. DNA fragments of different size ranges were

purified from partial Tru9I digests of and *S. agalactiae* genomic DNA. As the Tru 9I restriction enzyme generates staggered ends the DNA fragments had to be made blunt ended before ligation to the EcoRV or SmaI cut pTREP1-*nuc* vectors. This was achieved by the partial fill-in enzyme reaction using the 5'-3' polymerase activity of Klenow enzyme. Briefly Tru9I digested DNA was dissolved in a solution (usually between 10-20 μ l in total) supplemented with T4 DNA ligase buffer (New England Biolabs; NEB) (1X) and 33 μ M of each of the required dNTPs, in this case dATP and dTTP. Klenow enzyme was added (1 unit Klenow enzyme (NEB) per μ g of DNA) and the reaction incubated at 25°C for 15 minutes. The reaction was stopped by incubating the mix at 75°C for 20 minutes. EcoRV or SmaI digested pTREP-*nuc* plasmid DNA was then added (usually between 200-400 ng). The mix was then supplemented with 400 units of T4 DNA ligase (NEB) and T4 DNA ligase buffer (1X) and incubated overnight at 16°C. The ligation mix was precipitated directly in 100% Ethanol and 1/10 volume of 3M sodium acetate (pH 5.2) and used to transform *L. lactis* MG1363 (Gasson, *J. Bacteriol.* 154:1-9 (1983)). Alternatively, the gene cloning site of the pTREP-*nuc* vectors also contains a BglII site which can be used to clone for example Sau3AI digested genomic DNA fragments.

L. lactis transformant colonies were grown on brain heart infusion agar and nuclease secreting (*Nuc*⁺) clones were detected by a toluidine blue-DNA-agar overlay (0.05 M Tris pH 9.0, 10 g of agar per litre, 10 g of NaCl per liter, 0.1 mM CaCl₂, 0.03% wt/vol. salmon sperm DNA and 90 mg of Toluidine blue O dye) essentially as described by Shortle, 1983 [*supra*], and Le Loir *et al.*, 1994 [*supra*]). The plates were then incubated at 37°C for up to 2 hours. Nuclease secreting clones develop an easily identifiable pink halo. Plasmid DNA was isolated from *Nuc*⁺ recombinant *L. lactis* clones and DNA inserts were sequenced on one strand using the *NucSeq* sequencing primer described in figure 3, which sequences directly through the DNA insert.

Whilst the example described above related specifically to *Group B Streptococcus*, it will be apparent to one skilled in the art that the same screening technique may be used to detect exported and secreted proteins in other gram positive bacteria, for example *Streptococcus pneumoniae*.

5 **Example 2; Screening Group B Streptococcal derived genes in DNA vaccination experiments.**

pcDNA3.1+ as a DNA vaccine vector

10 The commercially available pcDNA3.1+ plasmid (Invitrogen), referred to as pcDNA3.1 henceforth, was used as a vector in all DNA immunisation experiments involving gene targets derived using the LEEP system. pcDNA 3.1 is designed for high-level stable and transient expression in mammalian cells and has been used widely and successfully as a host vector to test candidate genes from a variety of pathogens in DNA vaccination experiments (Zhang *et al.*, 1997; Kurar and Splitter,
15 1997; Anderson *et al.*, 1996).

20 The vector possesses a multiple cloning site which facilitates the cloning of multiple gene targets downstream of the human cytomegalovirus (CMV) immediate-early promoter/enhancer which permits efficient, high-level expression of the target gene in a wide variety of mammalian cells and cell types including both muscle and immune cells. This is important for optimal immune response as it remains unknown as to which cells types are most important in generating a protective response *in vivo*. The plasmid also contains the ColE1 origin of replication which allows convenient high-copy number replication and growth in *E. coli* and the ampicillin resistance gene (B-lactamase) for selection in *E. coli*. In addition pcDNA 3.1 possesses a T7
25 promoter/priming site upstream of the MCS which allows for *in vitro* transcription of a cloned gene in the sense orientation.

30 **Preparation of DNA vaccines**

Oligonucleotide primers were designed for each individual gene of interest derived using the LEEP system. Each gene was examined thoroughly, and where possible, primers were designed such that they targeted that portion of the gene thought to

5 encode only the mature portion of the protein (**APPENDIX I**). It was hoped that expressing those sequences that encode only the mature portion of a target gene protein, would facilitate its correct folding when expressed in mammalian cells. For example, in the majority of cases primers were designed such that putative N-terminal signal peptide sequences would not be included in the final amplification product to be cloned into the pcDNA3.1 expression vector. The signal peptide directs the polypeptide precursor to the cell membrane via the protein export pathway where it is normally cleaved off by signal peptidase I (or signal peptidase II if a lipoprotein). Hence the signal peptide does not make up any part of the mature protein whether it be displayed on the bacterium's surface or secreted. Where a N-terminal leader peptide sequence was not immediately obvious, primers were designed to target the whole of the gene sequence for cloning and ultimately, expression in pcDNA3.1.

15 All forward and reverse oligonucleotide primers incorporated appropriate restriction enzyme sites to facilitate cloning into the pcDNA3.1 MCS region. All forward primers were also designed to include the conserved Kozak nucleotide sequence 5'-gccacc-3' immediately upstream of an 'atg' translation initiation codon in frame with the target gene insert. The Kozak sequence facilitates the recognition of initiator sequences by eukaryotic ribosomes. Typically, a forward primer incorporating a BamH1 restriction enzyme site the primer would begin with the sequence 5'-cgggatccgccaccatg-3', followed by a sequence homologous to the 5' end of that part of a gene being amplified. All reverse primers incorporated a Not I restriction enzyme site sequence 5'-ttgcgccgc-3'. All gene-specific forward and reverse primers were designed with compatible melting temperatures to facilitate their amplification.

25 All gene targets were amplified by PCR from *S. agalactiae* genomic DNA template using Vent DNA polymerase (NEB) or rTth DNA polymerase (PE Applied Biosystems) using conditions recommended by the manufacturer. A typical amplification reaction involved an initial denaturation step at 95°C for 2 minutes followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at the appropriate melting temperature for 30 seconds, and extension at 72°C for 1 minute (1 minute per kilobase of DNA being amplified). This was followed by a final extension period at 72°C for 10 minutes. All PCR amplified products were extracted once with phenol chloroform (2:1:1) and once with chloroform (1:1) and ethanol precipitated.

Specific DNA fragments were isolated from agarose gels using the QIAquick Gel Extraction Kit (Qiagen). The purified amplification gene DNA fragments were digested with the appropriate restriction enzymes and cloned into the pcDNA3.1 plasmid vector using *E. coli* as a host. Successful cloning and maintenance of genes was confirmed by restriction mapping and by DNA sequencing. Recombinant plasmid DNA was isolated on a large scale (>1.5 mg) using Plasmid Mega Kits (Qiagen).

It was decided to include the *S. agalactiae rib* gene as a positive control in at least one trial of DNA immunisation experiments. Rabbit antiserum against the Rib protein (Stalhammar-Carleman *et al.*, 1993) and highly purified preparations of the Rib protein itself (Larsson *et al.*, 1999; Larsson *et al.*, 1996) have been shown to confer protection against lethal infection with strains expressing the antigen. All serotype III strains have been shown to express the Rib antigen and Southern blot analysis performed in the laboratory has confirmed that *S. agalactiae* serotype III (strain 97/0099) does contain the *rib* gene, hence the *rib* gene as part of a DNA vaccine would represent a potential positive control for all DNA immunisation experiments. Oligonucleotide primers were designed (**Appendix I**) that targeted only the mature portion of the *rib* gene and which included appropriate restriction enzyme sites for cloning into pcDNA3.1. *rib* was amplified using rTth DNA polymerase (PE Applied Biosystems) using conditions recommended by the manufacturer. Conditions for cloning were similar to that described previously.

Preparation of a *S. agalactiae* standard inoculum

Strain validation

S. agalactiae serotype III (strain 97/0099) is a recent clinical isolate derived from the cerebral spinal fluid of a new born baby suffering from meningitis. This haemolytic strain of Group B Streptococcus was epidemiologically tested and validated at the Respiratory and Systemic Infection Laboratory, PHLS Central Public health laboratory, 61 Collindale Avenue, London NW9 5HT. The strain was subcultured only twice prior to its arrival in the laboratory. Upon its arrival on a agar slope, a sweep of 4-5 colonies was immediately used to inoculate a Todd Hewitt/5% horse blood broth which was incubated overnight statically at 37 °C. 0.5 ml aliquots of this overnight culture were then used to make 20% glycerol stocks of the bacterium for long term

storage at -70 °C. Glycerol stocks were streaked on Todd Hewitt/5% horse blood agar plates to confirm viability.

5 ***In vivo* passaging of Group B Streptococcus**

A frozen culture (described under strain validation) of *S. agalactiae* serotype III (strain 97/0099) was streaked to single colonies on Todd-Hewitt/5% blood agar plates which were incubated overnight at 37°C. A sweep of 4-5 colonies was used to inoculate a Todd Hewitt/5% horse blood broth which was again incubated overnight. A 0.5 ml aliquot from this overnight culture was used to inoculate a 50 ml Todd Hewitt broth (1:100 dilution) which was incubated at 37 °C. 10-fold serial dilutions of the overnight culture were made (since virulence of this strain was unknown) and each were passaged intra-peritoneally (IP) in CBA/ca mice in duplicate. Viable counts were performed on the various inocula used in the passage. Groups of mice were challenged with various concentrations of the pathogen ranging from 10^8 to 10^4 colony forming units (cfu). Mice that developed symptoms were terminally anaesthetized and cardiac punctures were performed (Only mice that had been challenged with the highest doses, i.e. 1×10^8 cfu, developed symptoms). The retrieved unclotted blood was used to inoculate directly a 50ml serum broth (Todd Hewitt/20% inactivated foetal calf serum). The culture was constantly monitored and allowed to grow to late logarithmic phase. The presence of blood in the medium interfered with OD₆₀₀ readings as it was being increasingly lysed with increasing growth of the bacterium, hence the requirement to constantly monitor the culture. Upon reaching late logarithmic phase/early stationary phase, the culture was transferred to a fresh 50 ml tube in order to exclude dead bacterial cells and remaining blood cells which would have sedimented at the bottom of the tube. 0.5 ml aliquots were then transferred to sterile cryovials, frozen in liquid nitrogen and stored at -70 °C. A viable count was carried out on a single standard inoculum aliquot in order to determine bacterial numbers. This was determined to be approximately 5×10^8 cfu per ml.

30

Intra-peritoneal Challenge and virulence testing of Group B Streptococcus standard inoculum

To determine if the standard inoculum was suitably virulent for use in a vaccine trial, challenges were carried out using a dose range. Frozen standard inoculum strain

aliquots were allowed to thaw at room temperature. From viable count data the number of cfu per ml was already known for the standard inoculum. Initially, serial dilutions of the standard inoculum were made in Todd Hewitt broth and mice were challenged intra-peritoneally with doses ranging from 1×10^8 to 1×10^4 cfu in a 500 μ l volume of Todd Hewitt broth. The survival times of mouse groups injected with different doses of the bacterium were compared. The standard inoculum was determined to be suitably virulent and a dose of 1×10^6 cfu was considered close to optimal for further use in vaccine trials. Further optimisation was carried out by comparing mice challenged with doses ranging between 5×10^5 and 5×10^6 cfu. The optimal dose was estimated to be approximately 2.5×10^6 cfu. This represented a 100% lethal dose and was repeatedly consistent with end-points as determined by survival times being clustered within a narrow time-range. Throughout all these experiments, challenged mice were constantly monitored to clarify symptoms, stages of symptom development as well as calculating survival times.

Vaccine trials

Vaccine trials in mice were accomplished by the administration of DNA to 6 week old CBA/ca mice (Harlan, UK). Mice to be vaccinated were divided into groups of six and each group were immunised with recombinant pcDNA3.1 plasmid DNA containing a specific target-gene sequence derived using the LEEP system. A total of 100 μ g of DNA in Dulbecco's PBS (Sigma) was injected intramuscularly into the tibialis anterior muscle of both hind legs. Four weeks later this procedure was repeated using the same amount of DNA. For comparison, control mice groups were included in all vaccine trials. These control groups were either not DNA-vaccinated or were immunised with non-recombinant pcDNA3.1 plasmid DNA only, using the same time course described above. Four weeks after the second immunisation, all mice groups were challenged intra-peritoneally with a lethal dose of *S. agalactiae* serotype III (strain 97/0099). The actual number of bacteria administered was determined by plating serial dilutions of the inoculum on Todd-Hewitt/5% blood agar plates. All mice were killed 3 or 4 days after infection. During the infection process, challenged mice were monitored for the development of symptoms associated with the onset of *S. agalactiae* induced-disease. Typical symptoms in an appropriate order included piloerection, an increasingly hunched posture, discharge from eyes, increased lethargy and reluctance to move which was often the result of apparent paralysis in the lower body/hind leg region. The

latter symptoms usually coincided with the development of a moribund state at which stage the mice were culled to prevent further suffering. These mice were deemed to be very close to death, and the time of culling was used to determine a survival time for statistical analysis. Where mice were found dead, a survival time was calculated by averaging the time when a particular mouse was last observed alive and the time when found dead, in order to determine a more accurate time of death.

Interpretation of Results

A positive result was taken as any DNA sequence that was cloned and used in challenge experiments as described above and gave protection against that challenge. DNA sequences were determined to be protective;

-if that DNA sequence gave statistically significant protection (to a 95% confidence level ($p > 0.05$) as determined using the Mann-Whitney U test.

-if that DNA sequence was marginal or non-significant using Mann-Whitney but showed some protective features. For example, one or more outlying mice may survive for significantly longer time periods when compared with control mice. Alternatively, the time to first death may also be prolonged when compared to counterpart mice in control groups.

It is acceptable to allow marginal or non-significant results to be considered as potential positives when it is possible that the clarity of some results may be affected by problems associated with the administration of the DNA vaccine. Indeed, much varied survival times may reflect different levels of immune response between different members of a given group.

Results

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 1 (Figure 4a)

	Mean Survival Times (hours)				
	pcDNA3.1	17(ID-8)	18(ID-9)	20(ID-25)	rib
1	26.833	14.916	27.750	30.500	88.666

2	42.333	94.000 (T)	34.333	33.333	28.166
3	47.916	45.166	41.083	34.083	37.250
4	28.333	30.750	47.083	23.500	37.250
5	42.333	74.666	94.000 (T)	94.000 (T)	94.000 (T)
6	25.333	25.000	26.166	30.500	45.750
Mean	37.549	51.899	48.849	43.083	57.066
sd	9.3943	32.214	26.257	28.768	31.556
p value 1		0.4049	0.4049	0.5000	0.1481
p value 2	> 39.0	> 39.0	> 39.0	> 39.0	

(T) - terminated at conclusion of experiment but showing symptoms of infection.

5 **p value 1** refers to statistical significance when compared to pcDNA3.1 controls.

p value 2 refers to statistical significance when compared to rib positive control.

10

All DNA vaccine's showed a pattern of protection similar to that obtained with the rib DNA vaccine, which was initially used as a positive control.

15

17 (ID-8)

20

Mice immunised with the '17 (ID-8)' DNA vaccine did not show significantly longer survival times when compared with the unvaccinated control group. However, there are two outlying mice one of which survived the term of the experiment despite developing symptoms. The group also exhibited a much wider range of survival times reflected by a mean survival value which is approximately 14 hours higher than that demonstrated by the unvaccinated control group.

25

18 (ID-9)

5 Mice immunised with the '18 (ID-9)' DNA vaccine did not show significantly longer survival times when compared with the unvaccinated control group. However, there is one outlying mouse which survived the term of the experiment despite developing symptoms.

20 (ID-25)

10 Mice immunised with the '20 (ID-25)' DNA vaccine did not show significantly longer survival times when compared with the unvaccinated control group. However, there was one outlying mouse which survived the term of the experiment despite developing symptoms.

15 **Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 2 (Figure 4b)**

	Mean Survival Times (hours)			
	pcDNA	UnVacc	22(ID-10)	28(ID-13)
1	45.000	27.916	44.666	72.000 (T)
2	37.333	45.083	51.416	33.000
3	37.333	37.583	40.791	36.083
4	35.291	24.583	44.666	72.000 (T)
5	24.333	37.583	36.916	49.166
6	45.000	33.166	57.833	36.083
Mean	35.858	34.549	43.691	52.449
sd	7.4342	8.2567	5.3825	18.850
p value 1		> 39.0	0.1137	0.2340
p value 2	0.4679		0.0323	0.1137

20 (T) - terminated at conclusion of experiment but showing symptoms of infection.

p value 1 refers to statistical significance when compared to pcDNA3.1 controls.

p value 2 refers to statistical significance when compared to unvaccinated controls.

5 There was no significant difference in the survival times exhibited by the pcDNA3.1 and unvaccinated control groups. This is confirmed by their very similar mean survival times of 35.858 hours (pcDNA3.1) and 34.166 hours (Unvaccinated).

10

22 (ID-10)

Mice immunised with the '22 (ID-10)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group but not when compared with the pcDNA3.1 control group. In addition, the time to first death in this group was prolonged by approximately 12 hours when compared to the pcDNA3.1 and unvaccinated control groups. The mean survival time of 43.691 hours is also considerably higher than that determined for both control groups.

20

28 (ID-13)

Mice immunised with the '28 (ID-13)' DNA vaccine did not show significantly longer survival times when compared with the pcDNA3.1 and unvaccinated control groups. However there are three outlying mice, two of which survived the term of the experiment despite showing symptoms. In addition, the time to first death in this group was prolonged by approximately 9 hours when compared to the pcDNA3.1 and unvaccinated control groups. The mean survival time of 52.449 hours is also considerably higher than that determined for both control groups, as well demonstrating a wider range of survival times.

30

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 3 (Figure 4c)

35

	Mean Survival Times (hours)				
	UnVacc.	70(ID-42)	94(ID-48)	86(ID-47)	51(ID-37)
1	27.583	25.166	34.666	32.416	43.749
2	27.583	42.666	49.500	32.416	38.333
3	24.583	34.666	27.000	42.500	50.666
4	22.250	42.666	30.500	34.500	45.166
5	35.916	30.583	30.500	34.500	69.082
6	22.250	25.166	42.666	42.500	31.166
Mean	27.583	35.149	34.433	35.266	49.399
sd	5.1691	7.6444	8.8495	4.1758	11.846
p value		0.0628	0.0321	0.0153	0.0041

- 5 **p value** refers to statistical significance when compared to unvaccinated controls.

70 (ID-42)

- 10 Mice immunised with the '70 (ID-42)' DNA vaccine, marginally did not show significantly longer survival times when compared with the unvaccinated control group. However, the first death in this group is prolonged (by approximately 3 hours) when compared with the unvaccinated group. In addition, the group has a mean survival time
15 which is approximately 8 hours longer than the unvaccinated group.

94 (ID-48)

- 20 Mice immunised with the '94 (ID-48)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group.

86 (ID-47)

Mice immunised with the '86 (ID-47)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group.

5

51 (ID-37)

Mice immunised with the '51 (ID-37)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group.

10

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 4 (Figure 4d)

15

	Mean Survival Times (hours)	
	UnVacc	9(ID-6)
1	32.666	35.250
2	21.666	30.958
3	23.916	69.333
4	22.999	52.333
5	25.916	44.916
6	35.916	47.083
Mean	25.432	46.041
sd	4.3291	16.096
p value		0.0101

(T) - terminated at conclusion of experiment but showing symptoms of infection.

20

p value refers to statistical significance when compared to unvaccinated controls

9 (ID-6)

Mice immunised with the '39(ID-6)' DNA vaccine showed significantly longer survival times when compared with the control group.

5

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 6 (Figure 4e)

10

	Mean Survival Times (hours)				
	pcDNA	UnVacc	32 (ID-15)	39(ID-17)	57(40)
1	33.541	36.000	25.041	52.333	28.333
2	36.750	29.999	30.458	44.750	32.708
3	36.750	32.749	44.833	44.750	36.083
4	36.750	44.500	30.458	36.250	40.333
5	29.000	28.333	64.833	36.250	72.000 (T)
6	30.750	31.666	72.000 (T)	28.583	33.750
Mean	34.558	34.316	39.124	44.016	38.103
sd	3.4036	6.3921	16.140	13.833	12.986
p value 1		> 39.0	0.4043	0.1867	0.4044
p value 2	0.2862		0.2873	0.0458	0.2113

15 (T) - terminated at conclusion of experiment but showing symptoms of infection.

p value 1 refers to statistical significance when compared to pcDNA3.1 controls

p value 2 refers to statistical significance when compared to unvaccinated controls.

20

There was no significant difference in the survival times exhibited by the pcDNA3.1 and unvaccinated control groups. This is confirmed by their

very similar mean survival times of 34.558 hours (pcDNA3.1) and 34.316 hours (Unvaccinated).

5 **32 (ID-15)**

Mice immunised with the '32 (ID-15)' DNA vaccine did not show significantly longer survival times when compared with the pcDNA3.1 and unvaccinated control groups. However, the '32 (ID-15)' group has
10 two outlying mice one of which survived the term of the experiment despite showing symptoms. This group also exhibits a wide range of survival times.

15 **39 (ID-17)**

Mice immunised with the '39 (ID-17)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group but was not significant when compared with the pcDNA3.1 control group. The group has a considerably higher mean
20 survival time of 44.016 hours than that determined for either of the control groups.

25 **57 (ID-40)**

Mice immunised with the '32 (ID-15)' DNA vaccine did not show significantly longer survival times when compared with the pcDNA3.1 and unvaccinated control groups. However, the '32 (ID-15)' group has
30 one outlying mouse which survived the term of the experiment despite showing symptoms.

SURVIVAL DATA-SET B

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 2 (Figure 5a)

35

	Mean Survival Times (hours)		
	pcDNA	UnVacc	13(ID-72)
1	45.000	27.916	69.166
2	37.333	45.083	36.333
3	37.333	37.583	43.916
4	35.291	24.583	32.166
5	24.333	37.583	36.333
6	45.000	33.166	43.916
Mean	35.858	34.549	43.582
sd	7.4342	8.2567	14.917
p value 1		> 39.0	0.4679
p value 2	0.4679		0.1880

p value 1 refers to statistical significance when compared to pcDNA3.1 controls.

p value 2 refers to statistical significance when compared to unvaccinated controls.

There was no significant difference in the survival times exhibited by the pcDNA3.1 and unvaccinated control groups. This is confirmed by their very similar mean survival times of 35.858 hours (pcDNA3.1) and 34.166 hours (Unvaccinated).

13 (ID-72)

Mice immunised with the '13 (ID-72)' DNA vaccine did not show significantly longer survival times when compared with the pcDNA3.1 and unvaccinated control groups. However, there is one outlying mouse which survived approximately 24 hours longer than the longest surviving mice in the pcDNA3.1 and unvaccinated control groups respectively. In addition, the time to first death in this group was prolonged when

compared to the pcDNA3.1 and unvaccinated control groups. The mean survival time of 43.582 hours is considerably higher than that determined for both control groups.

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 3 (Figure 5b)

	Mean Survival Times (hours)		
	UnVacc	3-60(ID-65)	3-5(ID-66)
1	27.583	54.416	42.916
2	27.583	31.000	42.916
3	24.583	43.000	32.874
4	22.250	34.916	42.916
5	35.916	38.958	27.333
6	22.250	34.916	30.916
Mean	27.583	40.458	37.791
sd	5.1691	8.9959	7.2860
p value		0.0098	0.0215

p value refers to statistical significance when compared to unvaccinated controls.

3-60 (ID-65)

Mice immunised with the '3-60 (ID-65)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group.

5 **3-5 (ID-66)**

Mice immunised with the '3-5 (ID-66)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group.

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 4 (Figure 5c)

	Mean Survival Times (hours)			
	UnVacc	3-40(ID-67)	3-30(ID-68)	3-38(ID-69)
1	32.666	79.750	35.500	68.583
2	21.666	35.833	28.333	29.916
3	23.916	30.500	31.208	29.916
4	22.999	22.708	98.000 (T)	31.041
5	25.916	28.583	73.500	32.166
6	35.916	40.791	32.333	29.916
Mean	25.432	39.474	53.308	38.324
sd	4.3291	22.998	30.961	16.940
p value		0.1149	0.0463	0.1132

5

(T) - terminated at conclusion of experiment but showing symptoms of infection.

p value refers to statistical significance when compared to unvaccinated controls

10

3-40 (ID-67)

15

Mice immunised with the '3-40 (ID-67)' DNA vaccine did not show significantly longer survival times when compared with the unvaccinated control group. However, there is one outlying mouse which survived approximately 43 hours longer than the longest surviving mice in the unvaccinated control group.

20

3-30 (ID-68)

Mice immunised with the '3-30 (ID-68)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group.

3-38 (ID-69)

5 Mice immunised with the '2-19 (ID-73)' DNA vaccine did not show significantly longer survival times when compared with the unvaccinated control group. However, there was one outlying mouse which survived approximately 32 hours longer than the longest surviving mice in the unvaccinated control group. In addition, the time to first death was
 10 prolonged (by approximately 8 hours) when compared to the unvaccinated controls.

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 5 (Figure 5d)

	Mean Survival Times (hours)				
	UnVacc	141(ID-70)	3-20(ID-71)	2-19(ID-73)	3-6(ID-74)
1	27.833	47.500	36.166	36.166	44.666
2	45.666	52.833	44.833	49.833	36.000
3	45.666	49.333	26.750	55.833	75.416
4	34.333	46.250	36.166	68.583	36.000
5	34.333	47.500	55.916	33.333	55.916
6	45.666	36.500	44.833	30.583	36.000
Mean	37.566	48.683	37.234	48.749	49.599
sd	7.8558	2.5672	8.4103	14.497	16.587
p value		0.0101	0.5000	0.2336	0.1854

15 **p value** - refers to statistical significance when compared to unvaccinated controls.

20 **141 (ID-70)**

Mice immunised with the '141 (ID-70)' DNA vaccine exhibited significantly longer survival times when compared with the unvaccinated control group.

3-20 (ID-71)

Mice immunised with the '3-20 (ID-71)' DNA vaccine did not show significantly longer survival times when compared with the unvaccinated control group. However, there is one outlying mouse which survived approximately 10 hours longer than the longest surviving mice in the unvaccinated control group.

2-19 (ID-73)

Mice immunised with the '2-19 (ID-73)' DNA vaccine did not show significantly longer survival times when compared with the unvaccinated control group. However, there are three outlying mouse which survived approximately 4, 10 and 23 hours longer than the longest surviving mice in the unvaccinated control group. This is reflected in the higher mean survival time of 48.749 hours and a much wider range of survival times.

3-6 (ID-74)

Mice immunised with the '3-6 (ID-74)' DNA vaccine did not show significantly longer survival times when compared with the unvaccinated control group. However, there are three outlying mouse which survived approximately 4, 10 and 23 hours longer than the longest surviving mice in the unvaccinated control group. This is reflected in the higher mean survival time of 49.599 hours and a much wider range of survival times.

Statistical analysis of survival times - LEEP DNA immunisation and GBS challenge Trial 6 (Figure 5e)

	Mean Survival Times (hours)			
	pcDNA3.1	UnVacc.	3-51(ID-75)	3-56 (ID-76)

1	33.541	36.000	36.333	46.583
2	36.750	29.999	30.291	29.833
3	36.750	32.749	32.000	40.166
4	36.750	44.500	52.333	46.583
5	29.000	28.333	72.000 (T)	46.583
6	30.750	31.666	40.499	---
Mean	34.558	34.316	44.591	40.791
sd	3.4036	6.3921	16.615	7.9070
p value 1		> 39.0	0.1876	0.0386
p value 2	0.2862		0.0867	0.0587

(T) - terminated at conclusion of experiment but showing symptoms of infection.

5 **p value 1** refers to statistical significance when compared to pcDNA3.1 controls

p value 2 refers to statistical significance when compared to unvaccinated controls.

10 There was no significant difference in the survival times exhibited by the pcDNA3.1 and unvaccinated control groups. This is confirmed by their very similar mean survival times of 34.558 hours (pcDNA3.1) and 34.316 hours (Unvaccinated).

15

3-51 (ID-75)

Mice immunised with the '3-51 (ID-75)' DNA vaccine did not show significantly longer survival times when compared with the pcDNA3.1 control group but was relatively close to significant when compared with the unvaccinated control group. The '3-51' group has two outlying mouse one of which survived the term of the experiment despite developing symptoms. The mean survival time of 44.499 hours is considerably higher than that determined for both control groups and the group also demonstrates as a much wider range of survival times.

20

25

3-56 (ID-76)

5 Mice immunised with the '3-56 (ID-76)' DNA vaccine exhibited significantly longer survival times when compared with the pcDNA3.1 control group but were marginally not significant when compared with unvaccinated control group.

10 **Example 3: Conservation and variability of candidate vaccine antigen genes among different isolates of Group B Streptococci**

An initial Southern blot analysis was carried out to determine cross-serotype conservation of novel Group B Streptococcal genes isolated using the LEEP system. Analysing the serotype distribution of a target gene will also determine their potential
15 use as antigen components in a GBS vaccine. The Group B Streptococcal strains whose DNA was analysed as part of this study are listed in **APPENDIX II**.

Amplification and labelling of specific target genes as DNA probes for Southern blot analysis.

20 Oligonucleotide primers were designed for each individual gene of interest derived using the LEEP system. Primers were designed to target the whole of the gene being investigated (All primers are listed in **APPENDIX III**). Specific gene targets were amplified by PCR using Vent DNA polymerase (NEB) according to the manufacturers instructions. Typical reactions were carried out in a 100 µl volume containing 50 ng of
25 GBS template DNA, a one tenth volume of enzyme reaction buffer, 1 µM of each primer, 250 µM of each dNTP and 2 units of Vent DNA polymerase. A typical reaction contained an initial 2 minute denaturation at 95°C, followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at the appropriate melting temperature for 30 seconds, and extension at 72°C for 1 minute (1 minute per kilobase of DNA
30 being amplified). The annealing temperature was determined by the lower melting temperature of the two oligonucleotide primers. The reaction was concluded with a final extension period of 10 minutes at 72°C.

All PCR amplified products were extracted once with phenol chloroform (2:1:1) and once with chloroform (1:1) and ethanol precipitated. Specific DNA fragments were isolated from agarose gels using the QIAquick Gel Extraction Kit (Qiagen). For use as DNA probes, purified amplified gene DNA fragments were labelled with digoxigenin using the DIG Nucleic Acid Labelling Kit (Boehringer Mannheim) according to the manufacturer's instructions.

Southern blot hybridisation analysis of Group B Streptococcal genomic DNA

Genomic DNA had previously been isolated from all strains of Group B Streptococci which were investigated for conservation of LEEP-derived gene targets. Appropriate DNA concentrations were digested using either *Hin* DIII, *Eco* RI or *Bgl* II restriction enzymes (NEB) according to manufacturer instructions and analysed by agarose gel electrophoresis. Following agarose gel electrophoresis of DNA samples, the gel was denatured in 0.25M HCl for 20 minutes and DNA was transferred onto HybondTM N⁺ membrane (Amersham) by overnight capillary blotting. The method is essentially as described in Sambrook *et al.* (1989) using Whatman 3MM wicks on a platform over a reservoir of 0.4M NaOH. After transfer, the filter was washed briefly in 2x SSC and stored at 4 °C in Saran wrap (Dow chemical company).

Filters were prehybridised, hybridised with the digoxigenin labelled DNA probes and washed using conditions recommended by Boehringer Mannheim when using their DIG Nucleic Acid Detection Kit. Filters were prehybridised at 68°C for one hour in hybridisation buffer (1% w/v supplied blocking reagent, 5x SSC, 0.1% v/v N-lauryl sarcosine, 0.02% v/v sodium dodecyl sulphate[SDS]). The digoxigenin labelled DNA probe was denatured at 99.9°C for 10 minutes before being added to the hybridisation buffer. Hybridisation was allowed to proceed overnight in a rotating Hybaid tube in a Hybaid Mini-hybridisation oven. Unbound probe was removed by washing the filter twice with 2x SSC- 0.1% SDS for 5 minutes at room temperature. For increased stringency filters were then washed twice with 0.1x SSC-0.1% SDS for 15 minutes at 68°C. The DIG Nucleic Acid Detection Kit (Boehringer Mannheim) was used to immunologically detect specifically bound digoxigenin labelled DNA probes.

Results of Southern blot analysis

All genomic digests and their corresponding Southern blots followed an identical lane order as described in Table I.

5 **Table I**

Lanes	1 kb molecular Weight Marker	515	A909	SB35	H36B	18RS21	1954/92
		Ia	Ia	Ib	Ib	II	II

Lanes	118/158	97/0057	BM110	BS30	M781	97/0099	3139
	II	II	III	III	III	III	IV

Lanes	1169-NT	GBS 6	7271	JM9	Group A <i>Streptococcus</i> <i>pneumoniae</i>	
	V	VI	VII	VIII	—	14

10 For comparative purposes, it was decided to analyse the serotype distribution of the GBS *rib* gene, which encodes the known protective immunogen Rib. Rib has previously been shown to be present in serotype III and some strains of serotype II but not in serotypes Ia or Ib (Stalhammar-Carlemalm *et al.*, 1993). Confirmation of this pattern would not only give increased confidence in interpreting subsequent results, it would also determine if a *rib* gene homologue was present in the remaining GBS

serotypes being investigated here. Primers designed for the amplification of *rib* and its subsequent cloning into pcDNA3.1 (Appendix I), were used to generate a *rib* gene probe for Southern blot analysis.

5 Southern blot analysis - *rib* (Figure 6)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

10

Genomic DNA from each strain was digested completely with *Hin* DIII (NEB) and electrophoresed at 40 Volts for 6 hours in 0.8% agarose, transferred onto Hybond N⁺ (Amersham) membrane by Southern blot and hybridised with the digoxigenin-labelled *rib* gene probe. Specifically bound DNA probe was identified using the DIG Nucleic

15

Acid Detection Kit (Boehringer Mannheim).

Comment

20

The Southern blot analysis described in Figure 7 indicates that the *rib* gene is not conserved across all GBS serotypes. *rib* appears to be absent from all serotype Ia and Ib strains (lanes 2 to 5) and from strains 118/158 and 97/0057 of serotype II (lanes 8 and 9). However, *rib* would appear to present in strains 18RS21 and 1954/92 of serotype II (lanes 6 and 7) and in all strains of serotype III (lanes 10 to 13). This is in agreement with previously published data (Stalhammar-Carlemalm *et al.*, 1993). *rib* would also appear to be present in strains representing serotypes VII and VII (lanes 17 and 18) but was absent from strains representing serotypes IV, V and V (lanes 14 to 16) as well as the control strains (lanes 19 and 20). The *rib* gene probe did hybridise with lower intensity to genomic DNA fragments from strains representing serotypes Ia, Ib, IV, VI, VII and serotype II strains 118/158 and 97/0057. This may indicate the presence of a gene in these strains with a lower level of homology to *rib*. These

25

30

hybridising DNA fragments may contain a homologue of the GBS *bca* gene encoding the Ca protein antigen which has been shown to be closely homologous to the Rib protein (Wastfelt *et al.*, 1996). If this is the case, it would be in agreement with previous work which showed all strains of serotypes Ia, Ib, II and III to be positive for one the two proteins (Stalhammar-Carlemalm *et al.*, 1993). However, the apparent

variable distribution of the *rib* gene amongst different GBS serotypes, makes it a less than ideal candidate for use in a GBS vaccine that is cross-protective against all serotypes.

5 **Southern blot analysis - 4 (ID-1) (photograph 7)**

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

10 Genomic DNA from each strain was digested completely with *Hin* DIII (NEB) and electrophoresed at 40 Volts for 6 hours in 0.8% agarose, transferred onto Hybond N⁺ (Amersham) membrane by Southern blot and hybridised with the digoxigenin-labelled 4 (ID-1) gene probe. Specifically bound DNA probe was identified using the DIG Nucleic Acid Detection Kit (Boehringer Mannheim).

15

Comment

The Southern blot analysis described in Figure 7 indicates that gene 4 (ID-1) is conserved across all GBS serotypes. The gene probe hybridised specifically to a *Hin* DIII-digested genomic DNA fragment of approximately 3.5 kb in DNA digests from all GBS representatives, but was absent from both the control strains (lanes 19 and 20).

20

Southern blot analysis - 5 (ID-2) (Figure 8)

25

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

30 Genomic DNA from each strain was digested completely with *Eco* RI (NEB) and electrophoresed at 40 Volts for 6 hours in 0.8% agarose, transferred onto Hybond N⁺ (Amersham) membrane by Southern blot and hybridised with the digoxigenin-labelled 5 (ID-2) gene probe. Specifically bound DNA probe was identified using the DIG Nucleic Acid Detection Kit (Boehringer Mannheim).

Comment

The Southern blot analysis described in Figure 7 indicates that gene 4 (ID-1) is conserved across all GBS serotypes. The gene probe hybridised specifically to a *Eco* RI-digested genomic DNA fragment of approximately 6.2 kb in DNA digests from all GBS representatives, but was absent from both the control strains (lanes 19 and 20).

5

Southern blot analysis - 15 (ID-7) (Figure 9)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

10

Genomic DNA from each strain was digested completely with *Eco* RI (NEB) and electrophoresed at 40 Volts for 6 hours in 0.8% agarose, transferred onto Hybond N⁺ (Amersham) membrane by Southern blot and hybridised with the digoxigenin-labelled 15 (ID-7) gene probe. Specifically bound DNA probe was identified using the DIG Nucleic Acid Detection Kit (Boehringer Mannheim).

15

Comment

The Southern blot analysis described in Figure 7 indicates that gene 15 (ID-7) is conserved across all GBS serotypes. The gene probe hybridised specifically to a *Eco* RI-digested genomic DNA fragment of approximately 6.2 kb in DNA digests from all GBS representatives, but was absent from both the control strains (lanes 19 and 20). The gene probe hybridised specifically with *Eco* RI -digested DNA fragments ranging from approximately 3.5 kb to 5.2 kb in size.

20

Southern blot analysis - 17 (ID-8) (Figure 10)

Figure 5

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

30

Genomic DNA from each strain was digested completely with *Hin* DIII (NEB) and electrophoresed at 40 Volts for 6 hours in 0.8% agarose, transferred onto Hybond N⁺ (Amersham) membrane by Southern blot and hybridised with the digoxigenin-labelled

17 (ID-8) gene probe. Specifically bound DNA probe was identified using the DIG Nucleic Acid Detection Kit (Boehringer Mannheim).

Comment

5 The Southern blot analysis described in Figure 7 indicates that gene 17 (ID-8) is conserved across all GBS serotypes. The gene probe hybridised specifically to a *Hin* DIII-digested genomic DNA fragment of approximately 2.3 kb in DNA digests from all GBS representatives, but was absent from both the control strains (lanes 19 and 20).

10

Southern blot analysis - 22 (ID-10) (Figure 11)

Figure 6

15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

20 Genomic DNA from each strain was digested completely with *Bgl* II (NEB) and electrophoresed at 40 Volts for 6 hours in 0.8% agarose, transferred onto Hybond N⁺ (Amersham) membrane by Southern blot and hybridised with the digoxigenin-labelled 22 (ID-10) gene probe. Specifically bound DNA probe was identified using the DIG Nucleic Acid Detection Kit (Boehringer Mannheim).

Comment

25 The Southern blot analysis described in Figure 7 indicates that gene 22 (ID-10) is conserved across all GBS serotypes. The gene probe hybridised specifically to a *Bgl* II-digested genomic DNA fragment of approximately 3.1 kb in DNA digests from all GBS representatives except serotype Ib strain H36B, where the gene probe hybridised specifically to a a *Bgl* II-digested genomic DNA fragment. Gene 22 (ID-10) was absent from both the control strains (lanes 19 and 20).

30

Conclusion

The Southern blot analyses described here, represents a preliminary investigation into the conservation level of LEEP-derived genes amongst different GBS serotypes. Initial results indicate that the genes 4 (ID-1), 5 (ID-2), 15 (ID-7), 17(ID-8) and 22

(ID-10) are present in all GBS serotypes and thus represent potential candidate genes for use in a GBS vaccine. Similar analyses are being currently carried out for each of the genes contained in this patent.

APPENDIX IID-8 (17)

Forward Primer

5' - cgggatccgccaccatgACCACTTCTCAAGCTGTTTTAGC - 3'

Reverse Primer

5' - ttgcggccgcACGATTATCAACAAAGTTCTG - 3'ID-9 (18)

10 Forward Primer

5' - cggatccgccaccatgGCTACTCATATTGGAAGTTACCAGC - 3'

Reverse Primer

5' - ttgcggccgcAGGGTTTATTTGTTGAAGTGTCTTG - 3'15 ID-10 (22)

Forward Primer

5' - cggatccgccaccatgTATCTATATCATTTACCAATGCCC - 3'

Reverse Primer

5' - ttgcggccgcTTTATGTATAGAAACAGCAGTCCC - 3'

20

ID-13 (28)

Forward Primer

5' - cggatccgccaccatgAAAGGAAGAACAACCTATTCGTTTAG - 3'

Reverse Primer

25 5' - ttgcggccgcAAGAGCAAATTTTCGTATCTCCTC - 3'ID-15 (32)

Forward Primer

5' - cggatccgccaccATGATTGTTGGACACGGAATTG - 3'

30 Reverse Primer

5' - ttgcggccgcTTTTTCTTCCTCCAAAATAACACTAGC - 3'ID-17 (39)

Forward Primer

5' - cggatccgccaccatgGCGACTAAAGAGTTAGGTGTTAG -3'

Reverse Primer

5' - ttgcggccgcTATAGTTTTAGTTTCAACTTGTCTAGATG -3'

5 ID-25 (20)

Forward Primer

5' - cgggatccaccatgTATACGAGTTTACAACCAAATCATG -3'

Reverse Primer

5' - ttgcggccgcGTCAGCTCGTACTGTTTTTTTAGC -3'

10

ID-37 (51)

Forward Primer

5' - cggatccgccaccatgTGTCAAATGAATAGTGAACATAAAAG -3'

Reverse Primer

15

5' - ttgcggccgcCTCAAATAATTTACCTCCAATTTCG -3'

ID-40 (51)

Forward Primer

5' - cggatccgccaccatgGCTCCATTCGAATTTAAAGATTC -3'

20

Reverse Primer

5' - ttgcggccgcTGATTTACCAGTTTGGAAGAGTTC -3'

ID-42 (70)

Forward Primer

25

5' - cggatccgccaccATGAATACTATTTATAATACATTGAGAACAG -3'

Reverse Primer

5' - ttgcggccgcTTCTTTGTTCCAACCTTCTGG -3'

ID-47 (86)

30

Forward Primer

5' - cggatccgccaccATGATAGAGTGGATTCAAACACATTTAC -3'

Reverse Primer

5' - ttgcggccgcTTTATGACTCAAGCGACGTGTTA -3'

ID-48 94

Forward Primer

5' - cggatccgccaccATGGAGTTAGTAATTAGAGATATTCGTAAG

Reverse Primer

5 5' - ttgcggccgcCTTGTCATATTCATCTCCCTTCAACID-67 (3-40)

Forward Primer

5' - cggatccgccaccatgGCTAGTTTTGTCATGAATCATAATGAC -3'

10 Reverse Primer

5' - ttgcggccgcGTTATTTGCTCGTTGTTTAGCTAAATC -3'ID-68 (3-30)

Forward Primer

15 5' - cggatccgccaccatgGCTCTTAGTTTTTTTATGGTTTCAGTTCAAGC -3'

Reverse Primer

5' - ttgcggccgcGAAGGCACCGCCACCTCC -3'ID-69 (3-38)

20 Forward Primer

5' - cggatccgccaccatgGGTGAAACCCAAGATACCAATCAAGC -3'

Reverse Primer

5' - ttgcggccgcAACACCTGGTGGGCGTTTGG -3'25 ID-70 (141)

Forward Primer

5' - cggatccgccaccATGGCTGGGAATCGTAATAACG -3'

Reverse Primer

5' - ttgcggccgcAGCCGTCTCTAAAACAGGCTTG -3'

30

ID-71 (3-20)

Forward Primer

5' - cggatccgccaccatgCTTCCAACGCAGCCGCAAAAC -3'

Reverse Primer

5' - ttgcggccgcATTAGTGTTATTTCTCCTGTTGCATAATCC -3'

ID-72 (13)

Forward Primer

5 5' - cgggatccaccatgTACACGCATATTGTTGAAAAAAG -3'

Reverse Primer

5' - ttgcggccgcAAATAATTTCTTTTGGTTGTTTG -3'

ID-73 (2-19)

10 Forward Primer

5' - cggatccgccaccatgAGTAATCAAGAAGTTTCAGCAAGC -3'

Reverse Primer

5' - ttgcggccgcCCATTGTGGAATATCAGCTGAAG -3'

15 ID-74 (3-6)

Forward Primer

5' - cggatccgccaccatgGTGCAGGCAGTGGTACCGCT -3'

Reverse Primer

20 5' - ttgcggccgcGCGCATTGTAACAAATTCCTCAG -3'

ID-75 (3-51)

Forward Primer

5' - cgggatccaccatgGCTGCCGAGAAGGATAAAG -3'

25 Reverse Primer

5' - ttgcggccgcATTATTTAGCTGCTTTTTTAATGG -3'

ID-76 (3-56)

Forward Primer

30 5' - cgggatccaccatgTGTCAGGTTGTTTATGCAAGTTTTC -3'

Reverse Primer

5' - ttgcggccgcTTTACTAATTGATAAAGAGCAACTTCG -3'

rib (control)

Forward primer

5' - ggggtaccggccaccATGGCTGAAGTAATTTTCAGGAAGT -3'

Reverse primer

5' - cggaattccgTTAATCCTCTTTTTTTCTTAGAAACAGAT

APPENDIX II

Listed below are the details (serotype and strain designation) of Group B Streptococcus strains whose DNA was analysed for gene conservation

5

SEROTYPE	STRAIN
Ia	515
Ia	A909
10 Ib	SB35
Ib	H36B
II	18RS21
II	1954/92
II	118/158
15 II	97/0057
III	BM110
III	BS30
III	M781
III	97/0099
20 IV	3139
V	1169/NT
VI	GBS VI
VII	7271
VIII	JM9

25

A group A Streptococcal strain (serotype M1, strain NCTC8198) and *Streptococcus pneumoniae* (serotype 14) were also included in the analysis for control purposes.

APPENDIX III

ID-1 (4)

forward primer

5 5' - atggaaaaaataacttggaaaaaattac -3'

reverse primer

5' - ctattttgttttagcgatgtctttatc -3'

ID-2 (5)

10 forward primer

5' - atgtcaaaacaaaaagtaacggcaac -3'

reverse primer

5' - ttatttatggccaataaccataagttaattg

15 ID-6 (9)

forward primer

5' - atgaaaaaagtttttttctcatggctatg -3'

reverse primer

5' - ttacttcaactgttgatagagcacttcc - 3'

20

ID-7 (15)

forward primer

5' - ttgttcaattttataggttttagaacttgg -3'

reverse primer

25 5' - ttaattttcattgcgtctcaaacc -3'

ID-8 (17)

forward primer

5' - atgacaaaaaaacttattattgctatattag -3'

30 reverse primer

5' - ttaacgattatcaacaaagttctgtac -3'

ID-10 (22)

forward primer

5' - atgatacgccagtttttaagagaa -3'

reverse primer

5' - ttatttatgtatagaaacagcagtc -3'

5 References

Anderson, R., Gao, X.-M., Papakonstantinou, A., Roberts, M. and Dougan, G. (1996) Immune response in mice following immunisation with DNA encoding fragment C of tetanus toxin. *Infection and Immunity*, **64**, 3168-3173.

10

Kurar, E. and Splitter, G.A. (1997) Nucleic acid vaccination of *Brucella abortus* ribosomal *L7/L12* gene elicits immune response. *Vaccine*, **15**, 1851-57.

15

Larsson, C., Stalhammar-Carlemalm, M., and Lindahl, G. 1996. Experimental vaccination against Group B Streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and . *Infect. Immun.* **64**: 3518-3523

20

Larsson, C., Stalhammar-Carlemalm, M., and Lindahl, G. 1999. Protection against experimental infection with Group B Streptococcus by immunization with a bivalent protein vaccine. *Vaccine*. **17**:454-458

25

Stalhammar-Carlemalm, M., Stenberg, L., and Lindahl, G. 1993. Protein Rib: a novel Group B Streptococcal protein that confers protective immunity and is expressed by most strains causing invasive infections: *J. Exp. Med.* **177**: 1593-1603

30

Wastfelt, M., Stalhammar-Carlemalm, M., (1996) Identification of a family of Streptococcal surface proteins with extremely repetitive structure. *J. Biol. Chem.* **271**: 18892-18897.

Zhang, D., Yang, X., Berry, J. Shen, C., McClarty, G. and Brunham, R.C. (1997) DNA vaccination with the major outer-membrane protein genes induces acquired immunity to *Chlamydia trachomatis* (mouse pneumonitis) infection. *Infection and Immunity*, **176**, 1035-40.

Claims:

1. A *Group B Streptococcus* protein having a sequence selected from those described in fig 1, or fragments or derivatives thereof.
5
2. A *Group B Streptococcus* polypeptide or peptide having a sequence selected from those described in fig 2, or fragments or derivatives thereof.
3. Derivatives or variants of the proteins, polypeptides, and peptides as claimed in
10 claims 1 and 2 which show at least 50% identity to those proteins, polypeptides and peptides claimed in claims 1 and 2.
4. A nucleic molecule comprising or consisting of a sequence which is:
15
 - (i) any of the DNA sequences set out in figure 1 and figure 2 herein or their RNA equivalents;
 - (ii) a sequence which is complementary to any of the sequences of (i);
 - (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
 - 20 (iv) a sequence which shows substantial identity with any of those of (i), (ii) and (iii); or
 - (v) a sequence which codes for a derivative, or fragment of a nucleic acid molecule shown in figure 1 or figure 2.
- 25 5. A vector comprising DNA encoding for the expression of any one or more proteins, polypeptides, peptides, fragments or derivatives thereof, as claimed in claims 1 to 3.
- 30 6. A vector as claimed in claim 5 further comprising DNA encoding any one or more of the following: promoters, enhancers, signal sequences, leader sequences,

translation start and stop signals, DNA stability controlling regions, or a fusion partner.

7. The use of a vector as claimed in claims 5 and 6 in the transformation or
5 transfection of a prokaryotic or eukaryotic host.
8. A host cell suitable for the transformation of vector as claimed in claims 5 and 6.
- 10 9. An antibody, an affibody, or a derivative thereof which binds to one or more of the proteins, polypeptides, peptides, fragments or derivatives thereof, as claimed in any one of claims 1 to 3.
- 15 10. An immunogenic composition comprising one or more of the proteins, polypeptides, peptides, fragments or derivatives thereof, or nucleic acid sequences as claimed in any one or more of claims 1-3 and claim 4.
11. An immunogenic composition as claimed in claim 10 which is a vaccine.
- 20 12. Use of an immunogenic composition as a claimed in claim 10 in the preparation of a medicament for the treatment or prophylaxis of *Group B Streptococcus* infection.
- 25 13. A method of detection of *Group B Streptococcus* which comprises the step of bringing into contact a sample to be tested with at least one antibody, affibody, or a derivative thereof, as described herein.
- 30 14. A method of detection of *Group B Streptococcus* which comprises the step of bringing into contact a sample to be tested with at least one protein, polypeptide, peptide, fragments or derivatives as described herein.

15. A method of detection of *Group B Streptococcus* which comprises the step of bringing into contact a sample to be tested with at least one nucleic acid molecule as described herein.

5

16. A kit for the detection of *Group B Streptococcus* comprising at least one antibody, affibody, or derivatives thereof as claimed in claim 9.

10

17. A kit for the detection of *Group B Streptococcus* comprising at least one *Group B Streptococcus* protein, polypeptide, peptide, fragment or derivative thereof as claimed in claims 1 to 3.

15

18. A kit for the detection of *Group B Streptococcus* comprising at least one nucleic acid molecule as claimed in claim 4.

20

19. A method of screening for DNA encoding bacterial cell envelope associated or surface antigens in gram positive bacteria comprising the steps of:

- combining a reporter vector including the nucleotide sequence encoding the mature form of the staphylococcus nuclease gene and an upstream promoter region with DNA from a gram positive bacteria.
- transforming the resultant vector into *Lactococcus lactis* cells.
- assaying for the secretion of staphylococcus nuclease protein in the transformed cells.

25

20. A method as claimed in claim 19 wherein the reporter vector is one of the pTREP1-*nuc* vectors shown in figure 4.

30

21. A method as claimed in claim 19 or claim 20 wherein the gram positive bacteria is *Group B Streptococcus*, *Streptococcus Pneumoniae*, *Staphylococcus aureus* or pathogenic group A streptococci.

22. A vector as shown in figure 4 for use in screening for DNA encoding bacterial cell envelope associated or secreted antigens in gram positive bacteria.
- 5 23. A method of determining whether a protein, polypeptide, peptide, fragment or derivative thereof as claimed in claims 1 to 3 represents a potential anti-microbial target which comprises inactivating said protein and determining whether *Group B Streptococcus* is still viable.

ID-1

FIG. 1

Clone 4

ATGGAAAAAATACTTGGAAAAAATTACTTGTTAGTACTGCTGCTCTTTCAGTAGT
TGCAGGAGGAGCAATTGCTGCTACTCACTCTAACTCAGTTGATGCTGCTTCAAAAA
AACTATCAAACCTTTGGGTCCCAACAGATTCAAAAGCGTCTTATAAAGCAATTGTT
AAAAAATTCGAGAAGGAAAACAAAGGCGTTACTGTAAAAAATGATTGAGTCTAATG
ACTCCAAAGCTCAAGAAAACGTAAAAAAAGACCCAAGCAAGGCAGCCGATGTATT
CTCACTTCCACATGACCAACTTGGTCAATTAGTAGAATCTGGTGTTATCCAAGAAA
TTCCAGAGCAATACTCAAAAGAAATTGCTAAAAACGACACTAAACAATCACTTAC
TGGTGCACAATATAAAGGGGAAAACCTTATGCATTCCCATTGTTGATTGAATCTCAAG
TTCTTTATTATAATAAAACAAAGTTAACTGCTGACGACGTTAAATCATACGAAACA
ATTACAAGCAAAGGGGAAATTCGGTCAACAGCTTAAAGCAGCTAACTCATATGTAA
CAGGTCCTCTTTTCCTTTCTGTAGGCGACACTTTATTTGGTAAATCTGGTGAAGATG
CTAAAGGCACTAACTGGGGTAATGAAGCAGGTGTTTCTGTCCTTAAATGGATTGCA
GATCAAAAGAAAAAATGATGGTTTTGTCAACTTGACAGCTGAAAATACAATGTCTAA
ATTTGGCGATGGTTCTGTTCATGCTTTTGAAAGTGGACCATGGGATTACGACGCTG
CTAAAAAAGCTGTCGGTGAAGATAAAATCGGTGTTGCTGTTTACCCAACAATGAAA
ATCGGTGACAAAGAAGTTCAACAAAAAGCATTCTTGGGCGTTAACTTTATGCCGT
TAACCAAGCACCTGCTGGTTCAAACACTAAACGAATCTCAGCTAGCTACAACTCG
CTGCATATCTAACTAATGCTGAAAGTCAAAAAAATTCAATTCGAAAAACGTCATATC
GTTCTGCTAACTCATCAATTCAATCTTCTGATAGCGTCCAAAAAGATGAACTTGC
AAAAGCAGTTATCGAAATGGGTAGCTCAGATAAATATACAACGGTTATGCCTAAG
TTGAGTCAAATGTCAACATTCTGGACAGAAAGTGCTGCTATTCTTAGCGATACTTA
CAGTGGTAAATCAAATCTAGCGATTACCTTAAACGTCTAAAACAATTGATAAAG
ACATCGCTAAAACAAAATAG

MEKNTWKLLVSTAALSVVAGGAIAATHSNSVDAASKKTIKLWVPTDSKASYKAIVK
KFEKENKGVTVKMIENDSKAQENVKKDPSKAADVFSPLPHDQLGQLVESGVIQEIQ
YSKELAKNDTKQSLTGAQYKGKTYAFPGIESQVLYYNKTKLTADDVKSYETITSKGK
FGQQLKAANSYVTGPLFLSVGDTLFGKSGEDAKGTNWGNEAGVSVLKWIADQKKND
GFVNLTAENTMSKFGDGSVHAFESGPWDYDAAKKA VGEDKIGVAVYPTMKIGDKEV
QQKAFLGVKLYAVNQAPAGSNTKRISASYKLAA YLTNAESQKIQFEKRHIVPANSSIQS
SDSVQKDELAKAVIEMGSSDKYTTVMPKLSQMSTFWTESAAILSDTYSGKIKSSDY
LKRLKQFDKDIKTKZ

ID-2

Clone 5

ATGTCAAAACAAAAAGTAACGGCAACTTTGTTGTTATCCACTTTAGTCTTATCGCT
ATCATCACCTTTAGTGACCTTAGCAGAACTATTAATCCAGAAACAAGCCTGACAA
TGGCAACAGCATCAACAGAAAGTTCTTCTGAAGCAGAGAAACAGGAAAAAACACA
ACCTACAGATTCAGAACTGCTTCACCTTCAGCCGAAGGAAGTATCTCAACAGAA
AAAACAGAGATTGGTACGACAGAGACATCATCAAGCAATGAATCATCATCAAGTT
CATCACATCAATCTTCTTCCAACGAAGATGCTAAAACATCTGATTCTGCTTCAACA
GCATCTACTCCTAGCACTAATACTACAAACAGTAGTCAAGCAGACAGTAAGCCAG
GTCAATCAACAAAGACTGAATTAACCTGAGCCTACCTTACCATTAGTAGAGCCT
AAAATAACTCCCGCTCCGTCTCAGATAGAAAGTGTTTCAGACAAATCAGAATGCTTC
TGTTCTGCTTTATCCTTTGATGATAACTTATTATCAACACCGATTTCACCAGTGAC
AGCAACGCCATTCTACGTAGAACACTGGTCTGGTCAGGATGCCTACTCTCACTATT
TATTGTCACATCGTTACGGTATCAAAGCTGAACAATTAGATGGGTACTTAAAATCT
TTAGGGATTCAATATGATTCTAATCGTATCAATGGTGCTAAGTTATTACAATGGGA
AAAAGATAGTGGTTTAGATGTCCGTGCTATTGTAGCTATTGCTGTCCTTGAAAGTTC
ATTGGGAAGTCAAGGAGTGGCTAAAATGCCAGGTGCTAATATGTTTGGTTATGGTG
CCTTTGATCATGACTCTAGCCATGCTAGTGCTTATAATGATGAAGAAGCAATTATG
TTGTTGACAAAAAATAACAATTATTAACAAACAACACTCTAGCTTTGAAATCCAAGA
TTTGAAAGCACAGAAATTATCTTCTGGACAACCTAATACAGTTACTGAGGGTGGTG
TTTATTATACAGATAACTCTGGAAGTGGTAAACGTCGTGCCAGATTATGGAAGAT
TTAGACCGCTGGATTGATCAACATGGAGGGACACCAGAAATTCCTGCTGCCTTGAA
AGCTTTATCGACAGCAAGTTTAGCAGATTTACCAAGTGGTTTTAGCTTATCAACAG
CGGTTAACACAGCTAGCTATATTGCATCAACTTATCCATGGGGTGAATGTACATGG
TATGTCTTTAACCGCGCTAAAGAGTTAGGTTATACATTTGATCCATTTATGGGTAAT
GGTGGAGATTGGCAACATAAGGCTGGCTTTGAAACAACACATTCACCAAAAGTAG
GCTATGCTGTATCATTTTCACCAGGACAAGCTGGTGCTGATGGCACTTACGGTCAC
GTAGCTATTGTTGAAGAAGTTAAAAAAGATGGTTCAGTTCTCATTTTCAGAATCTAA
TGCAATGGGACGTGGTATTGTCTCTTACCGTACTTTTAGTTTCAGCACAAAGCTGCAC
AATTAAGTTATGGTATTGGCCATAAATAA

MSKQKVTATLLLSTLVLSLSSPLVTLAETINPETSMTASTESSSEAEKQEKTOPTDS
ETASPSAEGSISTEKTEIGTTETSSSSNESSSSSSSHQSSSNEDAKTSDSASTASTPSTNTNS
SQADSKPGQSTKTELKPEPTLPLVEPKITPAPSQIESVQTNQNASVPALSFDDNLLSTPIS
PVTATPFYVEHWSGQDAYSHYLLSHRYGIKAEQLDGYLKSLGIQYDSNRINGAKLLQ
WEKDSGLDVRAIVAIAVLESSLGTQGVAKMPGANMFGYGAFDHDSSHASAYNDEEAI
MLLTKNTIIKNNNSSFEIQDLKAQKLSSGQLNTVTEGGVYYTDNSGTGKRRAQIMEDL
DRWIDQHGGTPEIPAALKALSTASLADLPSGFSLSAVNTASYLASTYPWGECTWYVF
NRAKELGYTFDPFMGNGGDWQHKAGFETTHSPKVGAVVSFSPGQAGADGTYGHVAI
VEEVKKDGSVLISESNAMGRGIVSYRTFSSAQAAQLTYGIGHKZ

FIG. 1 CONT'D

ID-3

Clone 6

GTGCATATGTTACAAAACATTGGACAAACAGGCATTCAAGCAACTCGAATTGCTTT
AGGTTGTATGAGAATGAGTGACTTGAAAGGAAAACAAGCTGAAGAAGTAGTTGGA
ACAGCATTAGATTTGGGTATTATAAATAATAAAGTGCAAGAAAGTGTCTCTGGCGT
CAAAGTGACTAAATCATTGTGTTATCAAGAACAAGAAATTGCTTCTTTTCAAGAGA
TTAATCAGATGACTTTCGTGAAGAACATGCGGACCATGACTTATGATGTCATGTTT
GATCCTTTAGTTCTTCTTTTATAGGTGCCTCCTACGTATTAACATTGGCTATGGGA
GCTTTTATGATTTCAAAGGTCAAGTTACTGTTGGTGACTTGGTAACATTTGTGACG
TATTTAGATATGTTGGTATGGCCCTTGATGGCGATTGGTTTCTTGTTCAATATGGTA
CAGCGTGGTAGTGTTTCTTATAACCGTATTAATAGTCTACTTGAGCAAGAATCGGA
TATAACTGATCCTTTAAATCCTATCAAACCTGTTGTCAATGGAACATTAAGATA
TGATATTGATTTCTTTAGATACGACAATGAGGAAACCTTAGCCGATATTCATTTTAC
CTTAGAAAAAGGTCAAACCTTAGGTTTGGTAGGTCAAACGGGATCAGGGAAGACA
AGTCTTATTAAGTTATTGCTACGTGAACATGATGTGACTCAGGGGAAAATTACTTT
AAATAAACATGATATACGTGATTATCGATTGTCTGAGTTACGTCAACTAATCGGTT
ATGTTCTCAAGATCAGTTTTTATTTGCTACCAGTATTTTAGAAAAATGTTTCGCTTTG
GAAATCCAACCTCTATCTATCAATGCTGTCAAAGAAGCAACTAAATTGGGCACATGTT
TACGATGACATTGAACAGATGCCAGCAGGATTTGAGACTCTAATTGGAGAAAAAG
GAGTCTCATTATCTGGTGGACAAAAACAAAGGATTGCGATGAGTCGTGCCATGATT
TTAGATCCAGATATTCTTATTTTGGATGATTCTCTATCAGCAGTGGACGCTAAAACG
GAACATGCTATTGTTGAGAATCTTAAAACGAATCGTCAAGGGAAATCGACTATTA
TTTCAGCACATCGTTTATCAGCTGTTGTGCACGCAGACCTTATCTTAGTTATGCGAG
ACGGCAGAGTCATTGAGCGAGGTCAACATCAAGAGTTGCTAAATAAAGGTGGTTG
GTATGCTGAAACGTATGCCTCACAGCAATTAGAAATGGAGGAAGCATTGATGAA
GTCTAA

MHMLQNIGQTGIQATRIALGCMRMSDLKGKQAEVVGTAALDLGIINNKVQESVSGVK
VTKSLCYQEQEIASFQEINQMTFVKNMRTMTYDVMFDPLVLLFIGASYVLTLAMGAF
MISKGQVTVGDLVTFVTYLDMLVWPLMAIGFLFNMVQRGSVSYNRINSLLEQESDITD
PLNPIKPVVNGTLRYDIDFFRYDNEETLADIHFTLEKGQTLGLVGQTGSGKTSLIKLLLR
EHDVTQGKITLNKHDIRDYRLSELRLIGYVPQDQFLFATSILENVRFGNPTLSINAVKE
ATKLAHVYDDIEQMPAGFETLIGEKGVSLSGGQKQRIAMSRAMILDPDILILDDSLSAV
DAKTEHAIVENLKTNRQGKSTIISAHRLSAVVHADLILVMRDGRVIERGQHQELLNKG
GWYAETYASQQLEMEEAFDEVZ

ID-4

Clone 6b

TTGATGAAGTCTAATCAATGGCAAGTCTTTAAGAGATTAATCTCCTATTTACGCCCT
TATAAATGGTTTACAGTATTAGCTCTATCTCTCTTATTGTTGACGACTGTTGTAAA

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

AATATTATTCCTTTAATTGCTTCACATTTTATTGATCACTATCTGACAAATGTTAAT
CAAACAGCAGTTCTTATTTTAGTGGGATATTATTCAATGTATGTCTTGCAGACCTTA
ATTCAATATTTTGGGAATCTCTTTTTTGGCGCGTGTTTCTTATAGTATTGTTAGAGAT
ATTCGTAGAGATGCTTTTGCTAATATGGAAAGGCTAGGCATGTCTTATTTTGATAG
GACACCGGCAGGATCTATTGTGTCACGTATTACTAATGATACTGAAGCAATATCTG
ATATGTTTTTCGGGTATTTTATCAAGTTTTATCTCGGCGATATTTATTTTACAGTTAC
TCTGTACACTATGTTGATGCTAGACATTAACTAACAGGACTCGTCGCTCTTTTGTT
ACCTGTTATCTTTATATTAGTGAATGTCTATCGGAAAAAATCAGTCACTGTCATTGC
TAAAACGAGAAGTTTACTTAGTGATATCAACAGTAAATTATCAGGAAGTATTGAAG
GAATTCGCATTGTACAGGCTTTTGGTCAAGAAGAGCGCTTGAAGACTGAATTTGAG
GAAATTAACAAAGAGCATGTTGTGTATGCCAATCGTTCTATGGCTCTTGATAGTCT
CTTCTTAAGACCGGCGATGTCTCTTTTAAACTCCTAGCATATGCTGTTCTTATGTC
TTATTTTGGATTTACAGGAGTTAAAGGAGGTCTTACGGCAGGATTAATGTATGCTT
TTATTCAGTACGTTAATCGTCTATTTGACCCTTTAATTGAAGTAACGCAAATTTT
CAACCTTACAAACATCAATGGTATCAGCAGGGCGTGTGTTTGATCTGATTGAT
GAAACAGGTTTTGAACCAAGCCAAAAAATACAGAAGCT

MKSNQWQVFKRLISYLRPYKWFTVLALSLLLLTTVVKNIIPLIASHFIDHYLTNVNQTA
VLILVGYYSMYVLQTLIQYFGNLFARVSYSIVRDIRRDAFANMERLGMSYFDRTPAG
SIVSRITNDTEAISDMFSGILSSFISAFIFTVTLYTMLMLDIKLTGLVALLPVIFILVNVY
RKKSVTVIKTRSLSDINSKLSGSIEGIRIVQAFGQEERLKT EFEEINKEHV VYANRSM
ALDSLFLRPAMSLKLLAYAVLMSYFGFTGVKGGTAGL MYAFIQYVNRLFDPLIEVT
QNFSTLQTS MV SAGRVFDLIDETGFEPSQKNTEA

ID-5

Clone 7

ATGAAAAGAAAAGACTTATTTGGTGATAAACA AACTCAATACACGAT
TAGAAAGTTAAGTGTTGGAGTAGCTTCAGTTGCAACAGGGGTATGTA
TTTTTCTTCATAGTCCACAGGTATTTGCTGAAGAAGTAAGTGTTTCTC
CTGCAACTACAGCGATTGCAAAGTCGAATATTAATCAGGTTGACAAC
CGGCAATCTACTAATTTAAAAGATGACATAAACTCAA ACTCTGAGAC
GGTTGTGACACCCTCAGATATGCCGGATACCAAGCAATTAGTATCAG
ATGAAACTGACACTCAAAAAGGAGTGACAGAGCCGGATAAGGCGAC
AAGCCTGCTTGAAGAAAATAAAGGTCCTGTTTCAGATAAAAATACCT
TAGATTTAAAAGTGGCACCATCTACATTGCAAAATACTCCCGACAAA
ACTTCTCAAGCTATAGGTGCTCCAAGTCCGACCTTGAAAGTTGCTAAT
CAAGCTCCACAGATTGAAAATGGTTACTTTAGGTTACATCTTAAAGA
ATTGCCTCAAGGTCATCCTGTAGAAAGCACTGGGCTTTGGATATGGG
GAGATGTTGATCAACCGTCTAGTAATTGGCCAAATGGTGCTATCCCT
ATGACTAATGCTAAGAAAGATGATTACGGTTATTATGTTGATTTTAA
ATTATCTGAAAAACAACGAAAACAAATATCTTTTTTAATTAATAACA
AAGCAGGAACAAATTTAAGCGGCGATCATCATATTCCATTATTACGA

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

CCTGAGATGAACCAAGTTTGGATTGATGAAAAGTACGGTATACATAC
TTATCAGCCCCTCAAAGAAGGGTATGTCCGTATTAACCTATTTGAGTTC
ATCTGGTAACTATGACCACTTATCAGCATGGCTCTTTAAAGATGTTGC
AACCCCCTCAACAACCTTGGCCAGATGGTAGTAATTTTGTGAATCAAG
GACTATATGGAAGGTATATTGATGTACCACTGAAAACCTAATGCCAAA
GAGATTGGTTTTCTAATCTTAGATGAAAGTAAGACAGGAGATGCAGT
GAAAGTTCAACCCAACGACTATGTTTTTTAGAGATTTAGCTAACCATA
ACCAAATTTTTGTAAAAGATAAGGATCCAAAGGTTTATAATAATCCT
TATTACATTGATCAAGTGCAGCTAAAGGATGCTCAACAAACTGATTT
AACAAGTATTCAAGCAAGTTTTACAACCTCTAGATGGGGTAGATAAAA
CTGAAATTTTAAAAGAATTGAAAGTGACAGATAAAAAATCAAAATGCT
ATACAAATTTCTGATATCACTCTCGATACTAGTAAATCTCTTTTAATA
ATCAAAGGCGACTTTAATCCTAAACAAGGTCATTTCAATATATCTTAT
AATGGTAACAATGTCACGACAAGGCAATCTTGGGAATTTAAAGACCA
ACTTTATGCTTATAGTGGAAATTTAGGTGCAGTTCTCAATCAAGATGG
TTCAAAGTTGAAGCCAGCCTCTGGTCACCGAGTGCTGATAGTGTCA
CTATGATTATTTATGACAAAGATAATCAAAACAGGGTTGTAGCGACT
ACCCCCCTTGTGAAAAATAATAAAGGTGTTTGGCAGACGATACTTGA
TACTAAATTAGGTATTAAAAACTATACTGGTTACTATTATCTTTACGA
AATAAAAAGAGGTAAGGATAAGGTTAAGATTTTAGATCCTTATGCAA
AGTCATTAGCAGAGTGGGATAGTAATACTGTTAATGACGATATAAAA
ACGGCTAAAGCAGCTTTTGTAAATCCAAGTCAACTTGGACCTAAAAA
TTTAAGTTTTGCTAAAATTGCTAATTTTAAAGGAAAACAAGATGCTGT
TATATACGAAGCACATGTAAGAGACTTCACTTCTGATCAATCTTTGG
ACGGAATAATAAAAAATCAACTTGGTACCTTTGCAGCCTTTTCAGAG
AACTAGATTATTTACAGAAATTAGGAGTTACACACATTCAGCTTTT
ACCGGTATTGAGTTATTTTTATGTTAATGAAATGGATAAGTCACGCTC
AACAGCTTACACTTCCTCAGACAATAATTACAATTGGGGCTATGACC
CACAGAGCTATTTTGCTCTTTCTGGAATGTATTCAGAGAAACCAAAA
GATCCATCAGCACGTATCGCCGAATTAAACAATTAATACATGATAT
TCATAAACGTGGCATGGGGGTTATACTTGATGTCGTCTATAATCACA
CTGCAAAAACCTTATCTCTTTGAGGATATAGAACCTAATTATTACT
TTATGAATGAAGATGGTTCACCAAGAGAAAGTTTTGGAGGGGGACGT
TTAGGAACCACTCATGCAATGAGTCGTCGTGTTTTGGTTGATTCCATT
AAATATCTTACAAGTGAATTTAAAGTTGATGGTTTCCGTTTTGATATG
ATGGGAGATCATGATGCGGCTGCGATTGAATTAGCTTATAAAGAAGC
TAAAGCTATTAATCCTAATATGATTATGATTGGTGAGGGCTGGAGAA
CATTCCAAGGCGATCAAGGTAAGCCGGTTAAACCAGCTGACCAAGAT
TGGATGAAGTCAACCGATACAGTTGGCGTCTTTTCAGATGATATTCGT
AATAGCTTGAAATCTGGTTTTCCAAATGAAGGTACTCCAGCTTTTCATC
ACAGGTGGCCCACAATCTTTACAAGGTATTTTTAAAAATATCAAAGC
ACAACCTGGGAATTTTGAAGCAGATTCGCCAGGAGATGTGGTGCAAGT
ATATTGCTGCACATGATAACCTTACCTTGCATGATGTGATTGCAAAAT
CAATTAATAAAGACCCTAAGGTAGCTGAAGAAGATATTCATAGACGT

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

CTGCGTTTAGGAAATGTAATGATTTTAAACATCTCAAGGGACAGCATT
CATTCAATTCTGGTCAAGAGTATGGTCGTACGAAGCGTTTACTTAACCC
TGATTACATGACAAAAGTTTCAGATGACAAATTGCCTAATAAAGCAA
CACTTATTGAAGCTGTTAAAGAATACCCATATTTTATTTCATGATTCAT
ATGATTCTTCAGATGCCATTAATCATTGTTGATTGGGCAGCAGCCACAG
ATAATAACAAACACCCAATTTCAACGAAAACACAGGCCTATACAGCA
GGTTTAATCACATTAAGGCGTTCAACAGATGCTTTCCGGAAATTGAG
CAAAGCAGAAATTGATCGTGAGGTTAGCTTGATTACAGAGGTAGGTC
AAGGTGATATTAAAGAAAAAAGATTTGGTTATTGCTTACCAAACAATA
GATTCTAAAGGCGATATTTACGCAGTATTTGTTAATGCTGATAGTAA
AGCTAGAAACGTTTTACTAGGTGAAAAATATAAACACCTTTTAAAAG
GGCAAGTAATTGTTGATGCTGATCAAGCGGGGATTAAACCAATCTCA
ACTCCTAGAGGTGTTCAATTTTGAAAAAGATAGTTTGCTGATTGATCCA
TTAACAGCAATTGTGATTAAAGTTGGCAAAGTTGCTCCTAGCCCTAA
GGAGGAATTGCAAGCAGATTATCCCAAAACACAATCTTTCAAGGGAT
CTAAAACGGTAGAAAAAGTAAATAGAATAGCTAATAAGACCTCAAT
AACTCCTGTAGTTTCTAATAAGACCGATTCATATCTGACAAATGAAG
CTAATTTGCCAAAACTGGAGATAAGTCATCAAAAATACTAAGTGTA
GTAGGAATAAGCATTCTAGCAAGTCTACTTGCTCTACTAGGTCTCTCT
TTAAAGAGGAATCGCACTTAA

MKRKDLFGDKQTQYTIRKLSVGVASVATGVCIFLHSPQVFAEEVSVSPA
TTALAKSNINQVDNRQSTNLKDDINSNSETVVTPSDMPDTKQLVSDETDT
QKGVTEPDKATSLLEENKGPVSDKNTLDLKVAPSTLQNTDPDKTSQAIGA
PSPTLKVANQAPQIENGYFRLHLKELPQGHVPVESTGLWIWGDVDQPSSN
WPNGAIPMTNAKKDDYGYVDFKLSEKQRKQISFLINNKAGTNLSGDH
HIPLLRPEMNQVWIDEKYGIHTYQPLKEGYVRINYLSSSGNYDHLSAWL
FKDVATPSTTWPDGSNFVNQGLYGRYIDVPLKTNAKEIGFLILDESKTGD
AVKVQPNDYVFRDLANHNQIFVKDKDPKVYNPNPYIDQVQLKDAQQT
DLTSIQASFTTLDGVDKTEILKELKVTDKNQNAIQISDITLDTSKSLLIKG
DFNPKQGHFNISYNGNNVTTRQSWFKDQLYAYSGNLGAVLNQDGSKV
EASLWSPSADSVTMIIYDKDNQNRVVATTPLVKNNKGVWQTILDTKLGI
KNYTGYYYLYEIKRGKDKVKILDPAKSLAEWDSNTVNDDIKTAKAAF
VNPSQLGPKNLSFAKIANFKGKQDAVIYEAHVDRFTSDQSLDGKLKNQL
GTFAAFSEKLDYLQKLGVTHIQLLPVLSYFYVNEMDKSRSTAYTSSDNN
YNWGYDPQSYFALSGMYSEKPKDPSARIAELKQLIHDIHKRGMGVILDV
VYNHTAKTYLFEDIEPNYYHFMNEDGSPRESFGGRLGTTHAMSRRVL
VDSIKYLTSEFKVDGFRFDMMDHDAAAIELAYKEAKAINPNMIMIGEG
WRTFQGDQGKPKPADQDWMKSTDVGVFSDDIRNSLKSFGFPNEGTPA
FITGGPQSLQGIFKNIKAQPGNFADSPGDVVQYIAAHDNLTLDHVIKSI
NKDPKVAEEDIHRRLRLGNVMILTSQGTAFIHSGQEYGRTRKLLNPDYM
TKVSDDKLPNKATLIEAVKEYPYFIHDSYDSSDAINHFDWAAATDNNKH
PISTKTQAYTAGLITLRSTDAFRKLSKAEIDREVSLITEVGQGDIKEKDL

FIG. 1CONT'D

SUBSTITUTE SHEET (RULE 26)

VIA YQTIDSKGDIYAVFVNADSKARNVLLGEKYKHLLKGQVIVDADQA
GIKPISTPRGVHFEKDSLLIDPLTAIVIKVGKVAPSPKEELQADYPKTQSFK
GSKTVEKVNRIANKTSITPVVSNKTD SYLTNEANLPKTGDKSSKILSVVG
ISILASLLALLGLSLKRNRT*

ID-6

Clone 9

ATGAAAAAAGTTTTTTTTCTCATGGCTATGGTTGTGAGTTTAGTAATGATAGCAGG
GTGTGATAAGTCAGCAAACCCCAAACAGCCTACGCAAGGCATGTCAGTTGTAACC
AGCTTTTACCCAATGTATGCGATGACAAAAGAAGTATCTGGAGACCTAAATGATGT
GAGGATGATCCAATCAGGTGCAGGCATTTCCTTTGAACCGTCTGTAAATGATG
TGGCAGCTATTTATGACGCGGATTTGTTTGTGTTACCAATCACATACCTTAGAAGCTT
GGGCAAGGGATCTAGACCCTAATTTAAAAAAATCAAAGGTTAATGTGTTTGAAGC
GTCAAAACCTCTGACACTAGATAGAGTCAAAGGGCTAGAAGATATGGAAGTCACA
CAAGGCATTGACCCTGCGACACTTTATGACCCACATACCTGGACGGATCCCGTTTT
AGCTGGTGAGGAAGCTGTTAATATCGCTAAAGAGCTAGGACATTTGGATCCTAAAC
ACAAAGACAGTTACACTAAAAAGGCTAAGGCTTTCAAAAAAGAAGCAGAGCAACT
AACTGAAGAATACACTCAAAAATTTAAAAAGGTGCGCTCAAAAACATTTGTGACG
CAACACACGGCATTCTTATCTGGCTAAACGATTCGGCTTGAAACAACCTTGGTAT
CTCGGGTATTTCTCCAGAGCAAGAGCCCTCTCCTCGCCAATTGAAAGAAATTCAAG
ACTTTGTTAAAGAATACAACGTCAAGACTATTTTTGCAGAAGACAACGTCAACCCC
AAAATTGCTCATGCTATTGCGAAATCAACAGGAGCTAAAGTAAAGACATTAAGTC
CACTTGAAGCTGCTCCAAGCGGAAACAAGACATATCTAGAAAATCTTAGAGCAAA
TTTGGAAGTGCTCTATCAACAGTTGAAGTAA

MKKVFFLMAMVVSLVMIAGCDKSANPKQPTQGMSVVTSFYPMYAMTKEVSGDLND
VRMIQSGAGIHSFEPVSNDVAAIYDADLFVYQSHLEAWARLDLPNLKKS KVNFEAS
KPLTLDRVKGLEDMEVTQGIDPATLYDPHTWTD PVLAGEEAVNIAKELGHLDPKHKD
SYTKKAKAFKKEAEQLTEEYTQKFKKVRSKTFVTQHTAFSYLAKRFGLKQLGISGISPE
QEPSRQLKEIQDFVKEYNVKTIFAEDNVNPKIAHAIAKSTGAKVKTLSPLEAAPSGNK
TYLENLRANLEVLYQQLK*

ID-7

Clone 15

TTGTTCAATAAAAATAGGTTTTAGAACTTGGAATCAGGAAAGCTTTG
GCTTTATATGGGAGTGCTAGGATCAACTATTATTTTAGGATCAAGTCC
TGTATCTGCTATGGATAGTGTTGGAAATCAAAGTCAAGGTAATGTTTT
AGAGCGTCGCCAACGTGATGCGGAAAACAAAAGTCAGGGTAATGTT
TTAGAGCGTCGCCAACGTGATGCGGAAAACAAGAGCCAAGGCAATG
TTTAGAGCGTCGTCAACGCGATGTTGAGAATAAGAGCCAAGGCAAT

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

GTTTTAGAGCGTCGTCAACGTGATGCGGAAAACAAAAGTCAGGGCA
ATGTTCTAGAGCGCCGCCAACGTGATGCGGATAACAAGAGCCAAGTA
GGTCAACTTATAGGGAAAAATCCACTTTTTTCAAAGCCAAGTGTATCT
AGAGAAAATAATCACTCTAGTCAAGGTGACTCTAACAAACAGTCATT
CTCTAAAAAAGTATCTCAGGTTACTAATGTAGCTAATAGACCGATGT
TAACTAATAATTCTAGAACAATTTTCAGTGATAAATAAATTACCTAAA
ACAGGTGGTGATCAAAATGTCATTTTTTAACTTGTAGGTTTTGGTTTA
ATTTTGTTAACAAGTCGCTGCGGTTTGAGACGCAATGAAAATTAA

MFNKIGFRTWKSGKLWLYMGVLGSTIILGSSPVSAMDSVGNQSQGNVL
ERRQRDAENKSQGNVLERRQRDAENKSQGNVLERRQRDVENKSQGNV
LERRQRDAENKSQGNVLERRQRDADNKSQVGLIGKNPLFSKPTVSREN
NHSSQGDSNKQSFSKKVSQVTNVANRPMLTNNSRTISVINKLPKTGGDQ
NVIFKLVGFLILLTSRCGLRRNEN*

ID-8

Clone 17

ATGACAAAAAACTTATTATTGCTATATTAGCACTATGCACTATCTTAACCACTTCT
CAAGCTGTTTTAGCTAAAGAAAAATCACAACTGTTACCATAAAAAACAACCTATTC
GGTCTATATTAAAAAAGAAAAAAGAGACAAGCCGGATAATAAAAAGCAAATCAG
CGAGACACTTAAAGTTCCTTTAAAACCCAAAAAAGTAGTTGTTTTTGATATGGGAG
CTTTGGATACTATCACAGCTTTAGGAGCTGAAAAATCTGTTATTGGTATCCCGAAG
GCTAAAAATGCTCTAAGTTTATTGCCCAATAACGTCAAATCTGTTTATAAAGCTAA
GAGATACCAAGACGTAGGAAGTCTCTTCGAACCAAACTTTGAAGCTATTGCTCGTA
TGCAACCTGATGTGGTTTTCTAGGAGCACGTATGGCTTCTGTTGATAATATTGAA
AAATTAAAGGAGGCTGCACCTAAAGCAGCATTAGTATATGCTGGAGTCGACTCAA
AAAAAGTATTTGACAAAGGAGTTGCTGAGCGTGTCACAATGTTAGGGAAAATCTTC
GACCAAAATAAAAAGGCAAAAACCTTTAATAAAGATATCGCACAAAGCTGTTCTTA
AATTGCAGAAACTATTGAGAAAAAAGGTAAACCTACAGCTCTATTTGTAATGGC
AAACAGCGGTGAACTTTTAACTCAATCACCTTCTGGTCGTTTTGGTTGGATTTTCTC
TGTAGGTGGATTTAAAGCAGTCAATGAAAATGAAAAACTAAGTTCACATGGTACTC
CCGTATCTTATGAATACATCGCTGAAAAAAATCCTAACTATCTCTTTGTTTTAGATC
GTGGAGCGACTATTGGACAAGGAGCTTCATCAAAGAAGCTTTTAAATAACGATGTT
ATTAAAGCAACTGATGCTGTCAAAAACAAACGTGTTTCATGAGGTAGATGGAAAAG
ATTGGTATATCAATTCAGGCGGAAGCCGAGTAACACTCCGTATGATTAAAGATGTA
CAGAACTTTGTTGATAATCGTTAA

MTKKLIILAILALCTILTTSQAVLAKEKSQTVTIKNNYSVYIKKEKRDKPDN
KKQISETLKVPLKPKKVVFDMGALDTITALGAEKSVIGIPKAKNALSL
PNNVKSVMYKAKRYQDVGSLFEPNFIAIARMQPDVVFLGARMASVDNIE
KLKEAAPKAALVYAGVDSKKVFDKGVAERVMTMLGKIFDQNKKAKTFN
KDIAQAVLKLQKTIEKKGKPTALFVMANSCELLTQSPSGRFGWIFSVGG

FIG. 1CONT'D

SUBSTITUTE SHEET (RULE 26)

GGTATGCCAAACTGGCAAATTATCCATTCTGCTGAAGAAGTTCAAAAAGCCCTAGC
AGAAGGTCGTTTTTGCAGCACCAGACGGCTATATTTTCGATCCACGAGATGTTTTGG
CAAAAGAACTTTTGTATGGAAAGATGGCTCCTTTAGCATCCCAAGAGCAGATGGC
AGTTCATTGAGAACCATTAATAAATCCGATCTATCCCAAGCTGAGTGGCAACAAGC
TCAAGAGTTATTGGCAAAGAAAAATGCTGGTGATGCTACTGATACGGATAAACCT
GAAGAAAAGCAACAGGCAGATAAGAGCAATGAAAACCAACAGCCAAGTGAAGCC
AGTAAAGAAGAAAAAGAATCAGATGACTTTATAGACAGTTTACCAGACTATGGTC
TAGATAGAGCAACCCTAGAAGATCATATCAATCAATTAGCACAAAAAGCTAATAT
CGATCCTAAGTATCTCATTTTCCAACCAGAAGGTGTCCAATTTTATAATAAAAATG
GTGAATTGGTAACTTATGATATCAAGACACTTCAACAAATAAACCTTAA

MKKTYGYIGSVAAILLATHIGSYQLGKHHMGLATKDNQIAYIDDSKGKVKAPKTNKT
MDQISAEEGISAEQIVVKITDQGYVTSHGDHYHFYNGKVPYDAIISEELMTDPNYHFK
QSDVINEILDGYVIKVNGNYVYVLKPGSKRKNIRTKQQIAEQVAKGTKEAKEKGLAQV
AHLSCKEEVA AVNEAKRQGRYTDDGYIFSPTDIIDDLGDAYLVPHGNHYHYIPKKDLS
PSELAAAQAYWSQKQGRGARPSDYRPTPAPGRRKAPIPDVTPNPGQGHQPDNGGYHP
APPRPNDASQNKHQRDEFKKGKTFKELLDHLHRLDLKYRHVEEDGLIFEPTQVIKSNF
GYVVPBGDHYHIIPRSQLSPEMELADRYLAGQTDDNDSGSDHSKPSDKEVTHTFLGH
RIKAYGKGLDGKPYDTS DAYVFSKESIHSVDKSGVTAKHGDHFHYIGFGELEQYELDE
VANWVKAQGQADELVAALDQEQGKEKPLFDTKKVS RKVTKDGKVG YIMPKDGKDY
FYARYQLDLTQIAFAEQELMLKDKKHRYDIVDTGIEPRLAVDVSSLPMHAGNATYD
TGSSFVIPHIDHIHVVPYSWLTRNQIATIKYVMQHPEVRPDVWSKPGHEESG SVIPNVTP
LDKRAGMPNWKIHS AEVQKALAEGRFAAPDGYIFDPRDVLAKETFWWKDGSFSIPR
ADGSSLRTINKSDLSQA EWQQAQELLAKKNAGDATD TDKPEEKQQADKSNENQQPSE
ASKEEKESDDFIDSLPDYGLDRATLEDHINQLAQKANIDPKYLIFQPEGVQFY NKN GEL
VTYDIKTLQQINP*

ID-10

Clone 22

ATGATACGCCAGTTTTTAAAGAGAACACTTGATTTGGGTATATTTTATATATCATGATG
TTTGTCCTATTTTTTATTAGTTTCTATCTATATCATTTACCAATGCCCTATTTGTTTA
ATTCCTTAGGTTTAAATGTTATTGTTTTACTAGGAATTAGTATTTGGCAATACAGTC
GTTACAGGAAAAAAATGTTACATCTCAAATATTTTAATAGTAGTCAGGACCCCTCT
TTCGAACTTCAACCGAGTGATTACGCTTATTTTAATATTATTACACAATTAGAAGCT
AGAGAAGCGCAAAAAGTTTCTGAAACAATTGAACAAACCAATCATGTTGCACTTA
TGATAAAGATGTGGTCGCACCAAATGAAAGTTCCATTGGCAGCTATTTTATTAATG
GCCCAGACAAATCATCTCGATCCTAAGGAAGTTGAACAACAATTATTGAAATTGCA
ACATTATCTTGAAACGTTGTTAGCATTTTTTGAAATTTAGACAATATCGTGACGATTT
TCGTTTTGAAGCTGTTAGCCTTAGAGAAGTAGTAGTAGAAATTATAAAATCGTATA
AGGTTATTTGTCTATCCAAAAGCTTATCTATCATAATTGAAGGCGATAATATCTGG
AAACAGACAAAAAGTGGTTAACTTTTGCTCTTTCACAGGTGCTAGATAATGCCAT

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

AAAATATTCTAATCCTGAGTCAAAGATAATAATAAGCATAGGAGAAGAGAGTATT
AGAATACAAGACTACGGTATCGGCATACTCGAAGAGGATATCCCTAGACTTTTTGA
AGATGGCTTTACGGGTTACAACGGTCATGAGCACCAAAGGCAACAGGCATGGGG
TTATATATGACAAAAGAAGTCTTATCTAGTCTGAATTTGTCCATTTTCGGTGGATAGC
AAAATTAATTATGGGACTGCTGTTTCTATACATAATAA

MIRQFLREHLIWIYILYIMMFVLFISFYLYHLPMPYLFNSLGLNVIVLLGISIWQYSRYR
KKMLHLKYFNSSQDPSFELQPSDYAYFNIITQLEAREAQKVSETIEQTNHVALMIKMW
SHQMKVPLAAISLMAQTNHLDPKVEVEQQLKLQHYLETLLAFLKFRQYRDDFRFEAV
SLREVVVEIIKSYKVICLSKSLSIIEGDNIWKTDDKWLTFALSQVLDNAIKYSNPESKIIS
IGESIRIQDYGIGILEEDIPRLFEDGFTGYNGHEHQKATGMGLYMTKEVLSSLNLSISV
DSKINYGTAVSIHKZ

ID-11

Clone 23

ATGACTTATCAAAAAACAGTTGTTTTGGCTGGTGATTATTCCTACATTAGACAAATT
GAAACCACATTAAAATCTCTGTGTCTATCATGAGAATCTCTCAATTTTTATTTTT
AATCAAGATATTCCTCAAGAATGGTTTTTAGCTATGAAAGATAGGGTTGGACAAAC
TGGAATCAAATTCAGGATGTAAAGCTCTTCCATGATCACTTATCCCCAAAATGGG
AAAATAAAAAGCTTAATCATATTAATTATATGACCTATGCTCGTTATTTTCATACCTC
AGTACATCTCAGCTGATACAGTTTTATATCTTGACTCTGACTTAGTTGTTACTACTA
ATTTAGATAACCTCTTTCAAATTTCACTAGACAATGCATATTTAGCTGCAGTTCCAG
CTCTTTTTTGGGCTTGGATATGGGTTTAATGCTGGAGTAATGGTAATTAACAACCAA
CGTTGGCGACAAGAAAATATGACTATTAAATTAATTGAAAAAAATCAAAAGGAAA
TTGAGAATGCCAACGAAGGGGATCAAACAATTCTTAATCGCATGTTTGAAAATCAG
GTAATTTATTTAGATGATACCTACAATTTTCAAATTGGTTTTGATATGGGAGCTGCT
ATCGATGGGCATAAATTTATTTTTGACATCCCAATTACCCCACTCCCAAAAATTATT
CACTACATTTTCGGGAATCAAACCTTGGCAAACATTATCAAATATGAGACTCCGTGA
GGTATGGTGGCACTATAATTTACTTGAATGGTCAAGTATCATATCTAGTAAAAAAG
TATTTGGTTTAGACCACCCAATTAAACACAAAATTATCGTCTCAATTTCTTATTG
CTACAACCTTCTGATTGTATACCATCTATCTCAGAATTAGTCACTGCCCTTCCAGATT
GTCTATTTACATTGCATGCACCAACAGTTATGTCTGA

MTYQKTVVLAGDYSYIRQIETTLKSLCVYHENLSIFIFNQDIPQEWFLAMKDRVGO' TG
NQIQDVKLFHDHLSPKWENKKLNHINYMTYARYFIPQYISADTVLYLSDLVVTTNLD
NLFQISLDNAYLAAVPALFGLGYGFNAGVMVINNRWRQENMTIKLIEKNQKEIENAN
EGDQITILNRMFENQVIYLD DTYNFQIGFDMGAAIDGHKFIFDIPITPLPKIHYISGIKPW
QTLNMLREVWWHYNLLEWSSIISSKKVFGLDHPIKTQNYRLNFLIATTSDCIPSISEL
VTALPDCLFHLACTNSYV*

ID-12

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

Clone 27

GTGAAGAAAACATATTGTTATATCGGCTCAGTTGCTGCTATTTTACTAGCTACTCAT
ATTGGAAGTTACCAGCTTGGTAAGCATCATATGGGTCTAGCAACAAAGGACAATC
AGATTGCCTATATTGATGATAGCAAAGGTAAGGTAAAAGCCCCTAAAACAAACAA
AACGATGGATCAAATCAGTGCTGAAGAAGGCATCTCTGCTGAACAGATCGTAGTC
AAAATTACTGACCAAGGTTATGTTACCTCACACGGTGACCATTATCATTTTTTACAAT
GGGAAAGTTCCTTATGATGCGATTATTAGTGAAGAGTTGTTGATGACGGATCCTAA
TTACCATTTTAAACAATCAGACGTTATCAATGAAATCTTAGACGGTTACGTTATTA
AAGTCAATGGCAACTATTATGTTTACCTCAAGCCAGGTAGTAAGCGCAAAAACATT
CGAACCAACAACAAATTGCTGAGCAAGTAGCCAAAGGAAGTAAGAAGCTAAA
GAAAAAGGTTTAGCTCAAGTGGCCCATCTCAGTAAAGAAGAAGTTGCGGCAGTCA
ATGAAGCAAAAAGACAAGGACGCTATACTACAGACGATGGCTATATTTTTAGTCC
GACAGATATCATTGATGATTTAGGAGATGCTTATTTAGTACCTCATGGTAATCACT
ATCATTATATTCCTAAAAAAGATTTGTCTCCAAGTGAGCTAGCTGCTGCACAAGCC
TACTGGAGTCAAAAACAAGGTGCGAGGTGCTAGACCGTCTGATTACCGCCCGACAC
CAGCCCCAGGTGCTAGGAAAGCCCCACTTCCTGATGTGACGCCTAACCCTGGACAA
GGTCATCAGCCAGATAACGGTGGTTATCATCCAGCGCCTCCTAGGCCAAATGATGC
GTCACAAAACAAACACCAAAGAGATGAGTTTAAAGGAAAAACCTTTAAGGAACTT
TTAGATCAACTACACCGTCTTGATTTGAAATACCGTCATGTGGAAGAAGATGGGTT
GATTTTTGAACCGACTCAAGTGATCAAATCAAACGCTTTTGGGTATGTGGTGCCTC
ATGGAGATCATTATCATATTATCCCAAGAAGTCAGTTATCACCTCTTGAAATGGAA
TTAGCAGATCGATACTTAACCCGGCCAAACTGA

MKKTYCYIGSVAAILLATHIGSYQLGKHHMGLATKDNQLAYIDDSKKGKVKAPKTNKT
MDQISAEEGISAEQIVVKITDQGYVTSHGDHYHFYNGKVPYDAIISEELLMTDPNYHFK
QSDVINEILDGYVIKVNNGNYVYVLKPGSKRKNIRTKQQIAEQVAKGTKEAKEKGLAQV
AHLSCKEEVAAVNEAKRQGRYTDDGYIFSPTDIIDDLGDAYLVPHGNHYHYIPKKDLS
PSELAAAQAYWSQKQGRGARPSDYRPTPAPGRRKAPLPDVTNPNGQGHQPDNGGYHP
APPRPNDASQNKHQRDEFKKGKTFKELLDQLHRLDLKYRHVEEDGLIFEPTQVIKSNF
GYVVPHGDHYHIIPRSQLSPEMELADRYLTRPN*

ID-13

Clone 28

ATGGTAAATGATATATTAGAAAGAATGTATAAAGAGAATATTCCAAAATCTTACCT
TACATCCGTCCCATTAGTTATTTCTCAAAAAGGAAGAACAACCTATTCGTTTAGTAT
GACTGGTGGTCAACAAATAGATGGAGTGAAATTCACACAGATATATGAGGACTAT
ATGAAATTACTCAGTCAAGGTAAGGATATCGCAGAGTTATATCAAAAATATTCTAA
AGAAGAGTTGGCAAATCTAGGCATTAATATTTATCAATCCAATGATATAGAAAGG
ACTGAGGAAAGAACTTTTGATGAAATTATCAGTTGGGTTTCCAACCCTTATGCAAC
AAGACCAATTCAAGAAAGGCACACTATTCAATTAGAGCCAACAAGATTTTCACTA

FIG. 1CONT'D

SUBSTITUTE SHEET (RULE 26)

GAGGATAAGAAAAGAATTGAAGAAGCTGCAGCTCAAGGACTAAGCGAAATCGAC
CTTATTGATTTAGTTGACCTATATGATATTAATTTAGACAATACAAGCGTCAATCGC
CATATTGTGGGGTTATTGACTAATAACACCCAAGTAACATACTATTTCCAAGAACA
ATTAAATAAGGAGTTGCTGTCAATGGCTCACGCTTTAGATAACGTACAACAGGCCT
TTATTAAATTATTAAGTGAAGAGGAGATACGAAAATTTGCTCTTTAA

MVNDILERMYKENIPKSYLTSVPLVISQKGRTTYSFSMTGGQQIDGVKFTQIYEDYMK
LLSQGKDIAELYQKYSKEELANLGINIYQSNDIERTEERTFDEIISWVSNPYATRIPIQERH
TIQLEPTRFSLEDKKRIEAAAQGLSEIDLIDLVDLYDINLDNTSVNRHIVGLLTNNTQV
TYYFQEQLNKELLSMAHALDNVQQAFIKLLSEEEIRKFAL*

ID-14

Clone 31

ATGAATAAAAGAAGAAAATTATCAAAATTGAATGTAAAAAAACAACATTTAGCTT
ATGGAGCTATCACTTTAGTAGCCCTTTTTTCATGTATTTTGGCTGTAAACGGTCATCT
TTAAAAGTTCACAAGTTACTACTGAATCTTTGTCAAAAGCAGATAAAGTTCGCGTA
GCCAAAAAATCAAAAATGACTAAGGCGACATCTAAATCAAAAGTAGAAGATGTAA
AACAGGCTCCAAAACCTTCTCAGGCATCTAATGAAGCCCCAAAATCAAGTTCTCAA
TCTACAGAAGCTAATTCTCAGCAACAAGTTACTGCGAGTGAAGAGGCGGCTGTAG
AACAAGCAGTTGTAAACAGAAAATACCCCTGCTACCAGTCAGGCACAACAACTTA
TGCTGTTACTGAGACAACCTTACAAACCTGCTCAACACCAGACAAGTGGCCAAGTAT
TGAGCAATGGAAATACTGCAGGGGGCGGTCGGATCTGCTGCTGCAGCACAAATGGC
TGCTGCAACAGGAGTCCCTCAGTCTACTTGGGAACATATTATTGCCCGTGAATCAA
ATGGTAATCCTAATGTTGCTAATGCCTCAGGGAGCTTCAGGACTTTTCCAAACGAT
GCCAGGTTGGGGTTCAACAGCTACAGTTCAGGATCAAGTTAA

MNKRRKLSKLNKQHLAYGAITLVALFSCILAVTVIFKSSQVTTESLSKADKVRVAK
KSKMTKATSKSKVEDVKQAPKPSQASNEAPKSSSQSTEANSQQQVTASEEAAVEQAV
VTENTPATSAQQTYAVTETTYKPAQHQTSGQVLSNGNTAGAVGSAAAAQMAAATG
VPQSTWEHILARESNGNPVANASGASGLFQTMPGWGSTATVQDQVNSAIKAYRAQG
LSAWGY*

ID-15

Clone 32

ATGATTGTTGGACACGGAATTGATTTACAAGAGATAGAGGCGATTACTAAAGCAT
ATGAGCGTAATCAACGTTTTGCAGAACGCGTTTTGACCGAACAAGAATTGCTTCTT
TTTAAAGGAATTTCCAATCCCAAGCGTCAGATGTCTTTTTTAAACAGGGCGATGGGC
AGCAAAAGAGGCTTATAGCAAAGCACTTGGAACAGGAATTGGGAAAGTTAATTTT
CATGATATCGAAATTTTATCGGATGATAAAGGAGCGCCTTTGATTACAAAAGAACC

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

GTTTAATGGAAAATCTTTTGTTCATATCTCATAGTGGTAATTATGCACAAGCTAG
TGTTATTTTGGAGGAAGAAAAATGA

MIVGHGIDLQEIEAITKAYERNQRFALTEQELLFVKGISNPKRQMSFLTGRWAAKE
AYSKALGTGIGKVNFDIEILSDDKGAPLITKEPFNGKSFVSISHSGNYAQASVILEEEK*

ID-16

Clone 35

ATGATTTTTGTCACAGTGGGGACACATGAACAGCAGTTCAACCGTCTTATTAAAGA
AGTTGATAGATTAAAAGGGACAGGTGCTATTGATCAAGAAGTGTTCAATCAAACG
GGTTACTCAGACTTCGAACCTCAGAATTGTCAGTGGTCAAAATTTCTCTCATATGAT
GATATGAACTCTTACATGAAAGAAGCTGAGATTGTTATCACACATGGCGGCCAGC
GACGTTTATGTCAGTTATTTCTTTAGGGAAATTACCAGTTGTTGTTCTAGGAGAAA
GCAGTTTGGTGAACATATCAATGATCATCAAATACAATTTTTAAAAAAAATTGCCC
ACCTGTATCCCTTGGCTTGGATTGAAGATGTAGATGGACTTGCGGAAGCGTTGAAA
AGGAATATAGCTACAGAAAAATATCAGGGAAATAATGATATGTTTTGTCATAAATT
AGAAAAAATTATAGGTGAAATATGA

MIFVTVGTHEQQFNRLIKEVDRLKGTGAIDQEVFIQTGYSDFEQNCQWSKFLSYDDM
NSYMKEAEIVITHGGPATFMSVISLGLPVVPRRKQFGEHNDHQIQFLKKIAHLYPL
AWIEDVDGLAEALKRNIAATEKYQGNNDMFCHKLEKIIGEI*

ID-17

Clone39

TTGGAAGACAAATTATTCAACAAACATTTTATAGGCATTACTATTTTAAACTTTATT
GTTTATATGGTCTATTATTTGTTCAACCGTTATCATAGCTTTTATTGCGACTAAAGAG
TTAGGTGTTAGCACTAGCCAAGCAGGATTAGCAACGGGGATTTATATTGTAGGGAC
TTTGATTGCTCGTCTTATATTTGGTAAGCAATTAGAAGTTCTAGGACGTAAGTTAGT
TTTACGTGGAGGGGCTATTTTTTACTTACTAACAACCTTTAGCTTATTTTTTATATGCC
AAGTATCGGAGTAATGTATTTAGTTCGTTTCCTAAATGGTTTTGGTTATGGCGTCGT
GTCAACAGCAACTAATACTATTGTAACAGCCTATATACCAGCTGATAAAAGAGGTG
AGGGGATTAACCTTTACGGTCTATCAACAAGTTTAGCCGCAGCTATTGGTCCTTTTG
TAGGAACATTTATGCTAGACAACCTTCATATTAACCTTTAAAATGGTTATTGTATTAT
GTAGTATTTTAATTGCGATTGTAGTGTTGGGAGCATTGTGTTTCCCAGTCAAAAATA
TACTTTAAATCCAGAACAGTTAGCTAAATCAAATCATGGACTATTGATAGTTTC
ATTGAGAAAAAAGCAATTTTATCACAATTATTGCATTTTGTATGGGTATCTCCTAT
GCTTCCGTGTTAGGTTTCCAAAAATTATATACAACAGAAATTAATTTGATGACAGT
AGGAGCTTATTTCTTTATTGTTTATGCACTTGTCATCACTTTAACCAGACCATCTAT
GGGAAGATTAATGGACGCTAAGGGAGATAAGTGGGTGCTTTATCCAAGTTATCTGT
TCTTAACCTTTGGGACTTGCTTTATTAGGGAGTGCTATGGGAAGTGTTACCTACCTTC

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

TATCAGGTGCTTTGATTGGTTTTGGTTATGGCACCTTTATGTCTTGTGGCCAAGCAG
CATCAATCAAAGGTGTTGAGGAACATCGTTTCAATACAGCCATGTCAACTTACATG
ATAGGTCTTGATTAGGGTTAGGTGCTGGACCTTACATTTTGGGACTTGTTAAAGAT
GGTTTTCTTGGAGCTGGTGTGCAATCCTTTAGAGAATTATTCTGGATAGCAGCGATT
ATTCCTGTTGTTTGTGGTATTCTATATTTCTTAAAATCATCTAGACAAGTTGAAACT
AAAACCTATA
TAA

MEDKLFNKHFIGITILNFIVYMVYYLFTVIIAFIATKELGVSTSQAGLATGIYIVGTLIARL
IFGKQLEVLGRKLVLRGGAIFYLLTTLAYFYMP SIGVMYLVRFLNGFGYGVVSTATNTI
VTAYIPADKRGEINFYGLSTSLAAAIGPFVGT FMLDNLHINFKMVIVLCSILIAIVVLG
AFVFPVKNITLNPEQLAKSKSWTIDSFIEKKAIFITILAFLMGISYASVLGFQKLYTTEINL
MTVGAYFFIVYALVITLTRPSMGR LMDAKGDKWVLYPSYFLTLGLALLGSAMGSVT
YLLSGALIGFGYGT FMSCGQAASIKGVEEHRFNTAMSTYMIGLDLGLGAGPYILGLVK
DGFLGAGVQSFRELFWIAAIIPVVC GILYFLKSSRQVETKTIZ

ID-18

Clone 47

ATGAATAGTGAACCTAAAAGTCAGTCAAACGAAGTAAAAAATAGCAAGCAATCAG
AAGTGAAGAAAGATAAAAAAATGACAAAAAAGAACAATTAGCCTATCTCAAAG
AGCATGAGCAAGAAATCATAGATTATGTAAAATTACATAACAACCAAATTGAGTC
CGTTCAATTTCGATTGGTCAAGTGTAAGTAGAACAAGCGGGAATGGAACCTCCA
CAAGGGGGGTGATTATAATCTTTCACTGAGAGGAAAGTTTAATCATCTACAAAATTC
AAAATTAATAGTTGATTTTTTATTAGCTCATAAAAAATGATATCCCAAATATCAAAT
CAATGGGAATGCTAAATAAGCCATATATACATAAAAAATGGTATTTGGCACATTTAT
GAATAG

MILGGCQMNSEPKSQSNEVKNSKQSEVKKDKKMTKKEQLAYLKEHEQEIIDYVKLHN
NQIESVQFDWSSVKVEQSGNGTPQGGDYNLSLRGKFNLQNSKLIVDFYLAHKNDIPN
IKSMGMLNKPYIHKNGIWHIYEZ

ID-19

Clone 102

ATGAAAAAGATTTCGATTATCAAAGTTTATTAAAATGATTGTTGTTATTTTGTTTTTA
ATTAGTGTAGCAGCTAGTTTTTATTTTTTCCACGTTGCCCAAGTTCGAGATGATAAA
TCCTTTATTTCAAATGGTCAACGTAAGCCTGGAAACTCTTTATATGCTTATGATAAA
TCCTTTGATAAGCTATTAAAGCAAAAAATAGAAATGACAAACCAAATATAAAGC
AAGTTGCTTGGTATGTTCTGCTGCTAAGAAACTCATAAGACAGTTGTTGTCGTTTC
ATGGTTTTGCGAATAGCAAAGAGAATATGAAGGCATATGGTTGGCTGTTTCATAAG
TTAGGATACAATGTTCTTATGCCTGACAACATTGCACATGGTGAAAGTCATGGGCA

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

GTTGATAGGCTATGGCTGGAACGACCGCGAGAACATTATCAAATGGACAGAAATG
ATAGTGGATAAGAATCCATCAAGCCAAATTACTTTATTTGGTGTTCATGGGTGG
AGCAACAGTCATGATGGCTAGTGGTGAAAAATTACCTAGTCAGGTTGTTAATAT
CATTGAAGATTGTGGTTATTCTAGTGTTCGGGATGAATTAATAATTCAGGCTAAAG
AGATGTATGGTTTACCAGCCTTCCCCTCTTATATGAAGTTTCAACAATTTCTAAAA
TCAGAGCAGGTTTTTCGTATGGACAAGCAAGTAGTGTGCAACAATTGAAAAAGAA
TAATTTACCAGCCCTCTTTATTCATGGTGATAAGGATAATTTTGTTCACAAGTAT
GGTTTATGACAACATAAAGCTACAGCAGGTAAGAAAGAGCTTTATATTGTAAAA
GGGGCAAAACATGCGAAATCTTTTGAAACAGAGCCAGAAAAATATGAGAAACGTA
TCTCTAGTTTTTTGAAAAAATATGAAAAATAA

MKKIRLSKFIKMIVVILFLISVAASFYFFHVAQVRDDKSFISNGQRKPGNSLYAYDKSFD
KLLKQKIEMTNQNIKQVAWYVPAKKTHKTVVVVHGFANSKENMKAYGWL FHKLG
YNVLMPDNIAHGESHGQLIGYGWNDRENIKWTEMIVDKNPSSQITLFGVSMGGATV
MMASGEKLPSQVVNIIEDCGYSSVWDELKFQAKEMYGLPAFPLLYEVSTISKIRAGFSY
GQASSVEQLKKNNLPALFIHGDKDNFVPTSMVYDNYKATAGKKEL YIVKGAKHAKSF
ETEPEKYEKRISFLKKYEK*

ID-20

Clone 120

TTGAGGAGTAATATGGTAAAGACAGCAGTTTTAATGGCGACATACAATGGCGAAA
AATTTATATCTGAACAACCTTGATTCAATTCGCCAACAGACATTAAAACCAGATTAT
GTATTATTGAGGGATGATTGTTCAACGGATGAAACAGTCAATGTCGTCAATAACTA
TATCGCAAAACATGAGTTAGAAGGCTGGAAAATTGTTAAAAACGACAAAAACTTA
GGCTGGCGTTTTAAATTTTCGTCAATTACTTATTGATGTGTTAGCCTATGAGGTTGAC
TATGTCTTTTTTAGTGATCAAGATGATATTTGGTATCTTGATAAAAACGAACGACA
GTTTGCCATTATGTCAGATAACCCTCAAATTGAGGTTTTGAGTGCAGACGTTGATA
TCAAAACGATGTCTACAGAAGCCAGTGTTCCACATTTTCTAACTTTTTCTTCTAGTG
ATAGAATCAGTCAGTATCCTAAAGTATATGATTATCAAACATTCCGTCCCGGATGG
ACCATTGCTATGAAGAGAGATTTTGCGCAAGCTATCGCTTGA

MRSNMVKTAVL MATYNGEKFISEQLDSIRQQTLKPDYVLLRDDCSTDETVNVVNNYI
AKHELEGWKIVKNDKNL GWRLNFRQLLDVLA YEVDYVFFSDQDDIWYLDKNERQF
AIMSDNPQIEVLSADVDIKTMSTEASVPHFLTSSSDRISQYPKVYDYQTFRPGWTIAM
KRDFQAIAZ

ID-21

Clone 143

ATGATTCATGAGATTCACGATTGTCAATTTATTGAAAAAGGAAGTTACGTTTATTT
GAATTATATTAATGCTGAGGGCGAGAGAGTAGTTATTATAATCATAGATTTTGTCC

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

G TAGTGTTAGTCCTATTTTATATCGTCTATTTATGATTTTACTTGCACAAGAAGTAC
CTCACTTGCATGATTACATCTATAATGCAAGAGATGATCACTACGATACTTGGAAG
TTTAAAGAATTAAAGGAGTCAAACCATCCAGTCCTTTTGGCATTCTCTGAAAGGTG
GCACGATAGTCGCTTGACTTCTAAAAGCCTTGCAGAATGTTTACAATTAACCGACC
TTGATGAAGAAGTGAAATCGACCATCATTCAATTAAGACAGTTCGAAAAATCAGTC
AGAAATCCTTTGGCTCACCTGATTAAACCTTTTGATGAGCAAGAACTATATCGTAC
AACTCAATTTTCTTCTCAAGCATTTTATAGACCAGATTATCTTCTTGGCAAAGGTAAT
TGGTGTTGAGTATGATACTGTTAATTTTCACTACGATACGGTTAACAAGCTTATTAT
AAAGATACTTGAGTAA

MIHEIHDCQFIEKGSYVYLNINAEGERVVIIIIDFVRSVSPILYRLFMILLAQEVPHLHD
YTYNARDDHYDTWKFKELKESNHPVLLAFSERWHDSRLTSKSLAECLQLTDLDEEVKS
TIIQLRQFEKSVRNPLAHLIKPFDEQELYRTTQFSSQAFLDQIIFLAKVIGVEYDTVNFHY
DTVNKLIKILE*

ID-22

Clone 1

ATGGTAAAAGTTTCAAATTTAGGGTATCCACGTCTTGGTGAACAGCGCGAATGGAA
GCAAGCGATCGAAGCTTTCTGGGCAGGGAATCTTGAACAAAAAGATTTAGAAAAA
CAACTAAAACAATTACGTATCAATCATTTAAAGAAACAAAAAGAGGCAGGTATTG
ACCTTATTCCAGTGGGGGATTTTTCTTGTTATGATCATGTTTTGGATTTGTCATTTC
ATTCAATGTAATCCCAAAGCGTTTCGATGAGTATGAGAGGAATTTAGACCTTTATT
TTGCTATTGCAAGAGGTGACAAAGATAATGTCGCATCATCTATGAAAAAGTGGTTT
AATACCAACTACCACTACATAGTCCCAGAATGGGAGGTTGAGACTAAACCTCACTT
GCAGAATAATTACTTACTTGATCTTTATCTAGAAGCTAGGGAAGTAGTTGGTGATA
AAGCAAAGCCGGTTATC

MEEIMVKVSNLGYPRLGEQREWKAIEAFWAGNLEQKDLEKQLKQLRINHLKKQKE
AGIDLIPVGDFSCYDHVLDLSFQFNVIPKRFDEYERNLDLYFAIARGDKDNVASSMKK
WFNTNYHYIVPEWEVETKPHLQNNYLLDLYLEAREVVGDKAKPVI

ID-23

Clone 2

ATGGTGTTACTTTTATTGCTAATGGTAGCCAAGTCAAGTTTGATGGTTACATGGCTG
TTTATAACGATACTGACAAAAATAAAATGTTACCAGATATGGAGGAAGGAGAAAG
TTATCAAGTTAA

MVLLLLLMVAKSSLMVTWLFITILTKIKCYQIWRKEKVIKL

ID-24

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

Clone 14

ATGAACAAAAAATTTCCGGGATCGGCTTGGCTTCGATTGCAGTACT
TAGTTTAGCTGCATGTGGACATCGTGGTGCTTCTAAATCTGGTGGTAA
ATCAGATAGCTTGAAGGTTGCAATGGTAACAGATACCGGTGGTGTG
ATGATAAATCATTTAACCAATCTGGTTGGGAAGGTATGCAAGCTTGG
GGCAAGAAGAATGGCCTTAAAAAAGGAGCTGGTTTTGACTATTTCCA
ATCGGCAAGTGAATCTGATTATGCAACTAACTTAGATACAGCTGTGT
CTAGTGGTTATAAATTGATTTTCGGTATTGGATTTTCTCTTCATGATG
CTATTGATAAAGCAGCAGACAATAACAAAGATGTTAATTACGTCATC
GTTGATGATGTTATTAAAGGGAAAGATAATGTTGCAAGTGTTGTCTTT
GCGGATAATGAATCAGCTTACTTAGCAGGTATTGCAGCCGCTAAAC
TACCAAAACAAAAACAGTTGGCTTTGTAGGTGGTATGGAATCTGAGG
TTATTACCCGTTTTTGA AAAAAGGTTTTGAAGCAGGTGTCAAATCAGTTG
ATAAATCAATTAAAATTAAAGTTGACTATGCTGGTTCATTCGGTGAT
GCTGCTAAGGGTAAGACAATTGCAGCCGCACAATATGCTTCTGGCGC
AGATATT

MNKKISGIGLASIAVLSLAACGHRGASKSGGKSDSLKVAMVTDTGVD
DKSFNQSGWEGMQAWGKKNGLLKKGAGFDYFQSASESDYATNLDTAVS
SGYKLIFGIGFSLHDAIDKAADNNKDVNYVIVDDVIKGDNVASVVFAD
NESAYLAGIAAAKTTKTKTVGVFVGGMESEVITRFEKGFEAGVKSVDKSI
KIKVDYAGSFGDAAKGKTIAAAQYASGADI

ID-25

Clone 20

ATGTTACATTCTAAAAAAATACATTCCTTATCGCTTATTGCCGTTCTC
TCTTTAGCAACATATACGAGTTTACAACCAAATCATGTAGCGGCTGA
ACAATCACAAAAAACATCAACTGTTCTTATGAGTCAAAAAACTATTG
AACATAAGTTAAAAGTTGCAGATAAAGAAGCTGCTCCTCTCTACGCT
AAAATCGACCATATCCAACGACATATTGAAGTCAAAAAAGCAAAAG
ATTTAAAAGTTATTGAATTGTATATTAACAAAGATATCAACCAACTA
GAGAAGCAAAATAAACGTCTACTAACTAAATTCTATACTTCTATTGA
TAATCAAACATGGGATAGCACAAGTGAAGTCAAAAAATTGATTGATA
AGACAACCCTATCCACTAACGAAAAAGATAGATTA AAAATTATATTTT
GAACAACGTGCTTACCTTGAGACAAGGTTGAACGACCGCTATCAAAA
ATTTGATAACTCTATTGAAAACCAAATAAAGAACTAAAAATATTA
CGTCAAAAATAGAAAAAATCTATCAAAAACATGGTATTACAAAAGA
GGTATTAAAAACTTACTATGCTAAAAAACAGTACGAGCTGACTGA

FIG. 1 CONT'D

MLHSKKIHSLSLIAVLSLATYTSLOPNHVA AEQSQKTSTVLMSQKTIEHK
LKVADKEAAPLYAKIDHIQRHIEVKKAKDLKVIELYINKDINQLEKQNK
RLLTKFYTSIDNQTWDSTSEVKKLIDKTTLSTNEKDRLKLYFEQRAYLET
RLNDRYQKFDNSIENQNKELKILTSKIEKIYQKHGITKEVLKTTYAKKTV
RAD*

ID-26

Clone 25

Clone 25 (partial sequence)

CTGAATTCCCAAAAACGCTACAATCAAACCTTGGTATCCTACTTATGGTTTTTCTGAT
ACTTATGCATTCATGGTTACTAAAGAGTTTGCCAGACAGAATAAAAATCACCAAGAT
CTCTGATCTCAAAAAGTTATCAACAACCTATGAAGGCAGGGGTTGATAGTTCATGGA
TGAATCGCGAGGGAGATGGATACACTGATTCGCTAAAACATACGGTTTTTGAATTT
TCACATATTTACCCTATGCAAATTGGCTTAGTCTATGATGCGGTTGAAAGTAACAA
AATGCAATCTGTATTAGGCTACTCCACTGACGGTCGTATTTTCGAGCTATGATTTAG
AAATTTTAAGGGATGATAAAAAAATTCTTTCCTCCTTATGAAGCCTCTATGGTTGTCA
ACAATTCTATCATCAAAAAAAGATCCTAAACTAAAAAAATTACTCCATCGACTCGAT
GGTAAAATCAATTTAAAAACGATGCAAAACCTTAATTATATGGTAGATGATAAACT
TTAGAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCG
CTCACAATTCCACACAACATACGAGCCGGAAGCATAA

LNSQKRYNQWYPTYGFSDTYAFMVTKEFARQNKITKISDLKKLSTTMKAGVDSSWM
NREGDGYTDFAKTYGFEFSHIYPMQIGLVYDAVESNKMQSVLGYSTDGRISYDLEILR
DDKKFFPPYEASMVVNNSIHKDPKLLKLLHRLDGKINLKTMQNLNYMVDDKLLEAW
RNHGHSCFLCEIVIRSQFHTTYEPEA*

ID-29

Clone 37

ATGAAAAAATTACTTTCCCTAACATGTCTAATCATGATGTCTTTATGT
TTAGTGGCATGTACTAAGCAAGCAATGTCGTCTAAGCAAGCAATGTC
GTCTAAGCAAATTAAGATAAGAATAGTAAAGAAAAGGTGATTACT
GTTGCAACTTACAGCAAACCTACATCTACCTTTTTAGATTTGATTAAA
GATAATGTAAAAGAAAAAGGATATACTTTAAAGGTTGTCATGGTCTC
TGACTATATTCAGGCTAACATTGCTTTAGAAAACAAAGAACATGATG
CTAACCTTTTACAACATGAATTTTTCATGAGTATCTTTAATAAGGAAA

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

ATGATGGTCATCTAGTGTCAATTACACCAATTTATCATTTCATTGGCTG
GTTTTTATGGTCAACATTTGAAAAATATTGCCGAGCTTAAAGACGGT
GCTAAGGTAGCGATTCCGTCTGATCCTGCCAATATGACTAGAGCTCT
GCTATTATTGCAAGAAAAGAACTTATCACCTTAAAGAATACGTCCA
AAAAGACCAAGGCTATCGAAGATATTATTACTAACCCTAAAAAATTA
CGAATTGAACCTGTAGCATTACTTAACCTCAATCAGGCCTATTTTGAA
TATGACCTTGTCTTTAATTTCCCTGGATATGTGACAAAAATCAATCTA
GTTCTTAAAAGGGATAGATTATTATATGAGAAAAAACCAGATATCCG
TTTTGCAGGTGCCTTGGTAGCTCGTGAAGATAATAAAAAATAGTGATA
AAATAAAAGTACTTAAAGAAGTACTAACAAGTAAAGAGATTTCGTCA
CTATATCACTAAGGAGATTCCAAGTGAAGCAGACGTTGCGTTCTAG

MKKLLSLTCLIMMSLCLVACTKQAMSSKQAMSSKQIKDKNSKEKVITV
ATYSKPTSTFLDLIKDNVKEKGYTLKVVMVSDYIQANIALENKEHDANL
LQHEFFMSIFNKENDGHLVSITPIYHSLAGFYGQHLKNIAELKDGAKVAI
PSDPANMTRALLLLQEKKLITLKNNTSKKTKAIEDIITNPKKLRIEPVALLN
LNQAYFEYDLVFNFPGYVTKINLVPKRDRLLYEKKPDIRFAGALVARED
NKNSDKIKVLKEVLTSKEIRHYITKEIPSEADVAF*

ID-30

Clone 38

CTGTTGGCTAAGGAAACCACTATGTCTGTCCTTTGGTATCAAAATTCTGCAGAAGC
CAAGGCTTTATATTTACAAGGTTATAATGTTGCTAAAATGAAGTTAGATGATTGGT
TACAAAAGCCCAGTGAAAAACCATATTCAATTATCTTAGATTTAGATGAAACAGTT
TTAGATAATAGCCCATATCAAGCAAAGAATATTAAAGATGGCTCTAGTTTCACGCC
AGAGAGTTGGGATAAATGGGTGCAAAAGAAATCAGCTAAGGCTGTTGCGGGGTGCC
AAAGAATTTTTGAAGTATGCTAATGAAAAGGGAATAAAAATTTATTATGTCTCAGA
TCGTACAGATGCTCAAGTTGATGCGACTAAAGAAAATTTAGAGAAGGAAGGTATA
CCTGTTCAAGGGAAAGACCACTTGCTTTTCCTTAAAAAAGGAATGAAATCTAAAGA
GAGTCGCCGTCAGGCAGTTCAAAAAGATACCAATTTAATTATGCTTTTTTGGAGATA
ATTTAGTTGATTTTGCTGATTTTTCTAAATCATCTAGTACAGATAGAGAACAACACTAC
TAACTAAACTTCAAAGTGAGTTTGGTAGTAAATTTATTGTTTTTCCCAAATCCTATGT
ACGGTTCTTGGGAAAGTGCTATTTATCAAGGAAAACATCTGGATGTTCAAAAACAA
TTGAAAGAACGACAAAAAATGTTGCATTCTGATGATTAA

MAKLTVKDVDLKGKKVLVRVDFNVPLKDGVTNDNRITAALPTIKYIIEQGGRILFSH
LGRVKEEADKEGKSLAPVAADLAAGLQDVVFPVTRGAKLEEAINALEDGQVLLVE
NTRFEDVDGKKESKNDEELGKYWASLGDGIFVNDAFGTAHRAHASNVGISSNVEKAV
AGFLLENEIAYIQEAVETPERPFVAILGGSKVSDKIGVIENLLEKADKVLIGGGMTYTFY
KAQGIEIGTYLEKEDKLDVAKDSZ

ID-31

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

Clone 41

ATGGATAATAAAGGTAATAACGCCAATGTGATTGATGCAATCGCTGAGGGTGCAA
GCACAGGTGCACAAATGGCTTTCTCAATTGGTGCTAGTTTGATTGCCTTTGTTGGTT
TAGTTTCTTTGATTAA

MDNKGNNANVIDALAEASTGAQMAFSIGASLIAFVGLVSLI

ID-32

Clone 42

ATGAAAAAGAAAAACAAATCCTCTAACATTGCTATAATTGCAATCTT
TTTTGCTATTATGCTTGTCATTCATTTTTTGTGCATCATTTATTTTAGTT
TTTGGTTAGTCCCTATTAAACCTACTTTGATGCATATCCCAGTTATTA
TTGCATCTATAGCCTATGGACCTCGTATTGGTGCAACTCTAGGCGCCT
TAATGGGGGGGATCAGCGTAGCTAACAGCAGCATTGTTCTATTACCA
ACGAGTTACCTCTTCTCACCTTTTGTTGAAAATGGTAATTTTTATTCTG
CTAATTATTGCACTTGTACCACGTATTCTAATCGGGATTATTCCTTAT
TTCGTTTACAAATTACTACACAACCGCTTTGGTTTGGCTATCTCAGGT
GCTATAGGCTCTCTAACAAACACAGTATTTGTTTTATCTGGAATTTTT
ATCTTTTTTTCAAGTACTTATAATGGGAATATCAAGCTAATGCTCGCT
GGGATTATTTTCATCTAATTCATTAGCTGAGATGGTCATTGCAGCTATC
ATTGTATATCTAACTGATCCTCGTATTCTCAATATTAAACATTAA

MKKKNKSSNIAIAIFFAIMLVIHFLSSFIFSFVLVPIKPTLMHIPVILASIA
YPRIGATLGALMGGISVANSSIVLLPTSYLEFSPFVENGNFYSLIHALVPRILI
GIIPYFVYKLLHNRFGLAISGAIGSLTNTVFVLSGIFIFSSTYNGNIKML
AGIISNSLAEMVIAAIVVYLTDPRI LNIKH*

ID-33

Clone 43

TTGAATATGACATTACAAGACGAAATCAAAAAACGCCGTACTTTTGCCATCATCTC
TCACCCGGATGCTGGTAAGACGACTATTACTGAGCAATTATTATTTTTGGTGGTG
AAATTAGAGAAGCAGGGACAGTAAAAGGGAAAAAATCAGGTACTTTTGCAAAGTC
CGACTGGATGGATATTGAAAAGCAACGGGGTATCTCTGTTACTTCATCTGTTATGC
AATTTGATTACGCGGGGTAAACGTGTAA

MNMTLQDEIKKRRTFAIISHPDAGKTTITEQLLYFGGEIREAGTVKGKKS
GTF AKSDW
MDIEKQRGISVTSSVMQFDYAG

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

KRV

ID-34

Clone 44

ATGGCAGATAAAAACAGAACATTTAAACTTGTAGGTGCAGGATCTTC
TAGCACACAAGAAAAAATTGAAAAGCCTGCTCTTTCGTTTATGCAAG
ATGCGTGGCGTCGCTTGAAAAAAAACAAATTAGCAGTAGTTTCACTC
TATTTATTAGCTCTTTTACTTACTTTTTTCGTTAGCCTCAAATTTATTG
TAACTCAGAAGGATGCTAATGGGTTTGATTGAAAAAAGTAACGACA
TATCGCAACTTACCACCTAAATTGAGTTCAAACCTTCCTTTTTTGAAT
GGTAGCATTAAATCCATCA

MADKNRTFKLVGAGSSSTQEKIEKPALSFMQDAWRRLKKNKLA VVSLY
LLALLLTFSLASNLFVTQKDANGFDSKKVTTYRNLPPKLSSNLPFWNGSI
NPS

ID-35

Clone 46

ATGAAAAGAAAACAGTTTATAAAATTAGGAATTGCAACCTTACTAACGGTTATTTC
GCTTTACACACCAATAAACCTAGCTACAAATCATACCACAGAAAATATTGTTACTG
CTCAAGAGTATAAAACAAAGAGAATGGTACTTTACCTTTTAA

MKRKQFIKLG IATLLTVISLYTPINLATNHTTENIVTAQEYKTKENILFLL

ID-36

Clone 50

ATGTTTTATAATCCTTTACTTTTTATTGTACTAATTACAATTGCTGTATTTTTCTTAG
CTAAGAAAAAATGGCAATTACCGACATTTACTTTCATTGGTTTGCTATTTATCTATA
ACCAAGGGCTGTGGGAACAGTTGATTAAT

MFYNPLLFIVLITIAVFFLAKKKWQLPTFTFIGLLFIYNQGLWEQLIN

FIG. 1 CONT'D

ID-37

Clone 51/52

GTGGTGCAAATAATGAAAAAACATATAAAAAGTATCATACCAATAGT
TCTTATTGGTATGATACTAGGAGGCTGTCAAATGAATAGTGAACATA
AAAGTCAGTATAATGAAACAAAAAGTAGCAAGCAATCAGAAGTGAA
GAAAGATAAAAAAATGACAAAAAAGAACAATTAGCTTATCTCAA
GAGCATGAACAAGAAATAATTGATTTTGTAAAATCTCAGAATAAAAA
GATAGAATCTGTACAAATTGATTGGAATGATGTTTCGATGGAGTAAAG
GGGGAAATGGTACACCTCAAGGAGGAGGAGAGGGGATTTTACTTTT
GGGGAGATTAATAATGATTCTGAATCAAGTTGGAGAGTTGATATTGA
TATAGAAAAAGGACGGCTAGACCTAAAAAATATGTATTTAGGACAA
CCTATACGAATTGGAGGTAATTATTTGAGTAA

MVQIMKKHIKSIPIVLIGMILGGCQMNSEHKSQYNETKSSKQSEVKKDK
KMTKKEQLAYLKEHEQEIIDFVKSQNKKIESVQIDWNDVRWSKGGNGT
PQGGGEGILLFGEINNDSESSWRVDIDIEKGRDLKKNMYLGQPIRIGGKLF
E*

ID-38

Clone 53

ATGGAATTTTTGGCTTATAATGCTTTCACAGCAATCGGTGTTTCTATT
CCGCACGGTAATCATTTCCACTTTATTTCACTATAAGGATATGTCTCCA
TTAGAGTTAGAAGCAACAAGGATGGTGGCAGAGCATAGAGGACATC
ATATTGATGCATTAGGGAAAAAAGATTCTACAGAGAAACCAAAGCA
TATTTCTCATGAACCTAATAAGGAACCTCACACAGAGGAAGAACACC
ATGCAGTAACACCGAAAGACCAACGTAAAGGCAAACCAAATAGCCA
GATTGTCTACAGTGCTCAAGAAATTGAAGAGGCAAAAAAAGCTGGT
AAATACACAACATCTGATGGTTACATTTTTTGATGCTAAAGATATTAA
AAAAGATACAGGTACAGGTTATGTCATTCCACATATGACACATGAGC
ATTGGGTACCAAAGAAAGATTTATCAGAGTCGGAATTAAAAGCAGCT
CAAGAATTTCTTTTCAGGAAAATCTGAAGCAAATCAAGACAAACCAA
AACAGGTAAAACAGCTCAAGAAATCTATGAGGCAATTGAACCAAAA
GCAATTGTTAAACCTGAAGATTTATTATTTGGAATTGCACAAGCGAC
AGACTATAAGAATGGTACATTTGTAATTCCTCATAAAGATCATTACC
ATTATGTGGAATTAAAATGGTTTGATGAAGAAAAAGATCTTTTAGCT
GATTCAGATAAGACATATTCTTTAGAAGACTATTTAGCTACGGCTAA
ATATTACATGATGCACCCAGAAAAACGTCCTAAAGTTGAAGGATGGG
GTAAAGATGCTGAAATTTATAAGGAAAAGGACTCTAATAAAGCAGA
TAAACCAAGTCCTGCACCAACTGATAATAATCAACATCAAATTCTA

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

GTGACAAAACTTAAGTGCTGCAGAAGTATTCAAACAAGCAAAACC
AGAAAAAATTGTACCGCTTGATAAAATTGCTGCTCACATGGCATATG
CAGTTGGATTTGAAGATGATCAATTGATTGTTCTCATCATGATCATT
ATCATAATGTTCTATGGCATGGTTTGACAAGGGTGGTTTATGGAAA
GCACCAGAAGGCTATACATTACAACAACCTCTTCTCAACAATTAAATA
CTACATGGAACATCCTAATGAATTACCAAAAGAAAAGGGTTGGGGA
CACGACAGTGATCATAACAAAGGCTCAAATAAAGACAATAAAGCCA
AAAATTATGCTCCAGATGAAGAACCTGAAGATTCAGGGAAAGTAACT
CACAACATATGGTTTTTATGATGTTAATAAAGGTTTCAGACGAAGAAGA
ACCAGAAAAACAAGAAGATGAATCAGAGCTAGATGAATATGAACTA
GGAATGGCACAAAACGCTAAGAAATATGGTATGGATAGACAATCTTT
TGAAAAGCAACTCATCCAATTATCAAATAAATATAGTGTAAGTTTTG
AAAGC

MEFLAYNAFTAIGVSI PHGNH FHFH IYKDM SPLELEATRMV AEHRGHHI
DALGKKDSTEKPKHISHEPNKEPHTEEHHAVTPKDQRKGKPN SQIVYS
AQEIEEAKKAGKYTTSDGYIFDAKDIKKDTGTGYVIPHMTHEHWVPKK
DLSESELKAAQEFLSGKSEANQDKPKTGKTAQEIEAIEPKAIVKPEDLL
FGIAQATDYKNGTFVIPHKDHYHYVELKWFDEEKDLLADSDKTYSLED
YLATAKYMMHPEKRPKVEGWGKDAEYKEKDSNKADKPS PAPT DNK
STSNSSDKNLSAAEVFKQAKPEKIVPLDKIAAHMAYAVGFEDDQLIVPH
HDHYHNVPMAWFDKGGLWKAPEGYTLQQLFSTIKYYMEHPNELPKEK
GWGHDS DHNKGSNKDNKAKNYAPDEEPEDSGKVTHNYGFYDVNKG S
DEEPEKQEDESELDEYELGMAQNAKKYGM DRQSFEKQLIQLSNKYSV
SFES

ID-39 (Same as ID-76)

Clone 56

ATGAGGAAACGTTTTTCTTGCTAAATTTTATTGTTGTTACTTTTATTT
TCTTTTCTTTATTCTTTTCCGCTTTTAAAGGCCAAAGATTGTCAGGT
TGTTTATGCAAGTTTTCAAGGAGATCATTGGGACATTTGTAACGCATT
TGATTTTCCGTATTTACATCGCTTTGATCTCATTAAAGGTAAAGAAAA
TCAACTTTACTTTATAGGTTGTACAATTGCTAACAGTAAAGCCTACAC
TGAGGATTGGAGTGATAAAGGCCGAATTTTTGTTGCTCGTTTTAATAC
TCAAACCATACATTGGAAGGATTGCAACAATTGCCTCAAACCTTTAT
TAAAAAATCATGGATACTATGCCATTCAGGATGAAGGATATTCATTG
ATTACTTCAGTAGAAGGGGTACTCAAACCTCACTTATCCAGAATTTTCT
ACTACAGGCGACTGGCAATTAGAACGGCTTTTCGATGAGGAGACAAG
CGATGTGGTGAAAGTGGATATTAATCAGGATGGTAAGGATGAGTATG
TGATCATCCAAGGTTTTTCATGGAGATCGTTTACGTATCTTCACTGAAG
ATTTCCGGTCGAGAATTATTCCATTATCCTGAAAAAACCCCATTTGGTC
ACGCTATTTGGAGTGGTCGTTTACTTAATCAGACTTGTTTCGTATTCG

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

GGTGGCGATCAGAAAAAGCAGAATTAAGGCTTTTTTCACTTTGTAGAT
GGGCACTTGGTTTCAGAATTAGTAGATGCAAAAGCAGCTTCTAGTAA
TGTCTTAGCTTTTGAAAAAGATGGAAAAGCTTATCTTTTCTCAGCCAA
TAACGGACGTGGCGAAGTTGCTCTTTATCAATTAGTAAAATAA

MRKRFSLLNFIVVTFIFFFFILFPLFKAKDCQVVYASFQGDHWDICNAFDF
PYLHRFDLIKGENQLYFIGCTIANSKAYTEDWSDKGRIFVARFNTQNHT
LEGLQQLPQTLLKNHGYIAIQDEGYSLITSVEGVCLKLTYPEFSTTGDWQ
LERLFDEETSDVVKVDINQDGKDEYVIIQGFHGDRLRIFTEDFGRELFHY
PEKTPFGHAIWSGRLLNQTCFVFGWRSEKAELRLFHFVDGHLVSELVDA
KAASSNVLAFEKDGKAYLFSANNGRGEVALYQLVK*
ID-40

Clone 57

ATGAAGCACAAAGTTAAAAGCTTTTACGCTTGCTTTACTCTCAATATTC
TTTGTGTTTGGTGGAAAGGTCAGTGCAGAGACTGTGAATATTGTTTCT
GATACAGCATACGCTCCATTTCGAATTTAAAGATTCTGATCAAACCTTAT
AAAGGAATCGATGTTGACATCGTTAACGAAGTCGCTAAGCGTGCTGG
CTGGAATGTTAACATGACGTATCCAGGTTTTGATGCCGCGAGTTAACG
CTGTTCAATCTGGACAGGCAGATGCGCTAATGGCCGGAACCTACTGTT
ACTGAAGCACGTAAAAAAGTCTTTAATTTCTCAGATACTTATTACGAT
ACTTCCGTTATTCTTTATACTAAAAATAATAAAAGTCACAAACTAC
AAACAACCTAAAAGGAAAAGTAGTCGGTGTAATAAATGGAACAGCTG
CTCAAAGCTTCTTAGAAGAAAATAAATCTAAATACGGCTATAAAGTT
AAAACATTTGATACAAGCGACCTAATGAATAACAGCCTTGATTCTGG
TTCTATTTACGCCGCTATGGACGATCAACCAGTTGTGCAATTTGCGAT
AAATCAAGGAAAAGCTTACGCCATTAAACATGGAAGGCGAAGCAGTT
GGTAGCTTTGCATTTGCTGTCAAAAAAGGTAGTGGACACGATAATCT
AATTAAAGAATTTAACACAGCTTTTGCACAAATGAAATCAGATGGCA
CTTATAATGACATCATGGATAAATGGCTTGGAAAAGACGCTACAAAA
ACAAGCGGCAAAGCAACAGGTAATGCCAATGAAAAAGCAACTCCTG
TAAAGCCAAGTTATAAAATTGTTTCTGATTCTTCATTTCGCACCATTCTG
AATATCAAAACGGTAAAGGGGAAATATACTGGTTTTGATATGGAATTA
ATCACGAAAATTGCTAAACAGCAAGGTTTTAAACTTGATATCTCAA
TCCAGGTTTTGATGCCGCTTTAAATGCTGTCCAATCTGGGCAAGCTGA
CGGTGTTATTGCAGGAGCCACAATCACAGAAGCACGCCAAAAAATCT
TTGATTTTTCTGATCCTTATTACACATCTAGCGTTATCTTAGCGGTAA
AAAAGGAAGCAATGTCAAATCATACCAAGATTTAAAAGGAAAAACA
GTTGGTGCTAAAAATGGTACTGCCTCATATACTTGGTTATCAGACCAC
GCAGATAAGTACAACCTATCATGTAAAGCATTGATGAAGCATCTAC
AATGTATGATAGTATGAACTCAGGTTCAATTGATGCTCTAATGGATG
ACGAAGCCGTTCTTGCTTACGCTATTAATCAAGGTCGTAAATTTGAA
ACACCTATCAAAGGTGAAAAATCAGGCGATATCGGATTTGCAGTGAA

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

AAAAGGGGGCAAATCCAGAATTAATTAATAATGTTTAACAACGGGTCTTG
CTTCACTCAAAAAATCGGGTGAGTACGATAAACTTGTTAAAAAATAC
CTTTCCACAGCCAGCACTTCTTCAAACGATAAAGCTGCTAAACCTGT
AGATGAATCAACTATTTTAGGGTTAATTTCTAATAACTACAAACAATT
GCTATCTGGTATTGGAAGTACTTTAAGTTTAACTCTTATCTCGTTTGC
GATTGCTATGGTTATTGGTATTATCTTTGGTATGATGAGCGTATCACC
AAGTAATACTCTCCGCACAATTTCAATGATTTTTGTTGATATTGTCCG
TGGTATTCCACTCATGATTGTGGCCGCTTTTATTTTCTGGGGTATTCCT
AATTTAATCGAAAGCATCACAGGTCACCAAAGTCCAATTAATGACTT
CGTTGCTGCTACTATCGCTCTTTCTTTAAATGGTGGTGCGTACATTGC
TGAAATTGTACGTGGTGGTATTGAAGCTGTTCTTCTGGTCAAATGGA
AGCAAGTCGCAGCTTAGGTATTTCTTACGGCAAACTATGCAAAAGG
TTATCTTACCTCAAGCAGTACGCCTTATGTTACCAAACCTTTATCAACC
AATTTGTCATCTCATTAAAGGATACAACAATTGTATCAGCAATCGGA
CTTGTGGAAGTCTTCCAAACTGGTAAATCATAA

MKHKLKAFTLALLSIFVFGGKVSAETVNIVSDTAYAPFEFKDSDQTYK
GIDVDIVNEVAKRAGWNVNMTYPGFDAAVNAVQSGQADALMAGTTV
TEARKKVFNFSPTYDYDTSVILYTKNNNKVTNYKQLKGKVVGKNGTA
AQSFLEENKSKYGYKVKTFTDSDLMNNSLDGSIYAAMDDQPVVQFAI
NQGKAYAINMEGEAVGSFAFAVKKGSGHDNLIKEFNFAAQMKS DGTY
NDIMDKWL GKDATKTSGKATGNANEKATPVKPSYKIVSDSSFAPEYQ
NGKGKYTGFDMEITKIAKQQGFKLDISNPGFDAALNAVQSGQADGVIA
GATITEARQKIFDFSDPYTSSVILAVKKGSNVKSYQDLKGKTVGAKNG
TASYTWLSDHADKYNHVKAFDEASTMYDSMNSGSIDALMDDEAVLA
YAINQGRKFETPIKGEKSGDIGFAVKKGANPELIKMFNNGLASLKKSGEY
DKLVKKYLSTASTSSNDKAAKPVDESTILGLISNNYKQLLSGIGTTLSLTL
ISFALAMVIGIIFGMMSVSPSNTLRTISMIFVDIVRGIPLMIVA AFIFWGIPN
LIESITGHQSPINDFVAATIALSLNGGAYIAEIVRGGIEAVPSGQMEASRSL
GISYGKTMQKVILPQAVRLMLPNFINQFVISLKD TTIVSAIGLVELFQTGK
S*

ID-41

Clone 58

TTGGAAGGTTTACTTATTGCATTGATTCCCATGTTTGCGTGGGGGAAGTATTGGATT
GTTAGTAATAAAATTGGAGGGCGTCCAAATCAACAAACATTTGGAATGACTTTAGG
AGCATTGCTATTTGCGATTATCGTATGTTTATTAA

MEGLLLALIPMFAWGSIGFVSNKIGGRPNQQTFGMTLGALLFAIIVCLF

FIG. 1 CONT'D

27 / 60

ID-42

Clone 70

ATGAATACTATTTATAATACATTGAGAACAGATAAAAGGTTATAAAGT
TTATGAGGGGTATTTATATGAAATTACTGGTGAAGAATGTGAAGAAG
CCTTAGACCTTGTGATTCCTAAGAATATTGTATTTGCAGATACAGATA
CTTGTGGCTACACTTTTTTACTCAATGAAGATGGAACAGTTTATGATG
ATGTGACTTTCTACAAATTTGATGATAAATATTGGTTGGCTAGTCATA
AAGCTTTGGATTCTTATTTAGACAACATCAATTTTGACTATACCGTAA
CAGATATTTCTGACGAGTATAAAAATGCTGCAAATTGAAGGAAGATAT
TCGGGAGAAATTGCTCAGTCATTTTATGAATATGATATTTCAACACTT
AATTTTCGTACTCTTCGCATAGAGATGGACTTCATCAAAGGTGAGGA
AAGGTTATCTTGGCGTAGATTTGGTTTTTCTGGAGAATTTGGCTATCA
ATTTTTCCTACCATCTTCTATTTTGTCTACTTTTGTTCGGATGTCTGT
GAAGGTATAGCAGAGTGTGGGGATGAACCTTGATAGATATTTAAGGTT
TGAAGTGGGACAACCCATTACTGATATTTATCAACAAGAAGAATATT
CTTTATATGAAATAGGTTATTCTTGGAATCTAGATTTTCACAAAGGAA
GAATTTAGAGGTCGCGATAGCTTGTTAGAGCACATCAGATCAGCAAC
AGTTAAAAGTGTTGGATTCTCAACGAAGGAAAAAACTCGCTTCAGGAA
CACCAGTGCTATTTGATGACCAAATTGTTGGAAAGATTTTTTGGATAG
CAGACGAGAAACACTCTTCGGAAAATTACCTAGGTTTGTGATTGTT
AACCAAACATATGCTCATTACAGGAGTTACTTTTGTAAACAGAAGATGG
CCAAATTTTGAAAACACAATCAAGCCCTTATTGTATCCCAGAAAGTT
GGAACAAAGAATGA

MNTIYNLRTDKGYKVYEGYLYEITGEECEEALDLVIPKNIVFADTDTCG
YTFLLNEDGTVYDDVTFYKFDDKYWLASHKALDSYLDNINFDTYTVTDIS
DEYKMLQIEGRYSGEIAQSFYEYDISTLNFRTRLRIEMDFIKGEERLSWRRF
GFSGEFGYQFFLPSSIFATFVSDVCEGLAECGDELDRYLRFEVVGQPITDIY
QQEEYSLEYIGYSWNLDFTKEEFRGRDSLLEHIRSATVKSVGFSTKEKLA
SGTPVLFDQIVGKIFWLADEKHSSENYLGLMIVNQTYAHSGVTFVTE
GQILKTQSSPYCIPESWNKE*

ID-43

Clone 78/94

ATGGAGTTAGTAATTAGAGATATTCGTAAGCGGTTTCAGGAAACAGA
GGTCTTGAGAGGAGCAAGTTACCGATTTTATTCAGGTAAAATAACAG
GGGTCTTAGGTAGGAATGGTGCTGGGAAAACAACCTTTATTTAATATA
CTTTATGGGGATCTTGCAGCTGACAACGGGACCATTTGTTTATTGAAG
GATAATCACGAGTATCCTCTTACCGATAAGGATATTGGTATTGTTTAT

FIG. 1CONT'D

SUBSTITUTE SHEET (RULE 26)

TCCGAAAACCTACCTTCCAGAATTTTAAACAGGGTATGAATTTGTAAA
ATTTTACATGGATTTACATCCTTCAGATGATTTAATGACAATAGATGA
TTATTTAGATTTTATGGAAATAGGACAAACAGAGCGTCATAGAATTA
TCAAAGGATATTCTGATGGAATGAAGAGTAAGCTCTCATTAAATTTGC
CTGATGATTTCTAAGCCAAAAGTAATTTTACTAGATGAGCCACTGAC
TGCAGTTGATGTTGTATCAAGTATTGCAATAAAACGCCTTTTGTGGA
ATTAAGTGAGGATCATATTATTATATTATCAACTCATATAATGGCCTT
AGCAGAAGATCTATGTGATATTGTGGCTGTATTAGACAAAGGAAAAC
TCCAAACATTAGATATTGATCGTAAACATGAACAATTCGAAGAGCGT
CTTCTTCAAGTGTTGAAGGGAGATGAATATGACAAGTAA

MELVIRDIRKRFQETEVLRGASYRFYSGKITGVLGRNGAGKTTLFNILYG
DLAADNGTICLLKDNHEYPLTDKDIGIVYSENYLPEFLTGYEFVKFYMD
LHPSDDLMTIDDYLDMEIGQTERHRIKGYSDGMKSKLSLICLMISKPK
VILLDEPLTAVDVVSSIAIKRLLLELSEDHIIILSTHIMALAEDLCDIVAVL
DKGKLQTLDIRKHEQFEERLLQVLKGDEYDK*

ID-44

Clone 80

TTGTTTATGAGATATACAAATGGAAATTTTGAAGCCTTTGCAAGACCT
CGAAAACCTGAAGGTGTGGATAAAAAATCCGCTTATATTGTTGGTTC
TGGTTTAGCAGGATTAGCTGCCGCTGTCTTTTAAATACGTGACGGTCA
AATGGATGGTCAACGTATTCATATTTTGAAGAACTACCTCTTTCTGG
AGGATCACTTGACGGTGTCAAACGACCTGATATCGGTTTTGTAAACGC
GTGGTGGTCGTGAAATGGAAAATCACTTCGAATGTATGTGGGATATG
TACCGTTCCATCCCCTCTCTCGAAGTTCCAGATGCTTCTTATCTAGAT
GAATTTTATTGGCTTGACAAGGATGATCCCAATTCATCTAACTGTCGC
CTCATTTCATAAACAGGGGAATCGCTTAGAATCTGATGGTGATTTTAC
ACTCGGAACACATTCCAAAGAGTTAGTTAAGCTAGTCATGGAGACTG
AAGAGTCTTTAGGTGCTAAGACGATTGAAGAAGTTTTTTCAAAGAA
TTTTTTGAAAGTAATTTTGGACTTATTGGGCTACTATGTTTGCCTTTG
AGAAATGGCATTTCAGCGATTGAAATGCGTCGATATGCTATGCGCTTT
ATCCATCATATTGGTGGTCTGCCTGATTTCACTTCATTAATAATTAAT
AAATATAATCAATATGATTCTATGGTGAAACCAATCATCAGTTATTTA
GAGTCTCATAATGTAGATGTTCAATTTGATAGCAAGGTAACATAAT
CTCCGTAGACTTT

MFMRYTNGNFEAFARPRKPEGVDKKSAYIVGSLAGLAAVFLIRDGQ
MDGQRIHIFEELPLSGGSLDGVKRPDIGFVTRGGREMENHFECMWDMY
RSIPSLEVPDASYLDEFYWLDKDDPNSSNCRLHKQGNRLESDGDFTLGT
HSKELVKLVMETEESLGAKTIEEVFSKEFFESNFWTYWATMFAFEKWHS

FIG. 1 CONT'D

AIEMRRYAMRFIHHIGGLPDFFTSLKFNKYNQYDSMVKPIISYLESHNVDV
QFDSKVTNISVDF

ID-45

Clone 81

TTGTTGGCTTCTTTATTTATCGTCCGTTTGTCAAAATCGCTTTCGCTAA
GGAGGAGCAATATGAAAAAATTACTTAGATGGCTTCCTCCTGTACTT
TTCATTATTATCCTTATAGGAATGACTATCTTAGGTAAGTCCTATATC
AATAAAGTAACAGCTCACAAAATAAAACTCTATAACTCTCGAATGAC
TCCTACTATTTTAATTTTCAGGATCCAGTGCTACTCAAGAACGATTAA
CAGCATGTTAGCACAGCTCAACCAAATGGGAGAAAAACATAGCGTTT
TAAAGTTAACTGTCAAAAAAGACAATAGCATTATCTACAATGGACAA
ATTAGCGGCAATGACCACAAACCCTACATTGTCATTGGATTTGAAAA
TAATGAAGATGGTTATAGTAACATCAAAAAACAAACAAAATGGCTA
CAGATTGCTATGAATGATCTTCAGAAGAAATATAAATTTAAACGTTT
TAACGCTATCGGTCATTCAAATGGTGGCTTATCATGGACTATTTTCCT
AGAAGATTATTACGACTCTGATGAATTTGATATGAAATCATTGTAA
CAATGGGAACACCTTTTAACTTTGAAGAAAGTAACACCTCAAATCAT
ACTCAAATGCTTAAAGATTTAATCAGTAATAAAGGAAATATTCCATC
AAGTCTCATGGTATACAATTTGGCAGGAACCTAATTCATATGATGGTG
ATAAAATTGTTCCATTTGCTAGTGTGGAGACTGGTAAATATATTTTCC
AAGAAACCGCTAAACACTATACCCAACCTAACAGTAACCTGGTAATAAT
GCTACACATTCTGACTTGCCTGATAATCCTGAAGTTATCCAATATGTC
GCAGAAAAAATTCTTAAAAATGAGAAAGGTAAATTACCAAACCTC
ACTAA

MLASLFIVRLSKSLSLRRSNMKKLLRWLPPVLFIIILIGMTILGKSYINKVT
AHKIKLYNSRMTPTILISGSSATQERFNSMLAQLNQMGEEKHSVLKLTVK
KDNSIIFYNGQISGNDHKPYTVIGFENNEDGYSNIKKQTKWLQIAMNDLQK
KYKFKRFNAIGHSNGLSWTIFLEDYYDSDEFDMKSLLTMGTPFNFEES
NTSNHTQMLKDLISNKGNIPLMVYNLAGTNSYDGDKIVPFASVETGK
YIFQETAKHYTQLTVTGNNATHSDLPDNPEVIQYVAEKILKNEKGKLPK
PH

*

ID-46

Clone 83

TTGAAATTAGGTATTACAACATTCGGAGAGACAACAATCCTTGAAGAAACAAACC
AAAGCTATTCACATCCTGAGAGGATTCGCCAATTAGTTGCTGAGATTGAACTAGCT
GATCAAGTTGGTTTAGATGTATATGGTATTGGAGAGCACCATCGTGAAGATTTTGC

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

GGTCTCTGCACCCGAAATTATCCTAGCAGCAGGAGCGGTTAGAACTAATAATATCC
GTTTATCTAGTGCAGTAACGATTCTCTCTTCCAATGATCCTATTCGCGTCTATCAGC
AATTTTCAACGATTGACGCACTTTCAAATGGTAGAGCAGAAATTATGGCAGGGCGT
GGTTCCTTTATTGAGTCTTTTCCATTGTTTGGATACGATTTAGCGGATTATGATGAT
TTATTTAATGAAAAAATGGATATGTTGTTAGCAATTAACCTCAGCGACAAATCTCGA
TTGGAAAGGTCATTTGACACAAACAGTTAATGAGCGACCAATTTATCCAAGAGCAT
TACAAAGACAGTTATCAATATGGGTGGCAACAGGAGGAAATGTTGATTCTACAATT
CGTATTGCAGAACAAAGGTTTGCCAATTGTTTATGCAACTATTGGTGGGAATCCCAA
AGCCTTTCGTCAATTGGTCCATATTTATAAAGAAGTTGGTAAGTCCGTAATGGACA
CAAACCAGGAACAACATAAAAGTTGCTGCTCACTCTTGGGGATGGATTGAAGAGGA
TAATCAAACCGCTATTGACCGTTATTTTTTCCCTACGAAACAGACCGTCGATAATAT
TGCTAAGGGACGCCCTCATTGGTCTGAAATGACTAAAGAGCAGTATTTACGTTCAA
TAGGTCCAGAAGGTGCTATTTTTGTAGGAAATCCTGAAGTGGTTGCACATAAAATT
ATAGGACTTTGGTGA

MKLGITTFGETTILEETNQSYSHPERIRQLVAEIELADQVGLDVYGIGEHHRDFAVSAP
EIILAAGAVRTNNIRLSSAVTILSSNDPIRVYQQFSTIDALSNGRAEIMAGRGSFIESFPLF
GYDLADYDDL FNEKMDMLLAINSATNLDWKHLLTQTVNERPIYPRALQRQLSIWVAT
GGNVDSTIRIAEQGLPIVYATIGGNPKAFRQLVHIYKEVGKSVMDTNQEQLKVAHHSW
GWIEEDNQTAIDRYFFPTKQTVDNIAKGRPHWSEMTKEQYLR SIGPEGAIFVGNPEVV
AHKIIGLW

ID-47

Clone 86

ATGATAGAGTGGATTCAAACACATTTACCAAATGTATATCAAATGGG
TTGGGAAGGTGCTTACGGCTGGCAGACAGCTATTGTACAAACCCTTT
ATATGACTTTTTTGGTCGTTCTTATTGGAGGTTTAATGGGATTGTTAG
GAGGTTTATTCCTTGTTTTAACTAGTCCTAGAGGAGTTATTGCTAATA
AATTAGTATTTGGAGTTTTAGATAAAGTTGTTTCTGTTTTTAGAGCTC
TGCCCTTCATTATTCTTCTTGCTTTGATTGCGCCAGTAACTCGCGTAAT
TGTAGGAACAACACTTGGTTCACCAGCAGCTTTGGTACCTCTTTCTTT
GGCAGTTTTTCCCATTTTTTGCTCGTCAAGTTCAAGTTGTTTTAGCTGA
ACTTGATGGTGGAGTTATTGAGGCTGCACAAGCCTCAGGTGGAACAC
TTTGGGATATTATTGTAGTTTATCTTCGTGAAGGTCTACCAGATTTAA
TTCGAGTATCAACGGTACTTTGATTTCTTTAGTAGGTGAAACAGCTA
TGGCTGGCGCTATTGGTGCAGGAGGATTGGGTTCTGTTGCTATTACTA
AAGGATATAACTATTCTCGTGATGATATTACTTTAGTAGCGACTATTC
TGATTTTATTATTAATTTTCTTTATCCAATTTTTAGGTGATTTTTTAAC
ACGTCGCTTGAGTCATAAATAA

MIEWIQTHLPNVYQMGWEGAYGWQTAIVQTL YMTFWSFLIGGLMGLL
GGLFLVLTSPRGVIANKL VFGVLDKVVS VFRALPFIILLALIAPVTRVIVG

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

TTLGSPAALVPLSLAVFPFFARQVQVVLAEIDGGVIEAAQASGGTLWDII
VVYLREGLPDLIRVSTVTLISLVGETAMAGAIGAGGLGSVAITKGYNYSR
DDITLVATILILLIFFIQFLGDFLTRRLSHK*

ID-48 (same as ID-43)

ID-49

Clone 96

TTGGCAGTTAGTTTTTCATGAAGTATTTGGTTGGGATTCTGCTTTTTTTA
TTATGATTATCAATATTCCATTGCTCCTTCTTTGCTACTTTGGCTTAGG
TAAACAAACCTTTTTTAAAACTGTCTATGGTTCTTGGATTTTTCTGT
TTTTATTAAGTTAACACAAAGTGTACCAACTTTGACCCACAACCTCACT
CCTCGCAGCACTTTTTTGGAGGTGTTATTGTAGGATGTGGTTTGGGGAT
TGTTTTTTTGGAGCGACTCTTCAACTGGTGGAACGGGGATTATCATTCA
ATTCTTAGGAAAATATACTCCTATAAGCCTTGGACAAGGGGGTTATAT
TGATTGATGGACTTGTTACAATTGTTGGTTTCCTAGCTTTTGACAGTG
ATACGGTTATGTTTTCTATTATTGGGTTGATAACTATTAGTTATATTAT
TAATGCTATCCAAACTGGATTTACAACCTTAAGCACTGTCTTAATCGT
TTCTCAAGAGCACCAAAAAATTAAGACATATATCAATACTGTTCGCAG
ATAGAGGAGTAACAGAAATTCCCGTTAAAGGGGGGATATTCTGGAACT
AATCAAATCATGCTTATGACAACCTATTGCTGGTTATGAGTTTGCTAAA
TTACAAGAGGCAATAGCAGAAATTGACGAAACAGCCTTCATAACAGT
AACTCCAACATCACAAGCTTCTGGACGTGGATTTAGTCTTCAAAAAA
ATCATGGACGTCTTGATGAAGACATTCTTATGCCAATGTAA

MAVSFHEVFGWDSAFFIMIINIPLLLLCYFGLGKQTFCLKTVYGSWIFPFI
KLTQSVPTLTHNSLLAALFGGVIVGCGLGIVFWSDSSTGGTGIIIQFLGKY
TPISLGQGVILIDGLVTIVGFLAFDSDTVMFSIIGLITISYIINAIQTGFTTLST
VLIVSQEHQKIKTYINTVADRGVTEIPVKGGYSGTNQIMLMTTIAGYEFA
KLQEALAEIDETAFTVTPTSQASGRGFSLQKNHGRLDEDILMPM*

ID-50

Clone 99

ATGAAAGAAAAACAGTCGAAAAGGCTTATTTATATACTACTGATTGTTCCCATTAT
CTTTATAAGTGTTTTTACATACAGTATTAGCCAGCCTTCTAAACTACTTCCACCAAA
AGAATTAGTTATTCTAAGTCCAAATAGTCAAGCCATTTTAACAGGAACGATTCCAG
CTTTTGAGGAAAAATACGGTATAAAAGTTAAGCTTATTCAAGGTGGGACAGGGCA
ACTAATAGATAGATTAAGTAAGGAGGGTAAGCAGTTGAAGGCGGATATTTTCTTTG
GAGGAAATTATACGCAATTTGAAAGTCATAAGGCATTGTTTGAGTCTTACGTATCA

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

AAGAATGTTTCATACTGTTATTCCAGACTATATCCATCCGAGTGATACGGGCGACACC
TTATACTATAAATGGGAGTGTCTTGATTGTAAATAACGAATTAGCTAAGGGACTTA
CCATCAAGAGTTATGAAGATTTATTACAGCCTTCCTTAAAAGGTAAAATTGCCTTT
GCAGATCCTCTAGAGTCGACCTGCAAGCATGCAAGCTTGGCGTAA

MKEKQSKRLIYILLIVPIIFISVFTYSISQPSKLLPPKELVILSPNSQAILTGTPAFEEKYGI
KVKLIQGGTGQLIDRLSKEGKQLKADIFFGGNYTQFESHKALFESYVSKNVHTVIPDYI
HPSDTATPYTINGSVLIVNNELAKGLTIKSYEDLLQPSLKGKIAFADPLESTCKHASLA

ID-51

Clone 103

CCTCCTATCAAATGATGACAAACGTGAGAGGTACATGGAACAAATGCTCTTTAAAA
TTGAAAATGCAACCTGGCAGCGTGTGGTAAGAGCACTTTATCGTAAATACAATAAG
GAATTTTTTACATATCCAGCCGCCAAAACAAACCACCACGCTTTTGAATCAGGATT
GGCATATCACACGGCAACAATGGTTCGTTTGGCAGATAGTATCGGAGATATCTATC
CAGAACTTAATAAAAAGTTTGATGTTTGCTGGTATTATGCTACATGATTTAGCCAAG
GTCATAGAGTTATCGGGTCCTGATAATACAGAATATACTATTTCGAGGTAATCTTAT
CGGTCATATTTCACTTATTGATGAGGAATTAA

LLSNDDKRERYMEQMLFKIENATWQRVVRALYRKYNKEFFTYPAAKTNHHAFESGL
AYHTATMVRLADSIGDIYPELNKSLMFAGIMLHDLAKVIELSGPDNTEYTIRGNLIGHIS
LIDEEL

ID-52

Clone 104

ATGAAAAAAAAATAAAATTATCCGATTCAGTTTAGTTGGTGTCTACTT
GCGATACTATGCTTTAGTCTTTTTGCTTTATTGAAGCCTAACAGTCAA
CAATCATCATCTCAAAAGTTGAGGAATGAGGATATAAAAAAGACATC
CTCTCAAAAAAGAAATAAGAAATTACGATTACCAGCTGTATCATCAA
AAGATTGGAACCTTGATTTTGGTCAATCGTGACCATAAACATGAAGAA
TTAAGTCCAGATGTGGTGCCTGTTGAAAATATTTATTTGGATAAACGT
ATTACGAAGCAAGCTACTCAGTTTTTAGAGGCTGCTAGAGCAATTGA
TTCACGAGAACATTTAATTTTCGGGTATCGTAGTGTTGCCTATCAGGA
GAAGTTGTTCAATTCTTATGTTACTCAAGAGATGACTAGTAACCCCTAA
TTTGACGAGGGGACAAGCAGAAAAGTTGGTAAAACTTACTCTCAGC
CTGCAGGTGCTAGTGAACACCAGACTGGATTAGCGATGGATATGAGT
ACTGTAGATTCTTTGAATGAGAGCGATCCTAGAGTAGTCAGTCAGTT
GAAAAAGATAGCTCCACAATATGGTTTTGTCTTACGGTTTCCGGATG
GTAAACAGCAGAAACAGGGGTAGGTTATGAAGATTGGCATTACCG

FIG. 1 CONT'D

CTATGTTGGGGTAGAGTCTGCAAAATATATGGTCAAACATCATTAA
CATTAGAAGAATACATAACTTTATTAAAGGAGAATAACCAATGA

MKKNKIIRFSLVGVLLAILCFSLFALLKPNSQQSSSQKLRNEDIKKTSSQK
RNKKLRLPAVSSKDWNLILVNRDHKHEELSPDVVPVENIYLDKRITKQA
TQFLEAARAIDSREHLISGYRSVAYQEKLFSYVTQEMTSNPNLTRGQA
EKLVKTYSQPAGASEHQTGLAMDMSTVDSL NESDPRVVSQK KKIAPQY
GFVLRFPDGKTAETGVGYEDWHYRYVGVESAKY MVKHHLTLEEYITLL
KENNQ*

ID- 53

Clone 106

CTGTTATGTGGATTTCTTCCATCAATTCCTGTGTCTAATTCCGGGGGGG
TATGGTATAATAACAGTTATGAAAAATAAAAAAATCTTATTTGGGAC
TGGCCTTGCTGGTGTGGGTTTACTGGCAGCTGCTGGTTATACCCTAAC
TAAAAAAGTAACAGATTATAAACGTCAGCAAATCACTCAGACCTTAA
GAGAACTTTTTAGTCAGATGGGTGATATTCAGGTATTTTATTTTAATG
AATTTGAATCTGATATTAATAATGACCAGTGGTGGTCTTGTCTTGGA
GATGGCAGAATTTTCGAATTCATTTATCGTCAAGGTGTTCTTGATTAT
GTGGAGGTGAGCAAATGA

LLCGFLPSIPVSNSGGYGITVMKNKKILFGTGLAGVGLLAAAGYTLTKK
VTDYKRQQITQTLRELF SQMGDIQVFYFNEFESDIKMTSGGLVLEDGRIF
EFIYRQGVLDYVEVSK*

ID-54

Clone 108

ATGTATCAAACCTCAGACAAATAAGGAAAAATTTGTTTTATTTTGA
AATTATTTATC
CCAGTATTGATTTATCAATTTGCTAATTTTTCAGCTACTTTTATTGATTCGGTTATGA
CTGGACAGTATAGTCAGCTACATTTGGCAGGTGTGTCAACTGCTAGTAATTTATGG
ACTCCGTTTTTCGCTTTATTAGTAGGTATGATTTTCAGCATTAGTACCAGTAGTTGGT
CAACATTTGGGTAGAGGAAATAAAGAACAAATTCGCACAGAATTTTCATCAATTTCT
ATATTTAGGTTTGATACTGTCCTTAA

MYQTQTNKEKFVLFLKLFIPVLIYQFANFSATFIDSVMTGQYSQ LHLAGVSTASNLWTP
FFALLVGMISALVPVVGQHLGRGNKEQIRTEFHQFLYLGLLSL

ID-55

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

Clone 112

CTGCTCTTTT TAGCTAACTTTTCTAATTTATGGTATAATTGTATGGATT
GTTTAGCTAGAATGGAGAAGATGATGCAAGATGTTTTTCATTATAGGA
AGTAGAGGGTTGCCAGCTCGTTACGGTGGTTTTGAAACTTTTGTTTCA
GAATTGATTAATCATCAAAAAAGTTCCGACATAAAATACCATGTTGC
ATGCCTTAGTGATAAAGAACATCATACTCATTTTAACTTTGCTGACGC
TGATTGTTTTACTATAAATCCTCCCCAATTAGGGCCAGCACGTGTGAT
TGCTTATGATATTATGGCCATTAATTATGCCCTTGACTTGGTTAAGAC
ACATGATTTAAAAGAGCCTATTTTTTATATTTTAGGAAATACAATTGG
TGCCTTTATTTGGCATTTTGCCAATAAAATACATAAAGTCGGTGGCTT
ATTGTATGTTAATCCGGATGGTTTAGAGTGGAAGCGATCAAAGTGGT
CTCGTCCCACACAGCGTTATTTAAAATACGCCGAAAAATGTATGACT
AAAAATGCAGACCTAATTATTTCTGATAATATTGGTATTGAAAATTA
CATTCAATCTACCTACTCTAATGTGAAGACAAGGTTTCATTGCTTACGG
TACAGAGATTAATTCTAGGAAATTATCGTCAGATGATCCACGTGTCA
AACAGTTGTTTAAAAAATGGAATATTAAGTCTAAGGGTACTATCTA
ATCGTTGGTCGATTTGTCCCTGAAAACAATTATGAAACGGCTATTAG
GGAGTTCATGGCTTCAGATACTAAGCGTGATTTAGTTATTATCTGTAA
CCATCAAAATAACCCCTACTTTGAAAAGTTGTCCTTAAAGACAAACC
TTCAACAAGATAAAAGAGTTAAGTTTGTAGGTACGCTCTATGAAAAA
GATCTGCTGGATTATGTTTCGTCAACAAGCCTTTGCTTATATTCATGGG
CATGAAGTTGGCGGTACTAATCCAGGACTGCTTGAGGCTTTAGCTAA
TACTGATTTGAATCTTGTTCTAGATGTTGATTTCAACAAATCAGTAGC
AGGTCTCTCAAGTTTTTACTGGACTAAAAAAGAGGGGGATTTAGCTA
AGCTT

MLFLANFSNLWYNCMDCLARMEKMMQDVFIIGSRGLPARYGGFETFVS
ELINHQKSSDIKYHVACLSDKEHHTHFNFADADCFTINPPQLGPARVIAY
DIMAINYALDLVKTHDLKEPIFYILGNTIGAFIWHFANKIHKVGGLLYVN
PDGLEWKRKWSRPTQRYLKYAEKCMTKNADLIISDNIGIENYIQSTYSN
VKTRFIAYGTEINSRKLSSDDPRVKQLFKKWNKSKGYYLIVGRFVPENN
YETAIREFMASDTKRDLVIICNHQNNPYFEKLSLKTNLQQDKRVKFGVT
LYEKDLLDYVRQQAFAYIHGHEVGGTNPGLLEALANTDLNLVLDVDFN
KSVAGLSSFYWTKKEGDLAKL

ID-56

Clone 120

TTGAGGAGTAATATGGTAAAGACAGCAGTTTTTAATGGCGACATACAA
TGGCGAAAAATTTATATCTGAACAACCTTGATTCAATTCGCCAACAGA
CATTAAAACCAGATTATGTATTATTGAGGGATGATTGTTCAACGGAT
GAAACAGTCAATGTCGTCAATAACTATATCGCAAAACATGAGTTAGA

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

AGGCTGGAAAATTGTTAAAAACGACAAAAACTTAGGCTGGCGTTTAA
ATTTTCGTCAATTACTTATTGATGTGTTAGCCTATGAGGTTGACTATG
TCTTTTTTAGTGATCAAGATGATATTTGGTATCTTGATAAAAAACGAAC
GACAGTTTGCCATTATGTCAGATAACCCTCAAATTGAGGTTTTGAGTG
CAGACGTTGATATCAAAACGATGTCTACAGAAGCCAGTGTTCCACAT
TTTCTAACTTTTTCTTCTAGTGATAGAATCAGTCAGTATCCTAAAGTA
TATGATTATCAAACATTCCGTCCCGGATGGACCATTGCTATGAAGAG
AGATTTTGCGCAAGCTATCGCTTGA

MRSNMVKTAVLMATYNGEKFISEQLDSIRQQTLKPDYVLLRDDCSTDET
VNVVNNYLAKHELEGWKIVKNDKNLWRLNFRQLLDVLAYEVDYVFF
SDQDDIWYLDKNERQFAIMSDNPQIEVLSADV DIKTMSTEASVPHFLTFS
SSDRISQYPKVYDYQTFRPGWTIAMKRDFQAIA*

ID-57

Clone 123

GTGATTATGGATAAGTCTATTCCTAAAGCAACTGCTAAACGTTTATCA
CTGTACTACCGTATTTTTTAAACGTTTTAATACTGATGGCATCGAAAAA
GCTAGTTCCAAACAAATTGCAGATGCCCTAGGTATCGATTCTGCTACT
GTTCGACGTGATTTTTTCTTATTTTGGTGAAGTAGGACGCCGTGGTTTT
GGTTATGATGTCAAAAAAATTATGAAGTTCTTTGCAGAAATATTGAA
CGATCATTCTACAACAAATGTTATGCTGGTGGGGTGTGGAAATATCG
GTAGAGCTCTCTTGCATTATCGTTTCCACGATCGCAATAAAATGCAA
ATTTCAATGGCTTTTGTATTTAGATAGCAATGATTTAGTTGGTAAAACA
ACCGAGGATGGAATTCCTGTCTACGGTATTTTCGACTATCAATGACCA
TTTAATAGATAGTGATATTGAAACTGCTATCCTAACAGTACCTAGTAC
AGAAGCCCAAGAAGTTGCTGACATCTTAGTCAAAGCAGGTATAAAA
GGCATCTTGAGTTTTTCTCCAGTTCATTAAACATTACCAAAGATATC
ATTGTTTCAGTATGTAGATTTAACAAGCGAATTACAAACTTTACTTTAT
TTCATGAACCAGCAGCGATAA

MIMDKSIPKATAKRLSLYYRIFKRFNTDGIEKASSKQIADALGIDSATVRR
DFSYFGELGRRGFGYDVKKLMNFFAEILNDHSTTNVMLVGCGNIGRALL
HYRFHDRNKMQISMAFDLDSNDLVGKTTEGDGIPVYGISTINDHLIDSDIE
TAILTVPSTEAQEVADILVKAGIKGILSFSPVHLTLPKDIIQYVDLTSELQ
TLLYFMNQQR*

ID-58

Clone 125

FIG. 1 CONT'D

ATGGGTGCTAAAGGAGCAGATGTCATTCTCGTTTTATCACACTCTGGCATTGGAGA
TGATCGATATGAAGAAGGTGAAGAAAACGTTGGCTATCAAATTGCCAGCATCAAG
GGAGTGGATGCCGTTGTTACGGGACACTCACACGCTGAATTTCCATCAGGTAACGG
TACTGGCTTCTATGAAAAATACACTGGAGTTGATGGTATCAATGGAAAAATAAATG
GAACACCTGTTACAATGGCAGGCAAGTACGGGGATCACCTTGGTATTATTGATTTA
GGACTTAGTTATACTAATGGAAAATGGCAAGTCTCCGAAAGCAGTGCTAAAATCC
GTAAAATTGATATGAACTCAACAACCTGCTGACGAGCGTATCATTGCATTGGCTAAG
GAAGCACACGATGGCACTATCAACTATGTTTCGCCAACAAGTAGGTACAACAACCTG
CGCCAATTACAAGTTACTTTGCACTAGTTAA

MGA KGADVILVLSHSGIGDDRYEEGEENVGYQIASIKGVDAVVTGHSHAEPSPGNGTG
FYEKYTGVDGINGKINGTPVTMAGKYGDHLGIIDLGLSYTNGKWQVSESSAKIRKIDM
NSTTADERIALAKEAHDGTINYVRQQVGTTPITSYFALV

ID-59

Clone 135

TTGTCAATAAGGTTTCAAATCAGCTTGAAATATGATAAAATAAAACAGATTGTAAG
TGACTGTTTAAGCTTGTTTTTCAGAGAGGTTTTTATGAATACAAACACAATAAAAA
AGGTTGTAGCGACTGGAATTGGAGCTGCACTTTTTATCATTATAGGTATGCTAGTT
AA

MSIRFQISLKYDKIKQIVSDCLSLFFREVFMNTNTIKKVVATGIGAALFIIIGMLV

ID-60

Clone 145

ATGAAACATTTAAAATTTCAATCGGTCTTCGACATTATTGGTCCTGTTATGATTGGA
CCATCAAGTAGTCATACTGCAGGAGCTGTCCGCATTGGTAAAGTTGTCCATTCTAT
TTTTGGTGAACCTAGTGAAGTAACCTTTCATTTATACAATTCTTTTGCTAAAACCTTA
CCAAGGACACGGTACTGATAAAGCATTGGTTGCAGGGATTCTAGGAATGGATACA
GATAATCCAGATATTAA

MKHLKFQSVFDIIGPVMIGPSSHTAGAVRIGKVVHSIFGEPSEVTFHLYNSFAKTYQG
HGTDKALVAGILGMDTDNPD

ID-61

Clone 147

FIG. 1 CONT'D

GTGTCAGAAGGTGTTTTAATGTTTCTAAAAGAAGATGACGTAGAGACTTTTCTTCA
TATCCTGACAAATTCATTTAGCCAATTTATGGCACAATTTGATTTGTGTCATAAGGA
AATGATTAA

ID-62

Clone 150

ATGACCTACAAAGATTACACAGGTTTAGATCGGACTGAACTTTTGAGTAAAGTGCG
TCATATGATGTCCGACAAACGTTTTAA

MTYKDYTGldrTEllSKVRHMMsDKRF

ID-63

Clone S2

CTGAGTTGGGTCTTGGAACGGTCCTGTCAATCATACTAGCTATCAAGGAGACTAA
AATGTATTTAGAACAACTAAAAGAGGTAAATCCTTTAA

MSWVLETVLSIILAIKETKMYLEQLKEVNPL

ID-67

Clone 3-40

GTGAAAAAAAAAATTAGTCTCATCACTTCTAAAGTGTTCTCTAATCATT
ATTGTTAGCTTTGCTGGTGGAGCATTGCTAGTTTTGTCATGAATCAT
AATGACAATATTCCAAATGGTGGTGTCACTAAACTAGTAAAGTAAA
TTATAATAACATAACGCCTACAACAAAAGCTGTAAAAAGGTACAAA
ATAGTGTTGTTTCTGTTATCAATTATAACAACAAGAGAGTCGTTCTG
ACCTATCAGACTTCTATAGTCATTTTTTTTGGTAATCAGGGGGGGCAACA
CTGATAAGGGCTTACAAGTTTACGGTGAAGGCTCTGGAGTCATCTAT
AAAAAAGATGGTAAAAATGCCTATGTTGTCACTAATAACCACGTCAT
TGATGGGGCTAAACAAATTGAAATTCAACTAGCTGATGGCTCAAAAG
CAGTTGGGAACTTGTTGGGTCAGATACCTACTCTGATTTAGCCGTCG
TCAAAATTCCATCAGATAAAGTTTCAAATATTGCAGAATTTGCTGATT
CATCAAACTCAACATTGGTGAACTGCTATAGCGATCGGAAGCCCT
CTTGGAAGTGAATGCAAATTCTGTAAGTCAAGGTATTGTATCTAGT
TTAAAAAGAACTGTAACAATGACTAATGAAGAAGGACAAACAGTTT
CTACAAATGCTATCCAGACGGATGCTGCTATCAATCCTGGTAATTCA
GGTGGAGCACTTATCAATATTGAAGGACAGGTTATTGGAATTAATTC
TAGTAAAATTTCTTCTACATCAAATCAAACCTCAGGACAATCGTCAG

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

GAAATAGCGTTGAAGGTATGGGATTTGCCATTCCTTCAAATGATGTT
GTTAAGATTATCAATCAACTTGAGAGTAACGGACAAGTAGAGAGACC
TGCTCTAGGTATTTCTATGGCTGGATTAAGTAATTTACCATCCGATGT
TATTAGTAAACTGAAAATCCCAAGTAATGTTACTAATGGTATTGTAG
TAGCATCTATCCAATCTGGCATGCCAGCTCAAGGCAAACCTAAAGAAA
TACGATGTCATTACTAAAGTTGACGATAAAGAAGTAGCATCTCCAAG
TGATTTACAAAGTTTACTCTATGGCCACCAGGTAGGGGGATTCCATAA
CAGTAACCTTTTATCGTGGTGAAAATAAACAAACAGTCACTATAAAA
CTTACTAAACTAGTAAAGATTTAGCTAAACAACGAGCAAATAACTA
A

MKKKLVSLLKCSLIIVSFAGGAFASFVMNHNDNIPNGGVTKTSKVNY
NNITPTTKAVKKVQNSVSVINYKQQESRSDLSDFYSHFFGNQGGNTDK
GLQVYGEESGVIYKKDGKNAYVVTNNHVIDGAKQIEIQLADGSKAVGK
LVGSDTYSDLAVVKIPSDKVSNIAEFADSSKLNIGETALAIGSPLGTEYAN
SVTQGIVSSLKRTVTMTNEEGQTVSTNAIQTDAAINPGNSGGALINIEGQ
VIGINSSKISSTSNQTSQGSSGNSVEGMGFAIPSDNVVKIINQLESNGQVE
RPALGISMAGLSNLPDVISKLKIPSNVTNGIVVASIQSGMPAQGKLKKY
DVITKVDDKEVASPSDLQSLLYGHQVGDSITVTFYRGENKQVTIKLTKT
SKDLAKQRANN*

ID-68

Clone 3-30

ATGTTAAAATGGTATACAAACAAAGGAGGGAGGATGATAATGAAGA
AATGTTTTTTGGCTATTTGTTTAGCTCTTAGTTTTTTATGGTTTCAGT
TCAAGCAGATGAGGTGGACTATAACATTCCTCATTATGAGGGTAATC
TAACTATTCACAATGATAATAGTGCTGATTTTACAGAGAAGGTTACTT
ACCAATTTGATTCGTCCTATAATGGACAGTATGTCACGTTAGGTACG
GCGGGTAAGTTATCTGACAATTTTGATATTAATAATAAGCCACAGGT
TGAAGTTTCAATTAATGGTAAAGTAAGGAAAGTTAGTTACCAGATAG
AAGATTTGGAGGATGGCTACCGTTTGAAAGTGTTTAATGGTGGTGAA
GCAGGTGATACTGTTAAAGTCAATGTTTCAGTGGAAACTAAAAAATGT
TCTATTTATGCATAAGGATGTTGGTGAACCTTAACCTGGATTCCCTATTAG
CGACTGGGATAAAACGTTAGAGAAAGTAGATTTTTTGGATATCAACTG
ACAAAAAGGTTGCTCTTTCTCGTCTTTGGGGGCACTTGGGTATCTTA
AACTCCTCCTAAAATAAGACAAAATAATAATCGTTACCATTTGACA
GCTTTTAATGTAAACAAACGATTAGAATTTTCATGGTTATTGGGATAG
ATCTTATTTTAATCTACCTACAAACAGTAAAAATAATTACAAGAAAA
AAATTGAACATCAAGAGAAGATAATAGAGCGTCATGGTTTTATCCTA
AGTTTCTTGTTAAGGATATTATTACCTTCATTCTTTATTATTGTGACAC
TATTCATCTCAATTAGGGTGTTCCCTGTTTAGAAAAAAAGTTAATAAAT

FIG. 1CONT'D

SUBSTITUTE SHEET (RULE 26)

ACGGGCAATTCCCTAAGGATCATCATTTATATGAAGCACCTGAGGAC
CTTTCACCATTAGAGTTAACTCAAAGCATTTATAGTATGAGCTTTAAA
AATTTTCAAGATGAGGAGAAGAAAACCTCACCTTATCAGTCAAGAACA
ACTCATAACAGTCAATTCTATTAGACTTGATTGATAGAAAAGTATTGA
ATTATGATGATAACTTGTTATCTCTAGCTAACTTAGATAGAGCTTCTG
ATGCAGAAATAGATTTTATAGAGTTTGCTTTTGCGGATTCTACGAGTT
TGAAGCCAGATCAACTCTTTTCTAATTACCAATTTAGTTATAAAGAAA
CACTACGTGAACTGAAAAAGCAGCACAAGGCTTCAGATCTGCAAAAT
CAAATGAGACGCCGAGGAAGTAATGCCTTATCAAGAATTACGCGTCT
CACAAGGTTGATTTCTAAAGACAATATAAACTCTCTTAGAAGAAAGG
GAATTTTCATCCCCTTATCGTAAAATGTCTTCAGAAGAGTCTAAAGAA
TTATCTAGGTTAAAAAGATTCAGTTACCTATCACCTCTTATTTCTTTTG
TTGTTATAATTTATACGCTTTTTTTTAAATTATTTTACCTATTTCTGTAT
CTATCTCTTATTGTTTGGTGTTATCCTGTTGTTGAATAAAATCATTTTT
ATGATGACAAGAAAAATAAGTAACGGTTATATTGTAAGTGAAGATGG
AGCAAGTCGTGTCTACCAATGGACTAGTTTTAGGAACATGCTAAGGG
ATATCAAATCGTTTGATCGTTCAGAGTTAGAAAGTATCGTATTATGG
AATCGAATATTGGTTTACGCTACTTTATTCGGCTACGCTGACCGTGTT
GAGAAAGTACTCAGAGTGAACCAAATAGATATTCCAGAAAGATTTGC
AACATTGATAGTCATCGATTTGCGATTTTCAGTCAATCAATCTAGTAA
TCATTTTTCAACGATAACTGAAGATGTTAGTCACGCTTCTAATTTTAG
TGTTAATTCAGGCGGTTCTTCAGGTGGTTTCTCAGGCGGCGGAGGCG
GCGGAGGTGGCGGTGCCTTCTAA

MLKWYTNKGGRMIMKKCFLAICLALSFFMVSVQADEVDYNIPHYEGNL
TIHNDNSADFTEKVTYQFDSSYNGQYVTLGTAGKLSDNFDINNKPQVEV
SINGKVRKVSQIEDLEDGYRLKVFNGGEAGDTVKNVQWKLKNVLF
MHKDVGELNWIPISDWDKTLEKVDWFISTDKKVALSRLWGHLGYLKTP
PKIRQNNRYHLTAFNVNKRLEFHGYWDRSYFNLPTNSKNNYKKKIEH
QEKIIEHGFILSFLRLILPSFFIIVTLFISIRVFLFRKKVNKYGQFPKDHHL
YEAPEDLSPLELTQSIYSMSFKNFQDEEKKTHLISQEQLIQSILLDLIDRKV
LNYDDNLLSLANLDRASDAEIDFIEFAFADSTSLKPDQLFSNYQFSYKET
LRELKKQHKASDLQNQMRRRGSNALSRLTRLISKDNINSLRRKGISS
PYRKMSSEESKELSRLKRFSYLSPLISFVVIITLFLNYFTYFCIYLLFGVI
LLLNKIIIFMMTRKISNGYIVTEDGASRVYQWTSFRNMLRDIKSFDRSELE
SIVLWNRILVYATLFGYADRVEKVLRVNQIDIPERFANIDSHRFAISVNQS
SNHFSTITEDVSHASNFSVNSGGSSGGFSGGGGGGGGGGAF*

ID-69

Clone 3-38

ATGATGATTGTGAATAATGGTTATCTAGAAGGGAGAAAAAATGAAAA
AGAGACAAAAAATATGGAGAGGGTTATCAGTTACTTTACTAATCCTG

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

TCCCAAATTCCATTTGGTATATTGGTACAAGGTGAAACCCAAGATAC
CAATCAAGCACTTGGAAAAGTAATTGTTAAAAAAACGGGAGACAAT
GCTACACCATTAGGCAAAGCGACTTTTGTGTTAAAAAATGACAATGA
TAAGTCAGAAACAAGTCACGAAACGGTAGAGGGTTCTGGAGAAGCA
ACCTTTGAAAACATAAAACCTGGGAGACTACACATTAAGAGAAGAAA
CAGCACCAATTGGTTATAAAAAAACTGATAAAACCTGGAAAGTTAAA
GTTGCAGATAACGGAGCAACAATAATCGAGGGTATGGATGCAGATA
AAGCAGAGAAACGAAAAGAAGTTTTGAATGCCCAATATCCAAAATC
AGCTATTTATGAGGATACAAAAGAAAATTACCCATTAGTTAATGTAG
AGGGTTCCAAAGTTGGTGAACAATACAAAGCATTGAATCCAATAAAT
GGAAAAGATGGTCGAAGAGAGATTGCTGAAGGTTGGTTATCAAAAA
AAAATCCAGGGGTCAATGATCTCGATAAGAATAAATATAAAATTGAA
TTAACTGTTGAGGGTAAAACCACTGTTGAAACGAAAGAACTTAATCA
ACCACTAGATGTCGTTGTGCTATTAGATAATTCAAATAGTATGAATA
ATGAAAGAGCCAATAATTCTCAAAGAGCATTAAAAGCTGGGGAAGC
AGTTGAAAAGCTGATTGATAAAATTACATCAAATAAAGACAATAGA
GTAGCTCTTGTGACATATGCCTCAACCATTTTTTGATGGTACTGAAGCG
ACCGTATCAAAGGGAGTTGCCGATCAAATGGTAAAGCGCTGAATG
ATAGTGTATCATGGGATTATCATAAAACTACTTTTACAGCAACTACA
CATAATTACAGTTATTTAAATTTAACAAATGATGCTAACGAAGTTAA
TATTCTAAAGTCAAGAATTCCAAAGGAAGCGGAGCATATAAATGGG
GATCGCACGCTCTATCAATTTGGTGCGACATTTACTCAAAAAGCTCTA
ATGAAAGCAAATGAAATTTTAGAGACACAAAGTTCTAATGCTAGAAA
AAAACCTTATTTTTTCACGTAACCTGATGGTGTCCCTACGATGTCTTATGC
CATAAATTTTAATCCTTATATATCAACATCTTACCAAACCAAGTTTAA
TTCTTTTTTAAATAAAATACCAGATAGAAGTGGTATTCTCCAAGAGG
ATTTTATAATCAATGGTGATGATTATCAAATAGTAAAAGGAGATGGA
GAGAGTTTTAAACTGTTTTTCGGATAGAAAAGTTCCTGTTACTGGAGG
AACGACACAAGCAGCTTATCGAGTACCGCAAATCAACTCTCTGTAA
TGAGTAATGAGGGATATGCAATTAATAGTGGATATATTTATCTCTATT
GGAGAGATTACAACCTGGGTCTATCCATTTGATCCTAAGACAAAGAAA
GTTTCTGCAACGAAACAAATCAAAACTCATGGTGAGCCAACAACATT
ATACTTTAATGGAAATATAAGACCTAAAGGTTATGACATTTTTACTGT
TGGGATTGGTGTAACGGAGATCCTGGTGCAACTCCTCTTGAAGCTG
AGAAATTTATGCAATCAATATCAAGTAAAACAGAAAATTATACTAAT
GTTGATGATACAAATAAAATTTATGATGAGCTAAATAAATACTTTAA
AACAATTGTTGAGGAAAAACATTCTATTGTTGATGGAAATGTGACTG
ATCCTATGGGAGAGATGATTGAATTCCAATTAATAAATGGTCAAAGT
TTTACACATGATGATTACGTTTTGGTTGGAAATGATGGCAGTCAATTA
AAAAATGGTGTGGCTCTTGGTGGACCAACAGTGATGGGGGAATTTT
AAAAGATGTTACAGTGACTTATGATAAGACATCTCAAACCATCAAAA
TCAATCATTTGAACTTAGGAAGTGGACAAAAAGTAGTTCTTACCTAT
GATGTACGTTTAAAAGATAACTATATAAGTAACAAATTTTACAATAC
AAATAATCGTACAACGCTAAGTCCGAAGAGTGAAAAAGAACCAAAT

FIG. 1 CONT'D

ACTATTCGTGATTTCCCAATTCCCAAAATTTCGTGATGTTTCGTGAGTTT
CCGGTACTAACCATCAGTAATCAGAAGAAAATGGGTGAGGTTGAATT
TATTAAAGTTAATAAAGACAAACATTCAGAATCGCTTTTGGGAGCTA
AGTTTCAACTTCAGATAGAAAAAGATTTTTCTGGGTATAAGCAATTT
GTTCCAGAGGGAAGTGATGTTACAACAAAGAATGATGGTAAAATTTA
TTTTAAAGCACTTCAAGATGGTAACTATAAATTATATGAAATTTCAA
GTCCAGATGGCTATATAGAGGTTAAAACGAAACCTGTTGTGACATTT
ACAATTCAAAATGGAGAAGTTACGAACCTGAAAGCAGATCCAAATG
CTAATAAAAATCAAATCGGGTATCTTGAAGGAAATGGTAAACATCTT
ATTACCAACACTCCCAAACGCCCACCAGGTGTTTTTCCTAAACAGG
GGGAATTGGTACAATTGTCTATATATTAGTTGGTTCTACTTTTATGAT
ACTTACCATTTGTTCTTTCCGTCGTAAACAATTGTAA

MMIVNNGYLEGRKMKKRQKIWRGLSVTLLILSQIPFGILVQGETQDTNQ
ALGKVIVKKTGDNATPLGKATFVLKNDNDKSETSHETVEGSGEATFENI
KPGDYTLREETAPIGYKKTDKTWKVKVADNGATIIEGMDADKAEKRKE
VLNAQYPKSAIYEDTKENYPLVNVEGSKVGEQYKALNPINGKDGRREIA
EGWLSKKNPGVNDLDKNKYKIELTVEGKTTVETKELNQPLDVVLLDN
SNSMNNERANNSQRALKAGEAVEKLIDKITSNKDNRVALVTYASTIFDG
TEATVSKGVADQNGKALNDSVSWDYHKTTFTATTHNYSYLNLTNDAN
EVNILKSRIPEAEHINGDRTLQFGATFTQKALMKANEILETQSSNARK
KLIFHVTGVPPTMSYAINFNPISTSYQNQFNSFLNKIPDRSGILQEDFIIN
GDDYQIVKGDGESFKLFSDRKVPVTGGTTQAA YRVPQNQLSVMSNEGY
AINSGYIYLYWRDYNWVYPFDPKTKKVSATKQIKTHGEPTTLYFNGNIR
PKG YDIFTVGIGVNGDPGATPLEAEKFMQSISSTENYTNVDDTNKIYDE
LNKYFKTIVEEKHSIVDGNVTDPMGEMIEFQLKNGQSFTHDDYVLVGND
GSQLKNGVALGGPNSDGGILKDVTVTYDKTSQTIKINHLNLGSGQKVVL
TYDVRLKDNYISNKFYNTNNRTT LSPKSEKEPNTIRDFPIPKIRDVREFPV
LTISNQKKMGEVEFIKVNKDKHSESLLGAKFQLQIEKDFSGYKQFVPEGS
DVTTKNDGKIYFKALQDGNYKLYEISSPDGYIEVKTKPVVTFTIQNGEVT
NLKADPNANKNQIGYLEGNGKHLITNTPKRPPGVFPKTGGIGTIVYILVG
STFMILTICSFRRKQL*

ID-70

Clone 141

ATGAATAGAAAAGTTGAGGAAAAAATGGCTGGGAATCGTAATAACG
ATATGAATGTCTATTGTTCATTTTGTGGCAAAAGCCAAGATGAAGTA
AAAAAAATTATTGCAGGTAATGGTGTTCATTTGTAATGAATGTGTG
GCCTTATCACAAGAAATTATTAAGGAAGAATTAGCTGAGGAAGTACT

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

GGCTCATTTAGCAGAAGTACCAAAACCTAAGGAACTATTAGAAATAT
TAAATCAATATGTTGTAGGGCAAGATCGTGCTAAACGTGCTTTAGCA
GTTGCTGTCTACAATCATTACAAGCGTGTTAGTTATACCGAGAGTAGT
GACGATGATGTAGATTTGCAAAAATCCAACATTTTGATGATTGGTCC
AACTGGCTCAGGAAAAACCTTCTTAGCACAAACACTGGCTAAAAGCC
TTAATGTACCGTTTGCTATTGCAGATGCGACTTCATTGACCGAAGCAG
GATACGTTGGAGAAGATGTTGAGAATATTCTTCTTAAATTGATTCAA
GCTGCTGATTATAATGTCGAACGTGCTGAGCGTGGTATTATCTACGTT
GATGAAATAGATAAAATTGCTAAGAAAGGCGAAAATGTTTCTATCAC
ACGTGATGTGTCTGGTGAAGGTGTACAGCAAGCCCTTCTTAAAATTA
TTGAGGGTACGGTAGCAAGTGTTCCCCCACAGGGTGGGCGTAAACAT
CCTAACCAAGAAATGATTCAAATTAATACCAAGAACATCCTTTTTTATT
GTCGGTGGTGCTTTTGATGGTATTGAAGACCTTGTGAAGCAACGTTTA
GGCGAAAAAGTTATTGGTTTTGGACAGACAAGCCGTAAAATTGATGA
CAACGCTTCTTATATGCAAGAGATAATTTCTGAGGATATTCAAAGT
TTGGACTGATTCCAGAGTTTATTGGCCGTTTACCAGTAGTTGCAGCGT
TAGAACTTCTTACTGCAGAAGATCTGGTTCGTATTCTGACAGAACCA
CGCAATGCTTTGGTTAAACAATACCAAACCTTATTATCTTATGATGGT
GTAGAATTGGAATTTGACCAGGATGCTCTATTGGCTATCGCTGATAA
GGCTATCGAGCGCAAGACTGGTGCACGTGGTTTACGTTCTATTATTG
AAGAAACGATGCTTGATATCATGTTTGAAATTCCAAGCCAAGAAGAT
GTAACAAAAGTTCGTATCACAAAGGCTGCTGTTGAGGGTACTGACAA
GCCTGTTTTAGAGACGGCTTAG

MNRKVEEKMAGNRNNDMNVYCSFCGKSQDEVKKIAGNGVFICNECV
ALSQEIKEELAEVLAHLAEVPKPKELLEILNQYVVGQDRAKRALAVA
VYNHYKRVSYTESSDDVDLQKSNILMIGPTGSGKTFLAQTLAKSLNVP
FAIADATSLTEAGYVGEDVENILLKLIQAADYNVERAERGIIYVDEIDKIA
KKGENVSITRDVSGEGVQQALLKIEGTVASVPPQGGRKHPNQEMIQINT
KNILFIVGGAFDGIEDLVKQRLGEKVIGFGQTSRKIDDNASYMQEIISEDI
QKFGLIPEFIGRLPVVAALELLTAEDLVRLTEPRNALVKQYQTLISYDG
VELEFDQDALLAIADKAIERKTGARGLRSHIETMLDIMFEIPSQEDVTKV
RITKAAVEGTDKPVLETA*

ID-71

Clone 3-20

ATGAAAAGATTACATAAACTGTTTATAACCGTAATTGCTACATTAGG
TATGTTGGGGGTAATGACCTTTGGTCTTCCAACGCAGCCGCAAAACG
TAACGCCGATAGTACATGCTGATGTCAATTCATCTGTTGATACGAGC
CAGGAATTTCAAATAATTTAAAAAATGCTATTGGTAACCTACCATT
TCAATATGTTAATGGTATTTATGAATTAAATAATAATCAGACAAATTT
AAATGCTGATGTCAATGTTAAAGCGTATGTTCAAATAACAATTGACA

FIG. 1 CONT'D

ATCAACAAAGACTATCAACTGCTAATGCAATGCTTGATAGAACCATT
CGTCAATATCAAAATCGCAGAGATACCACTCTTCCCGATGCAAATTG
GAAACCATTAGGTTGGCATCAAGTAGCTACTAATGACCATTATGGGC
ATGCAGTCGACAAGGGGCATTTAATTGCCTATGCTTTAGCTGGAAAT
TTCAAAGGTTGGGATGCTTCCGTGTCAAATCCTCAAAATGTTGTCACA
CAAACAGCTCATTCCAACCAATCAAATCAAAAAATCAATCGTGGACA
AAATTATTATGAAAGCTTAGTTCGTAAGGCGGTTGACCAAAACAAAC
GTGTTTCGTTACCGTGTAACCTCATTGTACCGTAATGATACTGATTTAG
TTCCATTTGCAATGCACCTAGAAGCTAAATCACAAGATGGCACATTA
GAATTTAATGTTGCTATTCCAACACACAAGCATCATACACTATGGA
TTATGCAACAGGAGAAATAACACTAAATTAA

MKRLHKLFIATLGLGVMFTGLPTQPQNVTPIVHADVNSSVDTSQE
FQNNLKNALGNLFPQYVNGIYELNNNQTNLADVNVKAYVQNTIDNQ
RLSTANAMLDRTIROQYQNRDITLDPANWKPLGWHQVATNDHYGHAV
DKGHLIAYALAGNFKGWDASVSNPQNVVTQTAHSNQSNQKINRGQNY
YESLVRKAVDQNKRVRYRVTPLYRNDTDLVPFAMHLEAKSQDGTLEFN
VAIPNTQASYTMDYATGEITLN*

ID-72

Clone 13

ATGAAAAACTATCGAAAACTTATTGTACTACTACTTCTAATCTTTTTT
GCCATTTTTATGGGAGCATATGCTTACACGCATATTGTTGAAAAAAG
ATCCCTAACTAGCAATACTATTGAAAAAACTCTACCTGTGGTAAATC
AGATTAAGCCTCAAACCATTAAAGAATACCAAAATTACTTAACTAAG
GTAGCTAAACGTAATGTTCTTCTGTAGACATTCCTCAGGCATTAAAT
AATGAAAAGGTAGAAATTACTGCTACTGATGGCATGCAAACATTCAC
TTGGAATGATAAAAAATAATCCTAAGCAAAAGGTTATCTTCTATGTTT
ATGGAGGATCATATATCCATCAAGCTTCCGAATTACAATATATTTTTG
TCAATAAACTAGCTAAAAAATTAGATGCAAAAGTTGTCTTTCCTATTT
ACCCTAAAGCTCCTACATATAATTATAGTGATGCTATCCCCAAAATTA
AAAAATTATACCAAAATACATTAGCTAGCGTCACATCTCACAAACAG
ATTATCCTAGTAGGTGAAAGTGCAGGCGGAGGCCTTGCTTTAGGTAT
TGCTGATAACCTTGCACGGAGCATATCAAACAACCAAAAGAAATTAT
TTTAA

MKNYRKLIVLLLLIFFAIFMGAYAYTHIVEKRSLTSNTIEKTLPVVNQIKP
QTIKEYQNYLTKVAKRNVLPVDIPQALNNEKVEITATDGMQFTFTWNDK
NNPKQKVIFYVHGGSYIHQASELQYIFVNKLAKKLDKVVFPYIPKAPT
YNYSDAIPKIKKLYQNTLASVTSHKQIILVGESAGGGLALGLADNLARSIS
NNQKKLF*

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

ID-73

Clone 2-19

TTGATTCTAATAACTTCCTATGGGATAATATCTTTATCACAAAAATTG
AGGGAATTTATTATGAAGTTAAAACATATTGTCTTAGGATTAGCCTTA
ACAACACTTTTAGGAGTCACATTTAGTAATCAAGAAGTTTCAGCAAG
CTCAACTTCAAGTAAAGTTGTTAAAGTTGGTGTATGACCTTTTCTGA
CACTGAAAAAGCACGTTGGGATAAAATTGAAAAGCTAGTAGGTGAT
AAAGCTAAAATCAAATTTACAGAATTTACAGATTATACACAACCAAA
TCAAGCGACAGCCAATAAGGATGTGGATATTAATGCCTTTCAACATT
ACAATTTCTTAGAAAACCTGGAATAAGGAAAATAAGAAAAACTTAATT
CCACTTGAAAAGACTTACTTAGCTCCAATTCGTATCTATTCTGAGAAG
GTAAAATCTCTTAAAAAATTGAAAAAAGGAGCCACTATTGCAATTCC
AAATGATGCAACAAATGGTAGCCGTGCATTGTATGTCCTTCAGTCAG
CAGGTTTAATCAAATTGAATGTTTCTGGTAAGAAGGTTGCAACAGTT
GCTAATATCACATCTAATAAAAAGGATATTAATATTCAGGAGTTAGA
TGCGAGTCAAACACCACGTGCACTCAAAGATGTAGATGCAGCTATTA
TTAATAATACATACATTGAGCAAGCTAATTTAAAACCTTCAGATGCT
ATCTTTGTTGAGAAATCAGATAAAAATTCAAAACAATGGATTAATAT
CATTGCGGGACGTAAAAAATTGGAAAAAGCAAAAGAACGCTAAAGCT
ATCCAAGCTATCTTGGATGCTTATCACACAGATGAAGTGAAAAAAGT
TATCAAAGATACTTCAGCTGATATTCCACAATGGTAA

MILITSYGIISLSQKLREFIMKLKHIVLGLALTLLGVTFNSNQEVSSSTSS
KVVKVGVMTFSDTEKARWDKIEKLVGDKAKIKFTEFTDYTQPNQATAN
KDVDINAFQHYNFLENWNKENKKNLIPLEKTYLAPIRIYSEKVKSLKKL
KKGATIAIPNDATNGSRALYVLQSAGLIKLVSGKKVATVANITSNKKDI
NIQELDASQTPRALKDVDAAIINNTYIEQANLKPSDAIFVEKSDKNSKQW
INIIAGRKNWKKQKNAKAIQAILDAYHTDEVKKVIKDTSADIPQW*

ID-74

Clone 3-6

ATGTCAAATCAATATGATTATATCGTTATTGGTGGAGGTAGTGCAGG
CAGTGGTACCGCTAATAGGGCAGCCATGTATGGAGCAAAAGTCCTGT
TAATTGAAGGTGGACAAGTAGGTGGAACCTTGTGTTAACTTAGGTTGT
GTACCTAAGAAAATCATGTGGTATGGTGCACAAGTTTCTGAGACACT
CCATAAGTATAGTTCAGGTTATGGTTTTGAAGCCAATAATCTTAGTTT
TGATTTTACTACTCTAAAAGCTAATCGCGATGCTTACGTGCAGCGGTC
TAGACAGTCGTATGCCGCTAATTTTGAGCGTAATGGGGTCGAAAAGA

FIG. 1 CONT'D

TTGATGGATTTGCTCGTTTTATTGATAACCATACTATTGAAGTGAATG
GTCAGCAATATAAAGCTCCTCACATTACTATTGCAACAGGTGGACAC
CCTCTTTACCCTGATATTATTGGAAGTGAACCTGGTGAGACTTCTGAT
GATTTTTTTGGATGGGAGACCTTACCAAATTCTATATTGATTGTTGGG
GCGGGCTATATCGCGGCAGAACTTGCTGGAGTGGTTAATGAATTAGG
CGTTGAAACCCATCTTGCAATTTAGAAAAGACCATATTCTACGCGGAT
TTGATGACATGGTAACAAGTGAGGTTATGGCTGAAATGGAGAAATCA
GGTATCTCTTTACATGCTAACCATGTACCTAAATCTCTTAAACGCGAT
GAAGGTGGCAAGTTGATTTTTTGAAGCTGAAAATGGGAAAACGCTTGT
CGTTGATCGTGTAATATGGGCTATCGGCCGTGGACCAAATGTAGACA
TGGGACTTGAAAATACCGATATTGTTTTAAATGATAAAGATTATATC
AAAACAGATGAATTTGAGAATACTTCTGTAGATGGCGTGTATGCTAT
TGGAGATGTTAATGGGAAAATTGCCTTGACACCGGTAGCAATTGCAG
CAGGTCGTCGCTTATCAGAAAGACTTTTTAATCATAAAGATAACGAA
AAATTAGATTACCATAATGTACCTTCAGTTATTTTTACTCACCTGTA
ATTGGGACGGTAGGACTTTCAGAAGCAGCAGCTATCGAGCAATTTGG
AAAAGATAATATCAAAGTCTATACATCAACTTTTACCTCTATGTATAC
GGCTGTTACCAGTAATCGCCAAGCAGTTAAGATGAAGCTCATAACCC
TAGGAAAAGAGGAAAAAGTTATTGGGCTTCATGGTGTTGGTTATGGT
ATTGATGAAATGATTCAAGGTTTTTTCAGTTGCTATCAAAATGGGGGC
TACTAAAGCAGACTTTGATGATACTGTTGCTATTCACCCAACTGGATC
TGAGGAATTTGTTACAATGCGCTAA

MSNQYDYIVIGGGSAGSGTANRAAMYGAKVLLIEGGQVGGTCVNLGC
VPKKIMWYGAQVSETLHKYSSGYGFEANNLSFDFTTLKANRDAYVQRS
RQSYAANFERNGVEKIDGFARFDNHTIEVNGQQYKAPHITIAATGGHPLY
PDIIGSELGETSDDFFGWETLPNSILIVGAGYIAAELAGVVNELGVETHLA
FRKDHILRGFDDMTSEVMAEMEKSGISLHANHVPKSLKRDEGGKLIFE
AENGKTLVVDRVIWAIGRGPNVDMGLENTDIVLNDKDYIKTDEFENTSV
DGVYAIGDVNGKIALTPVAIAAGRRLSERLFNHKDNEKLDYHNVPSVIF
THPVIGTVGLSEAAAIEQFGKDNKVYTSTFTSMYTAVTSNRQAVKMKLI
TLGKEEKVIGLHGVGYGIDEMIQGFSAIKMGATKADFDDTVAIHPTGS
EEFVTMR*

ID-75

Clone 3-51

ATGAGTATCAAAAAAAGTGTGATTGGTTTTTGCCTCGAAGCTGCAGC
ATTATCAATGTTTGCTTGTGTAGACAGTAGTCAATCTGTTATGGCTGC

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

CGAGAAGGATAAAGTCGAAATTACGTGGTGGGCTTTTCCAACCTTTA
CTCAAGAAAAGGCTAAGGATGGAGTAGGTACTTATGAGAAAAAAGT
CATCAAGGCTTTTGAAGAGAAAAATCCTAATATAAAAGTAAACTAG
AGACAATTGATTTACATCTGGACCTGAAAAAATCACTACAGCAATT
GAAGCAGGGACAGCACCTGATGTGCTTTTTTGATGCACCAGGGCGAAT
TATTCAATATGGTAAAAATGGTAAATTAGCAGATTTGAATGATTTATT
TACAGACCAATTTATTAAGGATGTCAATAATAAGAACATCATTCAAG
CTTCTAAGTCTGGCGATAAAGCCTACATGTATCCAATAAGTTCTGCCC
CATTTTATATGGCGTTCAATAAAAAAATGCTTAAAGATGCAGGAGTT
TTGAAACTTGTAAGAAGGTTGGACTACTAGTGATTTTGAAAAAGT
ACTAAAAGCACTAAAAAATAAAGGCTATACACCAGGTTTATTCTTTG
CAAACGGGCAAGGAGGAGATCAAGGACCACGTGCATTTTTTGCTAAT
CTTTATAGTGCTCCAATAACAGATAAAGAAGTAACAAAATATACCAC
TGACACTAAAAATTCTGTAAAATCAATGAAAAAATAGTTGAATGGA
TTAAGAAAGGCTACTTGATGAATGGGTCTCAGTATGATGGCTCAGCT
GACATTCAAACTTCGCCAATGGACAAACTGCTTTCCTATCCTATG
GGCTCCAGCTCAACCAAAAATCAAGCAAAATTATTAGAGTCAAGTA
AAGTGGATTACCTTGAAGTGCCATTCCCATCAGAAGATGGAAAACCA
GATTTAGAATACCTTGTTAATGGTTTTGCGGTCTTTAATAATAAGAT
GAAAACAAAGTAAAAGCCTCTAAGAAATTTATCACTTTTATTGCTGA
TGATAAAAAATGGGGACCAAAAGATGTTATACGTACAGGTGCTTTCC
CAGTTAGAACATCATTGTTGGGATCTTTATAAAGGTGATAAACGTATG
ATGAAGATTTCAAAATGGACTCAATATTATTCACCATATTACAACAC
TATCGATGGATTTTCTGAAATGAGAACCTTATGGTTCCCAATGGTTCA
ATCTGTATCCAATGGTGATGAAAAACCAGCAGATGCTTTGAAAGACT
TACTCAAAAAGCAAATGATACCATTAAAAAAGCAGCTAAATAA

MSIKKSVIGFCLEAAALSMFACVDSSQSVMAAEKDKVEITWWAFPTFTQ
EKAKDGVGTYEKKVIKAFKKNPNKVKLETIDFTSGPEKITTAIEAGTAP
DVLFDAPGRIIQYGKNGKLADLNDLFTDQFIKDVNNKNIIQASKSGDKA
YMYPISSAPFYMAFNKKMLKDAGVLKL VKEGWTTSDFEKVLKALKNK
GYTPGSFFANGQGGDQGPRAFFANLYSAPITDKEVTKYTTDTKNSVKSM
KKIVEWIKKGYLMNGSQYDGSADIQNFANGQTAFTILWAPAQPKTQAK
LLESSKVDYLEVPFSEDGKPDLEYLVNGFAVFNNKDENKVKASKKFIT
FIADDKKWGP KD VIRTGAFPVRTSFGDLYKGDKRMMKISKWTQYYSPY
YNTIDGFSEMRTLWFP MVQSVSNGDEKPADALKDFTQKANDTIKKA
*

ID-76 (Same as ID-39)

Clone 3-56

ATGAGGAAACGTTTTTCCTTGCTAAATTTTATTGTTGTTACTTTTATTT
TCTTTTTCTTTATTCTTTTTCCGCTTTTAAAGGCCAAAGATTGTCAGGT

FIG. 1 CONT'D

SUBSTITUTE SHEET (RULE 26)

TGTTTATGCAAGTTTTCAAGGAGATCATTGGGACATTTGTAACGCATT
TGATTTTCCGTATTTACATCGCTTTGATCTCATTAAAGGTAAAGAAAA
TCAACTTTACTTTATAGGTTGTACAATTGCTAACAGTAAAGCCTACAC
TGAGGATTGGAGTGATAAAGGCCGAATTTTTGTTGCTCGTTTTAATAC
TCAAACCATACATTGGAAGGATTGCAACAATTGCCTCAAACCTTTAT
TAAAAAATCATGGATACTATGCCATTCAGGATGAAGGATATTCATTG
ATTACTTCAGTAGAAGGGGTACTCAAACCTCACTTATCCAGAATTTTCT
ACTACAGGCGACTGGCAATTAGAACGGCTTTTCGATGAGGAGACAAG
CGATGTGGTGAAAGTGGATATTAATCAGGATGGTAAGGATGAGTATG
TGATCATCCAAGGTTTTTCATGGAGATCGTTTACGTATCTTCACTGAAG
ATTTCCGGTCGAGAATTATTCATTATCCTGAAAAAACCCCATTTGGTC
ACGCTATTTGGAGTGGTCGTTTACTTAATCAGACTTGTTTCGTATTCTG
GGTGGCGATCAGAAAAAGCAGAATTAAGGCTTTTTTCACTTTGTAGAT
GGGCACTTGGTTTTCAGAATTAGTAGATGCAAAAGCAGCTTCTAGTAA
TGTCTTAGCTTTTGAAAAAGATGGAAAAGCTTATCTTTTCTCAGCCAA
TAACGGACGTGGCGAAGTTGCTCTTTATCAATTAGTAAAATAA

MRKRFSLLNFIVVTFIFFFILFPLFKAKDCQVVYASFQGDHWDICNAFDF
PYLHRFDLIKGENQLYFIGCTIANSKAYTEDWSDKGRIFVARFNTQNHT
LEGLQQLPQTLLKNHGYyaiQDEGYSLITSVEGVKLKLTYPFSTTGDWQ
LERLFDEETSDVVKVDINQDGKDEYVIIQGFHGDRLRIFTEDFGRELFHY
PEKTPFGHAIWSGRLLNQTCFVFGWRSEKAELRLFHFVDGHLVSELVDA
KAASSNVLAFEKDGKAYLFSANNGRGEVALYQLVK*

FIG. 1 CONT'D

nucS1

Bgl II Eco RV

5'-cgagatctgatatctcacaaacagataacggcgtaaataag -3'

nucS2

Bgl II Sma I

5'-gaagatcttccccgggatcacaaacagataacggcgtaaataag -3'

nucS3

Bgl II Eco RV

5'-cgagatctgatatccatcacaaacagataacggcgtaaataag -3'

nucR

Bam HI

5'-cgggatccttatggacctgaatcagcgttggtc -3'

NucSeq

5'-ggatgctttgtttcaggtgtatc -3'

pTREP_F5'-catgatatcggtacctcaagctcatatcattgtccggcaatgggtgtgggctttttttgttttagcggataa
caatttcacac -3'pTREP_R5'-gcggatcccccggttaattaatgttttaaacactagtcgaagatctcgogaattctcctgtgtgaaatt
gttatccgcta -3'pUC_F

5'-cgccagggttttcccagtcacgac -3'

V_R

5'-tcaggggggcgagacctatg -3'

V₁

5'-tcgtatgttggtggaattgtg -3'

V₂

5'-tccggtcgtatgttggtggaattg -3'

FIG. 2

49 / 60

pTREP-Nuc vectors allow cloning of genomic DNA into each frame with respect to the nuclease gene

(i)

pTREP1-nuc1 (EcoRV)	AAGTATCAGATCT-- <u>GATATC</u> --TCACAAACAGATAACGGCGTAAAT	Frame=+1
▲.....	
pTREP1-nuc2 (Sma I)	AAGTATCAGATCTT <u>CCCCGGA</u> -TCACAAACAGATAACGGCGTAAAT	Frame=+2
▲.....	
pTREP1-nuc3 (EcoRV)	AAGTATCAGATCT-- <u>GATATCC</u> ATCACAACAGATAACGGCGTAAAT	Frame=+3
▲.....	
Nuclease Gene	TCACAAACAGATAACGGCGTAAAT	

Cloning site is indicated by an arrow




FIG. 3

SUBSTITUTE SHEET (RULE 26)

GBS Vaccination - Trial 1




FIG. 4a

GBS Vaccination - Trial 2




FIG. 4b




FIG. 4c




FIG. 4d

GBS Vaccination - Trial 6




FIG. 4e

GBS Vaccination - Trial 2




FIG. 5a




FIG. 5b




FIG. 5c

GBS Vaccination - Trial 5




FIG. 5d

GBS Vaccination - Trial 6




FIG. 5e




FIG. 6

56 / 60




FIG. 7




FIG. 8




FIG. 9




FIG. 10

60 / 60





FIG. 11





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/31, 15/74, 15/62, 15/10, 9/16, 1/19, 1/21, C07K 14/315, 16/12, A61K 31/70, 39/09, G01N 33/53, 33/68, C12Q 1/68	A3	(11) International Publication Number: WO 00/06736 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/GB99/02444 (22) International Filing Date: 27 July 1999 (27.07.99) (30) Priority Data: 9816335.5 27 July 1998 (27.07.98) GB 60/125,163 19 March 1999 (19.03.99) US (71) Applicant (for all designated States except US): MICROBIAL TECHNICS LIMITED [GB/GB]; 20 Trumpington Street, Cambridge CB2 1QA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): LE PAGE, Richard, William, Falla [GB/GB]; University of Cambridge, Dept. of Pathology, Tennis Court Road, Cambridge CB2 1QP (GB). WELLS, Jeremy, Mark [GB/GB]; Institute of Food Research, Norwich Laboratory, Norwich Research Park, Colney, Norwich NR4 7UA (GB). HANNIFFY, Sean, Bosco [IE/GB]; University of Cambridge, Dept. of Pathology, Tennis Court Road, Cambridge CB2 1QP (GB). (74) Agents: CHAPMAN, Paul, William et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).		(81) Designated States: CA, CN, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 22 June 2000 (22.06.00)
(54) Title: NUCLEIC ACIDS AND PROTEINS FROM GROUP B STREPTOCOCCUS (57) Abstract Novel protein antigens from Group B <i>Streptococcus</i> are described, together with nucleic acid sequences encoding them. Their use in vaccines and screening methods is also described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

National Application No
PCT/GB 99/02444

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/31	C12N15/74	C12N15/62	C12N15/10	C12N9/16
	C12N1/19	C12N1/21	C07K14/315	C07K16/12	A61K31/70
	A61K39/09	G01N33/53	G01N33/68	C12Q1/68	

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE TREMBL E.M.B.L. Databases Accession Number: Q54914, 1 November 1996 (1996-11-01) PODBIELSKI A ET AL: "ORF 1 AND ORF2 5' REGION" XP002133342 97.2% identity in 141 aa overlap with SeqIdNo.12 abstract</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	3,4

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

17 March 2000

Date of mailing of the international search report

11.04.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/02444

(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 18930 A (HUMAN GENOME SCIENCES INC ;CHOI GIL H (US); HROMOCKYJ ALEX (US); J) 7 May 1998 (1998-05-07) SP0020: 51.9% identity in 262 aa overlap with SeqIdNo.133 -& DATABASE GENESEQ E.M.B.L. Databases Accession Number: W55078, 2 October 1998 (1998-10-02) CHOI G ET AL: "Streptococcus pneumoniae SP0020 protein" XP002133369 51.9% identity in 262 aa overlap with SeqIdNo.133 abstract</p> <p>---</p>	3-18,23
P,X	<p>WO 99 16882 A (MEDIMMUNE INC) 8 April 1999 (1999-04-08) -& DATABASE GENESEQ E.M.B.L. Databases Accession Number: Y05766, 8 April 1999 (1999-04-08) LUTTICKEN R ET AL : "Streptococcal adhesion mediator protein Lmb" XP002133343 99.7% identity in 306 aa overlap with SeqIdNo.12 abstract</p> <p>---</p>	1-18,23
A	<p>WO 94 10317 A (GEN HOSPITAL CORP ;BRIGHAM & WOMENS HOSPITAL (US)) 11 May 1994 (1994-05-11) figure 6</p> <p>---</p>	1-18,23
A	<p>MICHEL J L ET AL: "Cloned alpha and beta C-protein antigens of group B Streptococci elicit protective immunity" INFECTION AND IMMUNITY,US,AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 59, no. 6, June 1991 (1991-06), page 2023-2028-2028 XP002107260 ISSN: 0019-9567 the whole document</p> <p>---</p>	1-18,23
A	<p>LACHENAUER C S ET AL: "Cloning and expression in Escherichia coli of a protective surface protein from type V group B Streptococci" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY,US,SPRING ST., NY, vol. 418, no. 418, 9 December 1997 (1997-12-09), page 615-618-618 XP002107261 ISSN: 0065-2598 the whole document</p> <p>---</p>	1-18,23

INTERNATIONAL SEARCH REPORT

national Application No

PCT/GB 99/02444

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE SWISSPROT E.M.B.L. Databases Accession Number: P29850, 1 April 1993 (1993-04-01) PUYET A ET AL: " MALTOSE/MALTODEXTRIN-BINDING PROTEIN PRECURSOR" XP002125784 30.7% identity in 407aa overlap with SeqIDNo.2 abstract</p> <p>---</p>	1
A	<p>LARSSON C ET AL: "Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha" INFECT. IMMUN., vol. 64, no. 9, September 1996 (1996-09), pages 3518-3523, XP002125783 cited in the application</p> <p>---</p>	
A	<p>WO 95 06732 A (MASURE H ROBERT ;TUOMANEN ELAINE (US); PEARCE BARBARA J (US); UNIV) 9 March 1995 (1995-03-09)</p> <p>---</p>	
A	<p>DATABASE SWISSPROT E.M.B.L. Databases Accession Number: P42422, 1 November 1995 (1995-11-01) YOSHIDA K ET AL: "Hypothetical sensor-like Histidine Kinase in IDH 3' region" XP002133344 30.6% identity in 320 aa overlap with SeqIdNo.20 abstract</p> <p>---</p>	
A	<p>DATABASE SWISSPROT E.M.B.L. Databases Accession Number: P39845, 1 February 1995 (1995-02-01) TOGNONI A ET AL: "Peptide Synthetase 1" XP002133345 29.3% identity in 133 aa overlap with seqIdNo.26 abstract</p> <p>---</p>	

-/--

INTERNATIONAL SEARCH REPORT

national Application No
PCT/GB 99/02444

(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE TREMBL E.M.B.L. databases Accession Number: P94374, 1 May 1997 (1997-05-01) YOSHIDA K ET AL: "HOMOLOGOUS TO MANY ATP-BINDING TRANSPORT PROTEINS" XP002133346 30.2% identity in 235 aa overlap with SeqIdNo.82 abstract</p> <p>---</p>	
A	<p>WO 98 23631 A (KNOWLES DAVID JUSTIN CHARLES ; LONETTO MICHAEL ARTHUR (GB); SMITHKL) 4 June 1998 (1998-06-04) -& DATABASE GENESEQ E.M.B.L. Databases Accession Number: W62662, 9 November 1998 (1998-11-09) BLACK M ET AL: "Streptococcus pneumoniae polypeptide" XP002133370 38.8% identity in 85 aa overlap with SeqIdNo.123 abstract</p> <p>---</p>	
A	<p>WO 98 18931 A (DOUGHERTY BRIAN A ; HUMAN GENOME SCIENCES INC (US); ROSEN CRAIG A () 7 May 1998 (1998-05-07) -& DATABASE GENESEQ E.M.B.L. Databases Accession Number: V52187, 7 May 1998 (1998-05-07) BARASH S ET AL: "Streptococcus pneumoniae genome fragment SEQ ID NO:54" XP002133371 61.8% identity in 2138 bp overlap with SeqIdNo.124 abstract</p> <p>---</p>	
T	<p>WO 99 42588 A (BIOCHEM VACCINS INC ; BRODEUR BERNARD R (CA); CHARLEBOIS ISABELLE () 26 August 1999 (1999-08-26)</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 99/02444

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-18 and 23 (all partially) as relating to inventions 1, 6, 10, 13, 35, 41, 62, 63 and 67
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Invention 1: claims 1-18 and 23 (all partially)

A Group B Streptococcus protein having a sequence as depicted in SeqIdNo.2, a fragment, derivative or variant of said protein; a nucleic acid molecule comprising or consisting of SeqIdNo.1, a nucleic acid molecule complementary to said sequence, a nucleic acid molecule encoding for the a derivative or fragment of said protein; a vector comprising said nucleic acid molecule and afferent recombinant DNA practices; an antibody to said protein; an immunogenic composition comprising said protein or said nucleic acid and applications thereof; a method or kit of detection of Group B Streptococcus comprising said protein, said antibody, or said nucleic acid molecule; a method of determining whether said protein represents a potential antimicrobial target which comprises inactivating said protein and determining whether Group B Streptococcus is still viable.

2. Inventions 2-69: claims 1-18 and 23 (all partially)

Idem as subject 1 but limited to each of the polynucleotide and polypeptide sequences as depicted in SeqIdNo:3-137, wherein invention 2 is limited to SeqIdNo:3 and SeqIdNo:4, invention 3 is limited to SeqIdNo:5 and SeqIdNo:6, ..., invention 58 is limited to SeqIdNo:115, ..., and invention 69 is limited to SeqIdNo:136 and 137.

3. Inventions 70: claims 19-22 (all totally)

A method for screening for DNA encoding bacterial cell envelope associated or surface antigens in gram positive bacteria comprising a reporter vector including the nucleotide sequence encoding the mature form of the staphylococcus nuclease gene and an upstream promoter region with DNA from a gram positive bacterium; said method wherein the reporter vector is one of the pTREPl-nuc vectors; said method wherein the gram positive bacterium is Group B Streptococcus, Streptococcus pneumoniae, Staphylococcus aureus or pathogenic group A streptococci; said vector which is one of the pTREPl-nuc vectors

For the sake of conciseness, the first and 70th subject-matters are explicitly defined, the other subject-matters are defined by analogy to the subject-matter of invention 1.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/02444

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9818930	A	07-05-1998	AU	5194598 A	22-05-1998
			AU	6909098 A	22-05-1998
			EP	0942983 A	22-09-1999
			EP	0941335 A	15-09-1999
			WO	9818931 A	07-05-1998

WO 9916882	A	08-04-1999	AU	9507698 A	23-04-1999


WO 9410317	A	11-05-1994	AU	5626998 A	07-05-1998
			AU	689452 B	02-04-1998
			AU	5665494 A	24-05-1994
			CA	2146926 A	11-05-1994
			EP	0669985 A	06-09-1995
			FI	951979 A	29-06-1995
			HU	70981 A	28-11-1995
			JP	8505282 T	11-06-1996
			NO	951629 A	03-07-1995
			NZ	258684 A	24-04-1997
			PL	308555 A	21-08-1995
			US	5648241 A	15-07-1997
			US	5847081 A	08-12-1998
			US	5820860 A	13-10-1998
			US	5858362 A	12-01-1999
			US	5908629 A	01-06-1999
			US	5968521 A	19-10-1999
			US	5843444 A	01-12-1998
			ZA	9308171 A	07-03-1995

WO 9506732	A	09-03-1995	US	5928900 A	27-07-1999
			AU	709405 B	26-08-1999
			AU	7680994 A	22-03-1995
			CA	2170726 A	09-03-1995
			EP	0721506 A	17-07-1996
			FI	960977 A	30-04-1996
			JP	9504686 T	13-05-1997
			NO	960839 A	19-04-1996
			NZ	273497 A	25-03-1999
			US	5981229 A	09-11-1999


WO 9823631	A	04-06-1998	NONE		

WO 9818931	A	07-05-1998	AU	5194598 A	22-05-1998
			AU	6909098 A	22-05-1998
			EP	0942983 A	22-09-1999
			EP	0941335 A	15-09-1999
			WO	9818930 A	07-05-1998

WO 9942588	A	26-08-1999	AU	2505999 A	06-09-1999



US 096458350UP1



Creation date: 13-08-2003
Indexing Officer: VKIM1 - VANNAROTH KIM
Team: OIPEBackFileIndexing
Dossier: 09645835

Legal Date: 19-05-2003

No.	Doccode	Number of pages
1	SRNT	76

Total number of pages: 76

Remarks:

Order of re-scan issued on

